DEF 14A
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
(Rule 14a-101)
Schedule 14A Information
Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934 (Amendment No. )
Filed by the Registrant þ
Filed by a Party other than the Registrant o
Check the appropriate box:
o Preliminary Proxy Statement
o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
þ Definitive Proxy Statement
o Definitive Additional Materials
o Soliciting Material Pursuant to §240.14a-12
WellCare Health Plans, Inc.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
þ No fee required.
o Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
|
(1) |
|
Title of each class of securities to which transaction applies: |
|
|
(2) |
|
Aggregate number of securities to which transaction applies: |
|
|
(3) |
|
Per unit price or other underlying value of transaction computed
pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is
calculated and state how it was determined): |
|
|
(4) |
|
Proposed maximum aggregate value of transaction: |
|
|
(5) |
|
Total fee paid: |
o |
|
Fee paid previously with preliminary materials. |
|
o |
|
Check box if any part of the fee is offset as provided by Exchange
Act Rule 0-11(a)(2) and identify the filing for which the
offsetting fee was paid previously. Identify the previous filing
by registration statement number, or the Form or Schedule and the
date of its filing. |
|
(1) |
|
Amount Previously Paid: |
|
|
(2) |
|
Form, Schedule or Registration Statement No.: |
|
|
(3) |
|
Filing Party: |
|
|
(4) |
|
Date Filed: |
8735 Henderson Road Tampa,
Florida 33634 (813) 290-6200 www.wellcare.com
July 1, 2009
Dear Shareholder:
You are cordially invited to attend the 2009 annual meeting of shareholders of WellCare Health
Plans, Inc. to be held on July 30, 2009, at 10:00 a.m. Eastern Time, at the Grand Hyatt Tampa Bay,
2900 Bayport Drive, Tampa, Florida 33607.
At the meeting you will be asked to: (a) elect seven Directors; (b) approve and adopt an
amendment to our certificate of incorporation to declassify our Board of Directors; (c) approve and
adopt an amendment to our certificate of incorporation to provide that Directors may be removed
with or without cause (except for Class III Directors serving the remaining portion of a multi-year
term, who, if the amendment is approved and adopted, could not be removed without cause prior to
the end of their current multi-year term); (d) ratify the appointment of Deloitte & Touche LLP as
our independent registered public accounting firm for fiscal year 2009; and (e) transact such other
business as may properly come before the meeting or any adjournment or postponement of the meeting.
The accompanying proxy statement provides a detailed description of these proposals. We urge
you to read the accompanying materials so that you will be informed about the business to be
addressed at the annual meeting.
It is important that your shares be represented at the annual meeting. Accordingly, we ask
you, whether or not you plan to attend the annual meeting, to complete, sign and date your proxy
card and return it to us promptly in the enclosed envelope or to otherwise vote in accordance with
the instructions on your proxy card. You could save us money by voting through the internet or by
telephone. If you attend the meeting, you may vote in person, even if you have previously mailed
in your proxy. However, if you hold your shares in a brokerage account, or street name, you will
need to provide a proxy from the institution that holds your shares reflecting stock ownership as
of the record date to be able to vote by ballot at the meeting.
We look forward to seeing you at the meeting.
IF YOU PLAN TO ATTEND THE MEETING:
Registration and seating will begin at 9:30 a.m. Eastern Time on July 30, 2009. Shareholders
and their guests will be asked to sign-in and may be asked to present valid picture identification.
Shareholders holding stock in street name will need to obtain a proxy from the institution that
holds their shares to evidence stock ownership as of the record date. If you require special
accommodations (such as wheelchair access) to participate in this meeting, please send a written
request to Timothy S. Susanin, our Secretary, at WellCare Health Plans, Inc., 8735 Henderson Road,
Tampa, Florida 33634 by July 15, 2009 with your request. After July 15, we cannot guarantee that
we can accommodate your request.
Sincerely,
Heath G. Schiesser
President and Chief Executive Officer
WELLCARE HEALTH PLANS, INC.
8735 Henderson Road
Tampa, Florida 33634
Notice of Annual Meeting of Shareholders
|
|
|
TIME AND DATE
|
|
10:00 a.m. Eastern Time on July 30, 2009. |
|
|
|
PLACE
|
|
Grand Hyatt Tampa Bay
2900 Bayport Drive
Tampa, Florida 33607 |
|
|
|
PURPOSE
|
|
a. To elect seven Directors; |
|
|
|
|
|
b. To approve and adopt an amendment to our certificate of incorporation to declassify
our Board of Directors; |
|
|
|
|
|
c. To approve and adopt an amendment to our certificate of incorporation to provide that
Directors may be removed with or without cause (except for Class III Directors serving
the remaining portion of a multi-year term, who, if the amendment is approved and
adopted, could not be removed without cause prior to the end of their current multi-year
term); |
|
|
|
|
|
d. To ratify the appointment of Deloitte & Touche LLP as our independent registered
public accounting firm for fiscal year 2009; and |
|
|
|
|
|
e. To transact such other business as may properly come before the meeting or any
adjournment or postponement of the meeting. |
|
|
|
RECORD DATE
|
|
You can vote if you were a shareholder of record at the close of business on June 3, 2009. |
|
|
|
PROXY VOTING
|
|
It is important that you vote your shares. You can vote your shares by completing and
returning the proxy card sent to you. Most shareholders have the option of voting
through the internet or by telephone. Please refer to your proxy card to determine if
there are other voting options available to you. You can revoke a proxy at any time
prior to its exercise at the meeting by following the instructions in the accompanying
proxy statement. |
This notice and the enclosed proxy statement are first being made available to our shareholders on
or about July 1, 2009.
Timothy S. Susanin
Senior Vice President, General Counsel and Secretary
IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE ANNUAL
MEETING OF SHAREHOLDERS TO BE HELD ON JULY 30, 2009:
This proxy statement and our annual report to shareholders are available on our
website at http://www.wellcare.com/2009shareholdermeeting
Tampa, Florida
July 1, 2009
TABLE OF CONTENTS
|
|
|
|
|
|
|
PAGE |
|
|
|
|
|
|
|
|
|
1 |
|
|
|
|
1 |
|
|
|
|
1 |
|
|
|
|
3 |
|
|
|
|
6 |
|
|
|
|
8 |
|
|
|
|
10 |
|
|
|
|
12 |
|
|
|
|
19 |
|
|
|
|
23 |
|
|
|
|
34 |
|
|
|
|
34 |
|
|
|
|
49 |
|
|
|
|
51 |
|
|
|
|
52 |
|
|
|
|
52 |
|
|
|
|
52 |
|
|
|
|
53 |
|
|
|
|
54 |
|
|
|
|
|
|
AUDIT COMMITTEE CHARTER |
|
|
A-1 |
|
|
|
|
|
|
PROPOSED AMENDED AND RESTATED CERTIFICATE OF INCORPORATION |
|
|
B-1 |
|
WELLCARE HEALTH PLANS, INC.
8735 Henderson Road
Tampa, Florida 33634
Proxy Statement for Annual Meeting
To Be Held July 30, 2009
INTRODUCTION
This proxy statement is being furnished to shareholders of WellCare Health Plans, Inc., a
Delaware corporation, in connection with the solicitation of proxies by our Board of Directors for
use at our annual meeting of shareholders to be held on July 30, 2009, at 10:00 a.m. Eastern Time,
at the Grand Hyatt Tampa Bay, 2900 Bayport Drive, Tampa, Florida 33607, and any adjournment or
postponement of the meeting. This proxy statement is dated July 1, 2009 and is first being made
available to shareholders on or about July 1, 2009.
REDUCE PRINTING AND MAILING COSTS
If you share the same last name with other shareholders living in your household, you may
receive only one copy of our proxy statement and 2008 annual report. Please see the section
entitled Multiple Shareholders Having the Same Address at the end of this proxy statement for
more information on this important initiative to reduce printing and mailing costs.
You may help us reduce printing and mailing costs further by opting to receive future proxy
materials by e-mail. Please see the response to the question Can I access the proxy materials on
the internet? below for more information on electronic delivery of proxy materials.
ABOUT THE MEETING
What is the purpose of the annual meeting?
At the annual meeting, shareholders will be asked to consider and vote upon four proposals:
(a) to elect seven Directors; (b) to approve and adopt an amendment to our certificate of
incorporation to declassify our Board of Directors; (c) to approve and adopt an amendment to our
certificate of incorporation to provide that Directors may be removed with or without cause (except
for Class III Directors serving the remaining portion of a multi-year term, who, if the amendment
is approved and adopted, could not be removed without cause prior to the end of their current
multi-year term); and (d) to ratify the appointment of Deloitte & Touche LLP as our independent
registered public accounting firm for fiscal year 2009. You will also be asked to vote on such
other business as may properly come before the meeting or any adjournment or postponement of the
meeting. In addition, management will report on our performance and respond to your questions.
Who is entitled to vote at the meeting?
Only shareholders of record at the close of business on June 3, 2009, the date our Board of
Directors fixed as the record date for determining holders of issued and outstanding shares of our
common stock, par value $0.01 per share, are entitled to notice of and to vote at the annual
meeting.
What constitutes a quorum and why is one required?
The presence at the meeting, in person or by proxy, of the holders of a majority of the
aggregate voting power of our common stock issued and outstanding on the record date will
constitute a quorum for the transaction of business at the annual meeting. A quorum is required by
law for any action to be taken at the annual meeting. As of the record date, there were 42,227,869
shares of common stock issued and outstanding.
1
Abstentions, withhold votes and broker non-votes are counted for purposes of determining the
number of shares considered to be present or represented at the meeting for purposes of determining
quorum, but will not be considered cast on a matter. A broker non-vote occurs when a broker or
nominee, holding shares in street name for the beneficial owner, has not received voting
instructions from the beneficial owner and either does not have discretionary authority to vote on
the matter or has such discretionary authority but does not vote on the matter.
How do I vote?
If you complete and properly sign and return the accompanying proxy card in time for the
meeting, it will be voted as you direct. If you are a registered shareholder and attend the
meeting, you may deliver your completed proxy card in person. If your shares are held by a broker
in street name and you wish to vote at the meeting in person or by proxy, you must obtain a proxy
from your broker to evidence your ownership and voting rights.
Can I vote by telephone or electronically?
You may vote by telephone or electronically through the internet by following the instructions
included on your proxy card. We encourage you to vote by telephone or through the internet because
such votes are less costly for us to collect and tally. The deadline for voting by telephone or
through the internet is 1:00 a.m., Eastern Time, on July 30, 2009.
How many votes do I have?
Each share of common stock is entitled to one vote. The enclosed proxy card shows the number
of shares of common stock that you are entitled to vote.
Can I change my vote?
Unless your proxy specifies otherwise, proxies will be voted: (a) FOR the election of the
nominated Directors; (b) FOR the amendment to our certificate of incorporation to declassify our
Board of Directors; (c) FOR the amendment to our certificate of incorporation to provide that
Directors may be removed with or without cause (except for Class III Directors serving the
remaining portion of a multi-year term, who, if the amendment is approved and adopted, could not be
removed without cause prior to the end of their current multi-year term); (d) FOR the ratification
of Deloitte & Touche LLP as our independent registered public accounting firm for fiscal year 2009;
and (e) otherwise in the discretion of the proxies as to any other matter that may come before the
annual meeting or any adjournment or postponement of the meeting.
Any shareholder who has given a proxy has the power to revoke such proxy at any time before it
is voted either: (a) by filing a written revocation or a duly executed proxy bearing a later date
with Timothy S. Susanin, our secretary, at WellCare Health Plans, Inc., 8735 Henderson Road, Tampa,
Florida 33634; (b) by appearing at the annual meeting and voting in person; or (c) by re-voting by
telephone or on the internet. Attendance at the annual meeting will not in and of itself
constitute the revocation of a proxy. Voting by those present during the conduct of the annual
meeting will be by ballot.
How will my votes be counted?
One or more inspectors of election will count and tabulate all votes at the annual meeting.
What vote is required to approve each proposal?
Proposal One Election of Directors. The affirmative vote of a plurality of the votes of
the shares present by person or represented by proxy at the meeting and entitled to vote in the
election of Directors is required to elect a Director nominee. Withhold votes and broker non-votes
will not be treated as voting on this proposal and, accordingly, will have no affect on the outcome
of the vote. There is no cumulative voting for Directors.
Proposal Two Amendment of Certificate of Incorporation To Provide For Annual Election Of
All Directors. The affirmative vote of the holders of at least 662/3 percent
of the voting power of all shares entitled to vote generally in the election of Directors, voting
together as a single class, is required to approve Proposal Two. Because the number of votes
required to pass this proposal is 662/3 percent of the number of shares
entitled to vote, rather than the number of shares actually present and voting, abstentions and
broker non-votes will be votes not cast for this proposal and would therefore have the same effect
as votes against this proposal. Proposals Two and Three are cross-conditioned on each other. If
either Proposal Two or Proposal Three is not approved, then neither proposal will be approved.
2
Proposal Three Amendment of Certificate of Incorporation To Provide That Directors May Be
Removed With Or Without Cause. The affirmative vote of the holders of at least
662/3 percent of the voting power of all shares entitled to vote generally in
the election of Directors, voting together as a single class, is required to approve Proposal
Three. Because the number of votes required to pass this proposal is 662/3
percent of the number of shares entitled to vote, rather than the number of shares actually
present and voting, abstentions and broker non-votes will be votes not cast for this proposal and
would therefore have the same effect as votes against this proposal. Proposals Two and Three are
cross-conditioned on each other. If either Proposal Two or Proposal Three is not approved, then
neither proposal will be approved.
Proposal Four Ratification of Appointment of Independent Registered Public Accounting Firm.
The affirmative vote of the holders of a majority of the shares of common stock represented in
person or by proxy and entitled to vote at the meeting is required to approve this proposal.
Abstentions will be counted as represented and entitled to vote and will therefore have the effect
of a negative vote on this proposal. Broker non-votes will not be treated as voting on this
proposal and, accordingly, will have no affect on the outcome of this vote.
We will post the results of the voting on our website at www.wellcare.com.
Can I access the proxy materials on the internet?
The Notice of Annual Meeting, Proxy Statement and 2008 Annual Report are available on our
website at http://www.wellcare.com/2009shareholdermeeting. Instead of receiving future copies of
these materials by mail, most shareholders can elect to receive an e-mail that will provide
electronic links to them. Opting to receive your proxy materials online will save us the cost of
producing and mailing documents to your home or business.
If you are a shareholder of record you can enroll in the electronic proxy delivery service
electronically by going to www.investorvote.com. If you hold your shares in a brokerage account,
you may also have the opportunity to receive copies of these documents electronically. Please
check the information provided in the proxy materials mailed to you by the institution that holds
your shares regarding the availability of this service.
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
Who are the largest owners of our stock?
The table below sets forth certain information regarding beneficial owners known to us as of
June 17, 2009 of more than 5% of our outstanding shares of common stock. The ownership percentage
is based on the number of shares reported by the applicable beneficial owner and the number of
shares of our common stock outstanding as of June 17, 2009.
|
|
|
|
|
|
|
|
|
|
|
Ownership |
Name and Address |
|
Common Stock |
|
Percent (%) |
Fairholme Capital Management, et al.(1)
4400 Biscayne Boulevard, 9th Floor
Miami, FL 33137 |
|
|
8,313,407 |
|
|
|
19.7 |
|
Renaissance Technologies, et al. (2)
800 Third Avenue
New York, NY 10022 |
|
|
2,857,200 |
|
|
|
6.8 |
|
Barclays Global Investors, et al.(3)
400 Howard Street
San Francisco, CA 94105 |
|
|
2,306,969 |
|
|
|
5.5 |
|
|
|
|
(1) |
|
This disclosure is based upon a Schedule 13G/A filed by Fairholme
Capital Management, L.L.C. (Fairholme) and other affiliated entities
with the SEC on February 17, 2009. Fairholme and the other affiliated
entities reported shared voting and dispositive power as of December
31, 2008 as follows: (i) Fairholme, shared voting power as to
5,088,603 shares and shared dispositive power as to 8,025,777 shares;
(ii) Bruce R. Berkowitz, sole voting and dispositive power as to
287,630 shares, shared voting power as to 5,088,603 shares and shared
dispositive power as to 8,025,777 shares; and (iii) Fairholme Funds,
Inc., shared voting and dispositive power as to 4,166,200 shares. We
have not attempted to verify independently any of the information
contained in the Schedule 13G/A. |
|
(2) |
|
This disclosure is based upon a Schedule 13G filed by Renaissance
Technologies LLC (Renaissance) and James H. Simons (Simons) with
the SEC on February 13, 2009. Renaissance and Simons reported sole
voting and dispositive power as of December 31, 2008 as to 2,857,200
shares. We have not attempted to verify independently any of the
information contained in the Schedule 13G. |
|
(3) |
|
This disclosure is based upon a Schedule 13G filed by Barclays Global
Investors, N.A. (Barclays) and other affiliated entities with the
SEC on February 5, 2009. Barclays and the other affiliated entities
reported sole voting and dispositive power as of December 31, 2008 as
follows: |
3
|
|
|
|
|
(i) Barclays, sole voting power as to 1,171,495 shares and
sole dispositive power as to 1,397,117 shares; (ii) Barclays Global
Fund Advisors, sole voting power as to 581,075 and sole dispositive
power as to 816,712 shares; (iii) Barclays Global Investors, Ltd.,
sole voting power as to 19,090 shares and sole dispositive power as to
53,029 shares; (iv) Barclays Global Investors Japan Limited, sole
voting and dispositive power as to 15,330 shares; (v) Barclays Global
Investors Canada Limited, sole voting and dispositive power as to
24,781 shares; and (vi) Barclays Global Investors Australia Limited
and Barclays Global Investors (Deutschland) AG, sole voting and
dispositive power as to no shares. We have not attempted to verify
independently any of the information contained in the Schedule 13G. |
How much stock do our executive officers and Directors own?
The following table sets forth certain information with regard to the beneficial ownership of
our common stock as of the close of business on June 17, 2009 by: (a) each Director; (b) each of
the executive officers named in the Summary Compensation Table; and (c) all Directors and executive
officers (including seven executive officers who are not named in the Summary Compensation Table)
as a group.
|
|
|
|
|
|
|
|
|
Name |
|
Common Stock (1) |
|
Percent |
David Gallitano |
|
|
14,354 |
|
|
|
* |
|
Robert Graham |
|
|
17,260 |
|
|
|
* |
|
Regina Herzlinger |
|
|
46,959 |
|
|
|
* |
|
Kevin Hickey |
|
|
44,353 |
|
|
|
* |
|
Alif Hourani |
|
|
18,871 |
|
|
|
* |
|
Ruben King-Shaw, Jr. |
|
|
25,746 |
|
|
|
* |
|
Christian Michalik |
|
|
82,997 |
|
|
|
* |
|
Neal Moszkowski |
|
|
25,107 |
|
|
|
* |
|
Charles G. Berg |
|
|
380,799 |
|
|
|
* |
|
Heath G. Schiesser |
|
|
520,979 |
|
|
|
1.2 |
|
Todd S. Farha(2) |
|
|
618,835 |
(5) |
|
|
1.5 |
|
Thomas L. Tran |
|
|
75,000 |
|
|
|
* |
|
Paul L. Behrens(3) |
|
|
197,977 |
(5) |
|
|
* |
|
Anil Kottoor(4) |
|
|
|
(5) |
|
|
* |
|
Adam T. Miller |
|
|
64,605 |
|
|
|
* |
|
Thomas F. ONeil III |
|
|
70,912 |
|
|
|
* |
|
All Directors and Executive Officers as a Group (20 persons) |
|
|
1,689,991 |
|
|
|
3.9 |
|
|
|
|
* |
|
Less than one percent |
|
(1) |
|
Certain of our executive officers and Directors hold their shares in
brokerage accounts where there may be a loan balance from time to time
that is secured by all of the assets in the account, including shares
of our common stock. Accordingly, even though there may be
substantial assets in the account, the shares of our stock in these
accounts could technically be sold in a margin sale. |
|
(2) |
|
Mr. Farha resigned his positions as chairman and as President and
Chief Executive Officer effective January 25, 2008 and ceased
employment with us on March 31, 2008. |
|
(3) |
|
Mr. Behrens resigned his positions as Senior Vice President and Chief
Financial Officer effective January 25, 2008 and ceased employment
with us on March 31, 2008. |
|
(4) |
|
Mr. Kottoors employment was terminated effective December 19, 2008. |
|
(5) |
|
Based on information known to the Company. |
How is beneficial ownership determined?
For purposes of the preceding table, beneficial ownership is determined in accordance with
Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the Exchange Act), pursuant to
which a person or group of persons is deemed to have beneficial ownership of any common stock
that such person or group has the right to acquire within 60 days after June 17, 2009. For
purposes of computing the percentage of outstanding common stock beneficially owned by each person
named above, any shares that such person has the right to acquire within 60 days after June 17,
2009 are deemed outstanding but such shares are not deemed to be outstanding for purposes of
computing the percentage ownership of any other person. Each person has sole voting and
dispositive power with respect to all of the shares of common stock shown as beneficially owned,
subject to community property laws, where applicable. The table below provides additional detail
regarding managements securities ownership.
4
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Included |
|
Excluded |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock |
|
Stock Options |
|
Restricted |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options that |
|
that Vest in |
|
Stock Units that |
|
Performance |
|
|
|
|
|
|
Unvested |
|
Vested Stock |
|
Vest within |
|
More than 60 |
|
Vest in More |
|
Shares that Vest in |
Name |
|
Common Stock |
|
Common Stock |
|
Options |
|
60 Days |
|
Days |
|
than 60 Days |
|
More than 60 Days |
David Gallitano |
|
|
|
|
|
|
14,354 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Robert Graham |
|
|
2,777 |
|
|
|
|
|
|
|
14,483 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Regina Herzlinger |
|
|
18,331 |
|
|
|
|
|
|
|
28,628 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Kevin Hickey |
|
|
26,063 |
|
|
|
|
|
|
|
18,290 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Alif Hourani |
|
|
581 |
|
|
|
|
|
|
|
18,290 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ruben King-Shaw, Jr. |
|
|
15,081 |
|
|
|
|
|
|
|
10,665 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Christian Michalik |
|
|
31,050 |
|
|
|
|
|
|
|
51,947 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Neal Moszkowski |
|
|
10,822 |
|
|
|
|
|
|
|
14,285 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Charles G. Berg |
|
|
80,799 |
|
|
|
75,000 |
|
|
|
187,500 |
|
|
|
37,500 |
|
|
|
75,000 |
|
|
|
|
|
|
|
|
|
Heath G. Schiesser |
|
|
101,904 |
|
|
|
175,709 |
|
|
|
217,543 |
|
|
|
25,823 |
|
|
|
324,675 |
|
|
|
|
|
|
|
|
|
Todd S. Farha |
|
|
618,835 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
130,000 |
(1) |
Thomas L. Tran |
|
|
|
|
|
|
50,000 |
|
|
|
|
|
|
|
25,000 |
|
|
|
75,000 |
|
|
|
8,232 |
|
|
|
|
|
Paul L. Behrens |
|
|
197,977 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Anil Kottoor |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adam T. Miller |
|
|
13,732 |
|
|
|
14,054 |
|
|
|
35,409 |
|
|
|
1,410 |
|
|
|
80,458 |
|
|
|
10,681 |
|
|
|
|
|
Thomas F. ONeil III |
|
|
8,412 |
|
|
|
37,500 |
|
|
|
25,000 |
|
|
|
|
|
|
|
75,000 |
|
|
|
13,109 |
|
|
|
|
|
All Directors and
Executive Officers
as a Group (20
persons) |
|
|
329,755 |
|
|
|
479,928 |
|
|
|
774,889 |
|
|
|
105,419 |
|
|
|
1,007,505 |
|
|
|
72,535 |
|
|
|
130,000 |
|
|
|
|
(1) |
|
Pursuant to an award agreement dated June 6, 2005, Mr. Farha was
eligible to receive a maximum of 130,000 shares of our common stock
based upon the achievement of certain performance criteria.
Specifically, Mr. Farha was eligible to earn, if any shares, a (i)
threshold of 32,500 shares, (ii) target of 65,000 shares, or (iii) a
maximum of 130,000 shares on June 6, 2008 based on the achievement of
compounded annual percentage increases in diluted net income per share
over the three-year period measured from January 1, 2005 through
December 31, 2007. It has not yet been determined whether Mr. Farha
has earned any of these shares. See Potential Payments to Named
Executive Officers upon Termination or Change in Control above for a
discussion of Mr. Farhas separation agreement and the treatment of
these shares. |
5
PROPOSAL NUMBER ONE ELECTION OF DIRECTORS
Background to Proposal Number One
Our certificate of incorporation currently provides for a Board of Directors divided into
three classes, as nearly equal in number as the then total number of Directors constituting the
entire Board permits, with the term of office of one class expiring each year at the annual meeting
of shareholders. Each class of Directors is currently elected for a term of three years.
The Board of Directors presently consists of ten persons: Charles G. Berg, David J. Gallitano,
D. Robert Graham, Regina E. Herzlinger, Kevin F. Hickey, Alif A. Hourani, Ruben Jose King-Shaw,
Jr., Christian P. Michalik, Neal Moszkowski and Heath G. Schiesser. On January 25, 2008, the
Board, acting upon the recommendation of the Nominating and Corporate Governance Committee,
appointed Messrs. Schiesser and Berg to serve as Directors. On March 23, 2009, the Board, acting
upon the recommendation of the Nominating and Corporate Governance Committee, appointed Mr.
Gallitano to serve as a Director. Therefore, Messrs. Schiesser, Berg and Gallitano are being
considered for election by the shareholders for the first time at our 2009 annual meeting. The
Board of Directors currently has two vacancies. The Nominating and Corporate Governance Committee
and management are currently assessing possible candidates to fill these vacancies.
The term of the current Class I Directors (comprised of Messrs. Gallitano, Hickey and
Schiesser and Dr. Herzlinger) was to expire at our 2008 annual meeting of shareholders (the 2008
Annual Meeting); the term of the Class II Directors (comprised of Messrs. Graham, King-Shaw and
Michalik) will expire at our 2009 annual meeting of shareholders (the 2009 Annual Meeting); and
the term of the Class III Directors (comprised of Messrs. Berg, Hourani and Moszkowski) will expire
at our 2010 annual meeting of shareholders (the 2010 Annual Meeting). Because we did not hold
the 2008 Annual Meeting, Class I Directors were not elected in 2008 and, accordingly, the
successors to the Class I Directors will be elected and qualified at the 2009 Annual Meeting.
Relationship of Proposal One to Proposals Two and Three
As discussed below, pursuant to Proposals Two and Three, the shareholders are being asked to
approve and adopt amendments to our certificate of incorporation to declassify our Board of
Directors and to provide that Directors may be removed with or without cause (except for Class III
Directors currently serving the remaining portion of a multi-year term, who, if the amendment is
approved and adopted, could not be removed without cause prior to the end of their current
multi-year term). Because both the Class I and Class II Directors are up for election at the 2009
Annual Meeting, if they are elected and the proposed amendments to our certificate of incorporation
are approved, the Class I and Class II Directors will be up for election for one-year terms at the
2009 Annual Meeting. However, if the proposed amendments are not approved, the Class I Directors
(if elected) will serve for a two-year term to expire at our 2011 annual meeting of shareholders
(the 2011 Annual Meeting) and the Class II Directors (if elected) will serve for a three-year
term to expire at our 2012 annual meeting of shareholders (the 2012 Annual Meeting).
Class I Director Nominees
The Board of Directors proposes that David J. Gallitano, Regina E. Herzlinger, Kevin F. Hickey
and Heath G. Schiesser be elected to serve as Class I Directors. The Board proposes that each of
the Directors serve (i) for a one-year term to expire at the 2010 Annual Meeting, if Proposal Two
and Proposal Three are approved by the shareholders or (ii) for a two-year term to expire at the
2011 Annual Meeting, if Proposal Two and Proposal Three are not approved by the shareholders.
Unless a shareholder WITHHOLDS AUTHORITY, the holders of proxies representing shares of common
stock will vote FOR the election of David J. Gallitano, Regina E. Herzlinger, Kevin F. Hickey and
Heath G. Schiesser as Class I Directors. All of these nominees have informed the Board of
Directors that they are willing to serve as Directors. Except as discussed below with respect to
Mr. Schiesser, the Board of Directors has no reason to believe that any nominee will decline or be
unable to serve as a Director. However, if a nominee shall be unavailable for any reason, then the
proxies may be voted for the election of such person as may be recommended by the Board of
Directors.
On June 26, 2009, Mr. Schiesser, our President and Chief Executive Officer and a Director,
informed the Board of Directors that he intends to resign from his current officer and Director
positions upon the appointment of a new President and Chief Executive Officer. After being so
informed, the Board of Directors considered his nomination to stand for election as a Director at
the 2009 Annual Meeting. In light of Mr. Schiessers continuing tenure, the Board of Directors
has reaffirmed his nomination. The Board of Directors has formed a Committee on Leadership and
Executive Succession, comprised of certain Directors and a non-Director executive officer, to focus
on leadership transition at our Company.
6
Class II Director Nominees
The Board of Directors proposes that D. Robert Graham, Ruben Jose King-Shaw, Jr. and Christian
P. Michalik be elected to serve as Class II Directors. The Board proposes that each of the
Directors serve (i) for a one-year term to expire at the 2010 Annual Meeting, if Proposal Two and
Proposal Three are approved by the shareholders or (ii) for a three-year term to expire at the 2012
Annual Meeting, if Proposal Two and Proposal Three are not approved by the shareholders. Unless a
shareholder WITHHOLDS AUTHORITY, the holders of proxies representing shares of common stock will
vote FOR the election of D. Robert Graham, Ruben Jose King-Shaw, Jr. and Christian P. Michalik.
All of these nominees have informed the Board of Directors that they are willing to serve as
Directors. The Board of Directors has no reason to believe that any nominee will decline or be
unable to serve as a Director. However, if a nominee shall be unavailable for any reason, then the
proxies may be voted for the election of such person as may be recommended by the Board of
Directors.
The affirmative vote of a plurality of the votes of the shares present by person or
represented by proxy at the meeting and entitled to vote in the election of Directors is required
to elect a nominee.
THE BOARD OF DIRECTORS RECOMMENDS THAT THE SHAREHOLDERS VOTE FOR
THE ELECTION OF DAVID J. GALLITANO, REGINA E. HERZLINGER,
KEVIN F. HICKEY, HEATH G. SCHIESSER, D. ROBERT GRAHAM,
RUBEN JOSE KING-SHAW, JR. AND CHRISTIAN P. MICHALIK
7
BOARD OF DIRECTORS
Certain Information Regarding Our Directors
The following is certain information regarding our Directors and their ages as of June 5,
2009:
Nominees
Class I
David J. Gallitano (age 61) has been a member of our Board since March 2009. Mr. Gallitano
has been President of Tucker, Inc., a private investment and consulting firm, since 2002. Prior to
that, Mr. Gallitano was the Chairman and Chief Executive Officer of APW, Ltd., a manufacturer of
specialized industrial products and provider of related services, from 2003 to 2005. From 1993 to
2002, Mr. Gallitano served as Chairman and Chief Executive Officer of Columbia National Inc., a
mortgage banking company. From 1986 to 1993 Mr. Gallitano was the Executive Vice President,
Principal Transactions Group, for PaineWebber Incorporated. From 1982 to 1986 Mr. Gallitano was
with General Electric Corporation, first as Vice President, Strategic Planning and Business
Development for General Electric Credit Corporation and then as President and Chief Executive
Officer of General Electric Mortgage Capital Corporation. Mr. Gallitano was a consultant with
McKinsey & Company from 1975 to 1982 and he served as an electronics specialist with the United
States Air Force from 1966 to 1970. Mr. Gallitano currently serves on the board of directors of
The Hanover Insurance Group, Inc., a provider of a variety of commercial and personal insurance
products, where he also serves on the audit committee of the board. Mr. Gallitano holds a Bachelor
of Business Administration from The George Washington University and a Master of Business
Administration from the University of Chicago.
Regina E. Herzlinger (age 65) has been a member of our Board since August 2003.
Dr. Herzlinger is the Nancy R. McPherson Professor of Business Administration at the Harvard
Business School and has been teaching at Harvard since 1971. Dr. Herzlinger serves as a director
of a privately-held company. Dr. Herzlinger received her undergraduate degree from the
Massachusetts Institute of Technology and her Doctorate from Harvard Business School.
Kevin F. Hickey (age 57) has been a member of our Board since November 2002. Since January
2008, Mr. Hickey has served as Principal of HES Advisors, a strategic advisory firm serving the
health care, health care technology and life sciences industries. Mr. Hickey also currently serves
as a Senior Advisor to Verisk, Inc., a company specializing in health care predictive analytics.
From January 2006 to December 2007, Mr. Hickey served as President of D2Hawkeye, Inc. (now a part
of Verisk, Inc.). From October 1998 until January 2005, Mr. Hickey served as the Chairman and
Chief Executive Officer of IntelliClaim, Inc., a privately-held application service provider that
provides insurance payors with capabilities for enhancing claim processing efficiency and
productivity. From September 1997 until August 1998, Mr. Hickey was Executive Vice President of
Operations and Technology for Oxford Health Plans, Inc. Mr. Hickey also serves as a director of a
privately-held company. Mr. Hickey received his undergraduate degree from Harvard University, a
Master in Health Services Administration from the University of Michigan and a Juris Doctorate from
Loyola College of Law.
Heath G. Schiesser (age 41) has served as our President and Chief Executive Officer and as a
member of our Board since January 2008. Mr. Schiesser originally joined WellCare in 2002 as Senior
Vice President of Marketing and Sales. From January 2005 to July 2006, Mr. Schiesser also served
as President of WellCare Prescription Insurance. From July 2006 to January 2008, Mr. Schiesser
served as Senior Advisor to WellCare. Prior to joining WellCare, Mr. Schiesser worked at the
management consulting firm of McKinsey & Company, co-founded an online pharmacy for Express
Scripts, and worked in the development of new ventures. A graduate of Trinity University, Mr.
Schiesser received a Master of Business Administration from Harvard University.
On June 26, 2009, Mr. Schiesser, our President and Chief Executive Officer and a Director,
informed the Board of Directors that he intends to resign from his current officer and Director
positions upon the appointment of a new President and Chief Executive Officer. After being so
informed, the Board of Directors considered his nomination to stand for election as a Director at
the 2009 Annual Meeting. In light of Mr. Schiessers continuing tenure, the Board of Directors
has reaffirmed his nomination.
Class II
D. Robert Graham (age 72) has been a member of our Board since April 2007. Senator Graham is
currently Chair of the Board of Oversight of the Bob Graham Center for Public Service, a political
and civic leadership center at the University of
8
Florida and the University of Miami. From
September 2005 until June 2006, Senator Graham served a one-year term as a senior Fellow at Harvard
Universitys John F. Kennedy School of Government. From January 1987 to January 2005, he served in
the United States Senate. From January 1979 to January 1987 Senator Graham was the Governor of the
State of Florida. Senator Graham received his Bachelor of Arts degree from the University of
Florida and his Bachelor of Laws degree from Harvard Law School.
Ruben José King-Shaw, Jr. (age 47) has been a member of our Board since August 2003. Since
September 2008, Mr. King-Shaw has served as Chief Executive Officer of All-Med Services of Florida,
Inc., a durable medical supplies, respiratory therapy and infusion pharmacy. Mr. King-Shaw has
served as Chairman and Chief Executive Officer of Mansa Equity Partners Inc., a private equity
investment and advisory firm specializing in the health care sector, since July 2006. From October
2004 until June 2006, Mr. King-Shaw was a partner of Pine Creek Healthcare Capital, LLC and from
February 2004 until February 2005, he served as President of United Biosource. Mr. King-Shaw
served as Senior Advisor to the Secretary of the Department of the Treasury from January 2003 to
June 2003. From July 2001 to April 2003, Mr. King-Shaw served as Chief Operating Officer and
Deputy Administrator of the federal governments Centers for Medicare & Medicaid Services. Prior
to that, from January 1999 to July 2001, he served as Secretary of the Agency for Health Care
Administration of the State of Florida. Mr. King-Shaw serves as a director of several
privately-held companies. Mr. King-Shaw received his undergraduate degree from Cornell University
and a Master of Business Administration and a Master in Health Services Administration from Florida
International University.
Christian P. Michalik (age 40) has been a member of our Board since May 2002. Since July
2004, Mr. Michalik has served as Managing Director of Kinderhook Industries, a private equity
investment firm. Previously he was a partner in Soros Private Equity Partners LLC, the private
equity investment business of Soros Fund Management LLC, from January 1999 through December 2003.
From 1997 to 1998, Mr. Michalik was an investment manager with Capital Resource Partners, a private
equity investment firm. From 1995 to 1996, Mr. Michalik was an associate at Colony Capital, a real
estate investment firm. Mr. Michalik serves as a director of several privately-held companies.
Mr. Michalik received his undergraduate degree from Yale University and a Master of Business
Administration from Harvard Business School.
Directors continuing in office
Charles G. Berg (age 51) has served as our Executive Chairman and as a member of our Board
since January 2008. Mr. Berg also served as senior advisor to Welsh, Carson, Anderson & Stowe, a
private equity firm from January 2007 until April 2009. From July 2004 to September 2006, Mr. Berg
served as an executive of UnitedHealth Group. From April 1998 to July 2004, Mr. Berg held various
executive positions with Oxford Health Plans, Inc., which included Chief Executive Officer from
November 2002 to July 2004, President and Chief Operating Officer from March 2001 to November 2002,
and Executive Vice President, Medical Delivery, from April 1998 to March 2001. Mr. Berg serves as
a director of DaVita, Inc. Mr. Berg received his undergraduate degree from Macalester College and a
Juris Doctorate from the Georgetown University Law Center.
Alif A. Hourani (age 56) has been a member of our Board since August 2003. Since 1997, Mr.
Hourani has served as Chairman and Chief Executive Officer, currently as Executive Chairman, of
Pulse Systems, Inc., a practice management and clinical records software company. From 1987 to
1997, Mr. Hourani held various positions, including Chief Executive Officer of Physician
Corporation of America/Data Systems, Senior Vice President of Management Information Systems of
Physician Corporation of America and Manager of Computer Engineering at the Wolf Creek Nuclear
Operating Corporation. Mr. Hourani serves as a director of the Kansas Heart Hospital. Mr. Hourani
received his undergraduate degree from the University of Lyon and a Master of Science degree and
Doctorate from the University of Strasbourg.
Neal Moszkowski (age 43) has been a member of our Board since May 2002, serving as chairman
from May 2002 through October 2006. Since April 2005, Mr. Moszkowski has been Co-Chief Executive
Officer of TowerBrook Capital Partners LP, a private equity investment company. Prior to joining
TowerBrook, Mr. Moszkowski was Managing Director and Co-Head of Soros Private Equity Partners LLC,
the private equity investment business of Soros Fund Management LLC, where he served since August
1998. From August 1993 to August 1998, Mr. Moszkowski served as Vice President and Executive
Director in the Principal Investment area for Goldman, Sachs & Co. and Affiliates. Mr. Moszkowski
serves as a director of Bluefly, Inc., Integra LifeSciences Holdings Corporation and Spheris, Inc.
as well as several privately-held companies. Mr. Moszkowski received his undergraduate degree from
Amherst College and a Master of Business Administration from the Graduate School of Business of
Stanford University.
9
EXECUTIVE OFFICERS
Rex M. Adams (age 47) has served as our Chief Operating Officer since September 2008. Prior
to joining WellCare, Mr. Adams was the President and Chief Executive Officer of AT&T Incorporateds
East Region, from January 2007 to March 2008. For the period prior to AT&Ts acquisition of
BellSouth, Mr. Adams was an officer of BellSouth Corporation from July 2001 to December 2006,
serving in various leadership positions. During the merger transition period from February 2006 to
December 2006, Mr. Adams served as Web Development Officer. From December 2004 to January 2006,
Mr. Adams was the President of BellSouth Wholesale Services, and had similar responsibilities as
President and Chief Executive Officer of AT&T East Region. From January 2004 to November 2004,
Mr. Adams was Vice-President, Product Development and Management of BellSouth Corporation, where he
was responsible for product profitability, development and commercialization. From July 2001 to
November 2004, Mr. Adams was President of BellSouth Long Distance Services, where he was
responsible for profit and loss and all areas of BellSouths long distance business. From
September 2007 to October 2008, Mr. Adams served on the board of trustees for Yale-New Haven
Hospital, a premier teaching and research hospital, and as a member of its Finance and Audit
Committee. Mr. Adams holds a B.S. from the United States Military Academy at West Point and a
Masters of Business Administration from the Harvard Business School.
Walter W. Cooper (age 46) joined us in October 2006 as Senior Vice President of Strategic
Initiatives. He currently holds the position of Senior Vice President of Marketing and Sales and
has recently acted as the interim Senior Vice President of Human Resources and is currently acting
as the interim Senior Vice President of Health Services. Prior to joining WellCare, Mr. Cooper
served in senior-level positions with UnitedHealth Group, including positions as Senior Vice
President of United Retiree Solutions, Vice President of Marketing and Product and Vice President
of Strategic Initiatives for Specialized Care Services from November 2004 to September 2006. Mr.
Cooper received his Bachelor of Science in Mechanical Engineering and his Masters in Business
Administration degrees from Gannon University.
Michael L. Cotton (age 48) joined us in December 2005 and holds the position of President,
South Division. Prior to joining the Company, Mr. Cotton was World Wide Partner and Managing
Director for Mercer Human Resources Consulting from October 2001 to December 2005. Prior to
joining Mercer, Mr. Cotton was President and Chief Executive Officer of Mid-Valley CareNet, a
physician hospital organization, from November 1998 to October 2001. Mr. Cotton attended the Ohio
State University and received his undergraduate degree from Franklin University and a Masters in
Business Administration from Cleveland State University.
Alec Cunningham (age 42) joined us in January 2005. He has held several positions within the
Company, including Vice President of Business Development, Senior Vice President of Government
Relations, and currently President, Florida and Hawaii Division. Prior to joining us, Mr.
Cunningham held several positions with WellPoint Health Networks, Inc. from September 1996 to
December 2004, most recently Vice President of Business Development and Compliance. From August
1994 to September 1996, Mr. Cunningham worked for the Oklahoma Health Care Authority developing a
statewide Medicaid managed care program. Mr. Cunningham received his undergraduate degree from
Oklahoma State University and his Master in Business Administration from the University of Southern
California.
Adam T. Miller (age 43) joined us in January 2006. He has held several positions within the
Company, including currently Senior Vice President, National Medicare and Government Relations and
previously President, National Medicare, Chief Operating Officer of our Medicare Prescription Drug
Plan and Private Fee-For-Service businesses. From July 2001 to November 2005, Mr. Miller ran
UnitedHealth Groups Arizona Medicaid program and a related Medicare Special Needs program.
Earlier in his career, Mr. Miller was with General Electric in its Medical Systems business (GE
Medical) in a series of strategy, business development and operational roles, from May 1997 to
June 2001. In his last role at GE Medical, Mr. Miller served as Vice President and General Manager
of its global Cardiology Systems division. Prior to joining GE Medical, Mr. Miller was with the
Boston Consulting Group where he worked with clients in the pharmaceutical, managed care and
medical device industries on issues of growth and profitability enhancement, from 1993 to
1997. Mr. Miller is a graduate of Harvard Business School and the Wharton School of Business at
The University of Pennsylvania.
Thomas F. ONeil III (age 52) was appointed our executive Vice Chairman on June 3, 2009.
Prior to that, he served as our Senior Vice President, General Counsel and Secretary since
April 2008. Prior to joining WellCare, Mr. ONeil was a partner of the law firm DLA Piper US LLP
and its predecessor from June 2002 through March 2008. From December 1995 to June 2002, Mr. ONeil
served as Vice President, Chief Litigation Counsel of MCI Communications Corp., Senior Vice
President, Chief Counsel of MCI WorldCom, Inc. and General Counsel of The MCI Group. Earlier in
his career Mr. ONeil was a partner of the law firm of Hogan & Hartson LLP and he served as
Assistant U.S. Attorney at the U.S. Department of Justice from March 1986 to
December 1989. Mr. ONeil received his A.B. from Dartmouth College and his Juris Doctorate
10
from Georgetown University Law Center. Mr. ONeil is a member of the Board of Regents of Georgetown
University and the Board of Visitors of Georgetown University Law Center.
Daniel M. Parietti (age 46) joined us in September 2002 and has served in various capacities,
currently as President, North Division. From September 2001 to January 2002, Mr. Parietti served
as Chief Operating Officer of La Cruz Azul de Puerto Rico, a Puerto Rican health plan. From May
2000 to September 2001, Mr. Parietti served as Vice President, Network and Delivery Systems
Management for Health Net, Inc. From September 1993 to May 2000, Mr. Parietti worked in various
leadership positions for Humana, Inc. Mr. Parietti received his undergraduate degree from the
United States Military Academy at West Point, and a Masters in Business Administration from George
Mason University.
Jonathan P. Rich (age 48) has served as our Senior Vice President and Chief Compliance Officer
since August 2008. From July 2006 to July 2008, Mr. Rich was the General Counsel and Chief
Compliance Officer for health insurer Aveta Inc. From 1998 to 2006, Mr. Rich was a senior
executive at Oxford Health Plans, Inc. serving first as Vice President and Director of Litigation
and Legal Affairs and later as Senior Vice President and General Counsel. From 1989 to 1998,
Mr. Rich was an associate at the law firm of Simpson, Thacher & Bartlett in New York. Mr. Rich is
a graduate of the University of North Carolina and Columbia University Law School.
Timothy S. Susanin (age 45) joined WellCare in November 2008 as our Vice President and Chief
Counsel Dispute Management. Since June 2009 Mr. Susanin has been our Senior Vice President,
General Counsel and Secretary. Prior to joining WellCare, Mr. Susanin was with the Gibbons law
firm from 2001 to October 2008, first as counsel and then as partner. Mr. Susanin was an Assistant
U.S. Attorney for the District of Columbia and the Eastern District of Pennsylvania from 1992 to
1998 and an Associate Independent Counsel on the Whitewater investigation from 1998 to 2000. He
also served in the U.S. Navy Judge Advocate Generals Corps from 1988 to 1992. Mr. Susanin
received his undergraduate degree from Franklin & Marshall College and his Juris Doctorate from the
Villanova University School of Law.
Thomas L. Tran (age 52) has served as our Senior Vice President and Chief Financial Officer
since July 2008. Prior to joining WellCare, Mr. Tran was the President, Chief Operating Officer
and Chief Financial Officer of CareGuide, Inc., a publicly-traded population health management
company, from June 2007 to June 2008. From July 2005 to June 2007, Mr. Tran was Senior Vice
President and Chief Financial Officer of Uniprise, one of the principal operating businesses of
UnitedHealth Group that manages health care benefits programs for employers. From December 1998 to
July 2005, Mr. Tran served as Chief Financial Officer of ConnectiCare, Inc., an HMO based in
Connecticut. Prior to ConnectiCare, Mr. Tran was Chief Financial Officer of Blue Cross Blue Shield
of Massachusetts from May 1996 to July 1997, and Vice President of Finance and Controller of CIGNA
HealthCare from February 1993 to May 1996. Mr. Tran holds a degree in accounting from Seton Hall
University and a Masters of Business Administration in Finance from New York University.
Certain Legal Proceedings
As previously disclosed, in connection with government investigations, five putative
shareholder derivative actions were filed between October 29, 2007 and November 15, 2007, naming as
defendants certain of our current and former officers and Directors. The first two of these
putative shareholder derivative actions, entitled Rosky v. Farha, et al. and Rooney v. Farha, et
al., respectively, are supposedly brought on behalf of the Company and were filed in the United
States District Court for the Middle District of Florida. Two additional actions, entitled
Intermountain Ironworkers Trust Fund v. Farha, et al., and Myra Kahn Trust v. Farha, et al., were
filed in Circuit Court for Hillsborough County, Florida. All four of these actions are asserted
against all Company directors (and former director Todd Farha) except for David Gallitano, D.
Robert Graham, Heath Schiesser and Charles Berg and also name the Company as a nominal defendant. A
fifth action, entitled Irvin v. Behrens, et al., was filed in the United States District Court for
the Middle District of Florida and asserts claims against all Company directors (and former
director Todd Farha) except Heath Schiesser, David Gallitano and Charles Berg and against two
former Company officers, Paul Behrens and Thaddeus Bereday. All five actions contend, among other
things, that the defendants allegedly allowed or caused the Company to misrepresent its reported
financial results, in amounts unspecified in the pleadings, and seek damages and equitable relief
for, among other things, the defendants supposed breach of fiduciary duty, waste and unjust
enrichment. The three actions in federal court have been consolidated. Subsequent to that
consolidation, an additional derivative complaint entitled City of Philadelphia Board of Pensions
and Retirement Fund v. Farha, et al. was filed in the same federal court, but thereafter was
consolidated with the existing consolidated action. A motion to consolidate the two state court
actions, to which all parties consented, was granted, and plaintiffs filed a consolidated complaint
on April 7, 2008. On October 31, 2008, amended complaints were filed in the federal court and the
state court derivative actions. On December 30, 2008, the Company filed substantially similar
motions to dismiss both actions, contesting, among other things, the standing of the plaintiffs in
each of these derivative actions to prosecute the purported claims in the Companys name. In an
Order entered on March 30, 2009 in the consolidated federal action, the court denied the motions to
dismiss the Second Amended
11
Consolidated Complaint. On April 28, 2009, in the consolidated state
action, the court denied the motions to dismiss the Second Amended Consolidated Complaint. On
April 29, 2009, upon the recommendation of the Nominating and Corporate Governance Committee of the
Companys Board of Directors, the Board adopted a resolution forming a Special Litigation
Committee, comprised of a newly-appointed independent director, David J. Gallitano, to investigate
the facts and circumstances underlying the claims asserted in the federal and state derivative
cases and to take such action with respect to such claims as the Special Litigation Committee
determines to be in the best interests of the Company. On May 1, 2009, the Special Litigation
Committee filed in the consolidated federal action a motion to stay the matter until November 2009
to allow the Special Litigation Committee to complete its investigation, and following a hearing on
May 14, 2009, the Court granted that motion and stayed the federal action. The Special Litigation
Committee filed a substantially identical motion in the consolidated
state action, and a hearing on the motion has been set for
September 2, 2009. At this time, neither the Company nor any of its subsidiaries can predict the
probable outcome of these claims. For more information related to the Special Litigation
Committee, please see Corporate Governance and Related Matters below.
CORPORATE GOVERNANCE AND RELATED MATTERS
Corporate Governance Guidelines
The Board has developed and adopted Corporate Governance Guidelines to promote the functioning
of the Board and its committees. Among other things, the corporate governance guidelines set forth
criteria regarding Board member selection and qualification, establishment of committees and
committee composition, executive sessions, management succession and director compensation. The
guidelines also address the Boards expectations of each Director in furtherance of the Boards
primary responsibility of exercising its business judgment in the best interests of the Company.
In particular, the guidelines address meeting attendance and participation, other directorships and
access to independent advisors as well as new director orientation. The Corporate Governance
Guidelines also require that the Board conduct an annual performance evaluation to determine
whether it and its committees are functioning effectively. The Corporate Governance Guidelines are
available on our website at www.wellcare.com. Alternatively, any shareholder may request a print
copy of our Corporate Governance Guidelines by contacting us as described in the section entitled
Requests for More Information below.
Director Independence
Independence Standards
Our Corporate Governance Guidelines provide that a majority of the members of our Board must
meet the criteria of independence as required by the listing standards of the New York Stock
Exchange (the NYSE). In addition, each member of the Boards Audit Committee, Compensation
Committee and Nominating and Corporate Governance Committee must be independent. No Director
qualifies as independent unless the Board determines that the Director has no direct or indirect
material relationship with the Company. The Board reviews the independence of its members by
requiring that each member complete disclosure and independence questionnaires and by considering
all transactions and relationships between each Director or any member of his or her immediate
family and the Company and its subsidiaries. The purpose of this review is to determine whether
any such relationships or transactions are inconsistent with a determination that the Director is
independent. In making independence determinations, the Board applies the standards of the NYSE as
follows, in addition to any other relevant facts and circumstances:
|
|
|
A Director, who is, or has been within the last three years, an employee of the Company
or any subsidiary, or whose immediate family member is, or has been within the last three
years, an executive officer of the Company, is not independent until three years after the
end of such employment relationship; |
|
|
|
|
A Director who has received, or has an immediate family member who has received, more
than $120,000 per year in direct compensation from the Company or any subsidiary, other
than director and committee fees and pension or other forms of deferred compensation for
prior service (provided such compensation is not contingent in any way on continued
service), is not independent until three years after he or she ceases to receive more than
$120,000 per year in such compensation; |
|
|
|
|
A Director is not independent if he or she: is a current partner or employee of the firm
that is the internal or external auditor of the Company or any subsidiary; has an immediate
family member who is a current partner of such firm; has an immediate family member who is
a current employee of such firm and who personally worked on the Companys audit; was, or
has, an immediate family member who was, within the last three years, a partner or employee
of such firm and personally worked on the Companys audit within that time; |
|
|
|
|
A Director or an immediate family member who is, or has been within the last three
years, employed as an executive officer of another company where any of our present
executives at the same time serves or served on that companys |
12
|
|
|
compensation committee, is
not independent until three years after the end of such service or the employment
relationship; and |
|
|
|
|
A Director who, or whose immediate family member, is a current executive officer of a
company that has made payments to, or received payments from, our Company or any of our
subsidiaries for property or services in an amount which, in any of the last three fiscal
years, exceeded the greater of $1 million or 2% of such other companys consolidated gross
revenues, is not independent until three years after such payments fall below such
threshold. |
In addition, the Exchange Act and the NYSE rules impose additional independence and
qualification standards on our Audit Committee members. Under these standards, each Audit
Committee member, in addition to meeting the definition of independence applicable to all
Directors, is prohibited from having any direct or indirect financial relationship with the
Company, and cannot be an affiliate of the Company or any subsidiary of the Company. The Board has
determined that each member of the Audit Committee satisfies these additional standards.
Independent Directors
Under the standards set forth above, based upon recommendations from the Nominating and
Corporate Governance Committee of the Board (the Nominating Committee), the Board has determined
that seven of its current members, including each of the members of the Audit Committee, the
Compensation Committee and the Nominating Committee, are independent. The members that the Board
has determined are independent are Senator Graham, Dr. Herzlinger and Messrs. Gallitano, Hickey,
Hourani, Michalik and Moszkowski.
In making this determination, the Board considered the recommendation of the Nominating
Committee as well as the following relationships:
|
|
|
Senator Graham and/or his immediate family members have an ownership interest of
approximately 23% in The Graham Companies, the landlord under a lease agreement with one of
our subsidiaries with respect to office space in south Florida. The Board concluded that
this relationship did not impair Senator Grahams independence, primarily because we have
had a relationship with The Graham Companies for many years prior to Senator Graham
becoming a member of our Board. |
|
|
|
|
Mr. Hickey is a senior advisor to D2Hawkeye, Inc., now a part of Verisk, Inc., a company
where he previously served as President from January 2006 to December 2007. In February
2007, we entered into a services contract with D2Hawkeye pursuant to which D2Hawkeye has
developed an internet-based portal for certain of our health care providers. The Board has
reviewed the salient facts regarding this relationship, including compensation received
from D2Hawkeye by Mr. Hickey, Mr. Hickeys former ownership interest in D2Hawkeye, amounts
paid by us to D2Hawkeye, D2Hawkeyes revenues, the fact that D2Hawkeye has since been
purchased by a larger company, Insurance Services Office, Inc. (ISO), and other facts.
Following this review, our Board concluded that this relationship did not impair Mr.
Hickeys independence under the standards set forth above. In particular, our payments to
D2Hawkeye did not exceed the greater of $1 million or 2% of D2Hawkeyes gross revenues in
any year. |
|
|
|
|
Todd Farha, the Companys President and Chief Executive Officer until his resignation in
January 2008, in the past had invested in several funds managed, directly or indirectly, by
private equity firms affiliated with Messrs. Michalik and Moszkowski. In each case Mr.
Farhas investment represented less than 1% of the funds aggregate committed capital. Mr.
Farha also had a small direct investment in a company in which Mr. Michaliks firm held a
majority ownership interest. Based on a review of these circumstances, our Board
determined that these relationships did not impair the independence of Messrs. Michalik and
Moszkowski. In addition, Mr. Farha is a first cousin of Mr. Hourani. However, our Board
determined that this relationship did not impair Mr. Houranis independence. |
Non-Independent Directors
Mr. King-Shaw has been the Chief Executive Officer of All-Med Services of Florida, Inc., or
All-Med, since September 2008. Since December 2002, two of our subsidiaries have been parties to
agreements with All-Med pursuant to which All-Med provides durable medical equipment to members of
the Companys Florida health plans. Under these agreements, our subsidiaries paid All-Med an
aggregate amount in 2008 that exceeded both $1 million and 2% of All-Meds consolidated gross
revenues. Therefore, the Board has determined that Mr. King-Shaw is not independent.
The Board determined that Messrs. Schiesser and Berg are not independent based on the fact
that each also serves as an executive officer.
13
Board and Committee Meetings and Annual Meeting Attendance
During 2008, the Board of Directors held a total of 26 meetings. No incumbent Director
attended fewer than 75% of the aggregate number of meetings of the Board held during the period in
which the Director served on the Board and the number of meetings held by all committees of the
Board on which the Director served during the periods in which he or she served.
As stated in our Corporate Governance Guidelines, we believe it is important for the members
of our Board to attend the annual meeting of shareholders. The Corporate Governance Guidelines
further provide that, to the extent reasonably practicable, we will endeavor to schedule a regular
meeting of the Board on the same date as the annual meeting of shareholders. No current member of
our Board attended our last annual meeting of shareholders in 2007.
Presiding Director
The Board has designated Mr. Hickey to preside over executive sessions of our non-management
and independent Directors. In addition, Mr. Hickey has been designated the presiding Director for
purposes of receiving communications from interested parties pursuant to the corporate governance
rules of the NYSE and from shareholders pursuant to rules of the SEC. You may express your
concerns, whether such concerns relate to accounting-related matters or otherwise, by contacting
the presiding Director through the communication channels set forth in the section entitled
Communications with Directors below.
Committees of the Board of Directors
The Board of Directors has established the following standing committees: Audit Committee,
Compensation Committee, Nominating Committee, Regulatory Compliance Committee and Health Care
Quality and Access Committee. The functions, responsibilities and members of each of these
standing committees are described briefly below. Each of these committees operates pursuant to a
charter which is posted on our website at www.wellcare.com. All members of the Audit Committee,
the Compensation Committee and the Nominating Committee are independent Directors under our
Director independence standards as described above and the corporate governance rules of the NYSE.
In addition, all members of our Audit Committee are independent Directors under the SEC rules for
Audit Committees and are financially literate under the NYSE corporate governance rules.
Our five standing committees are described below and the members of these committees are
identified in the following table.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nominating and |
|
|
|
|
|
|
|
|
|
|
Corporate |
|
Regulatory |
|
Health Care Quality |
|
|
Audit |
|
Compensation |
|
Governance |
|
Compliance |
|
and Access |
Director |
|
Committee |
|
Committee |
|
Committee |
|
Committee |
|
Committee |
Charles Berg
|
|
|
|
|
|
|
|
X |
|
|
David Gallitano
|
|
|
|
X (chair)
|
|
X
|
|
|
|
X |
D. Robert Graham
|
|
|
|
|
|
X
|
|
X (chair)
|
|
X |
Regina Herzlinger
|
|
X* (chair) |
|
|
|
|
|
|
|
|
Kevin Hickey
|
|
|
|
|
|
X (chair)
|
|
X
|
|
X |
Alif Hourani
|
|
X
|
|
X
|
|
|
|
|
|
X |
Ruben King-Shaw, Jr.
|
|
|
|
|
|
|
|
|
|
X (chair) |
Christian Michalik
|
|
X*
|
|
|
|
X |
|
|
|
|
Neal Moszkowski
|
|
|
|
X |
|
|
|
|
|
|
Heath Schiesser
|
|
|
|
|
|
|
|
|
|
X |
|
|
|
* |
|
Dr. Herzlinger and Mr. Michalik are our audit committee financial experts, as defined in
the Exchange Act, and each has accounting or related financial management expertise. |
Audit Committee
The principal purpose of the Audit Committee is to assist the Board in the oversight of the
integrity of our financial statements, our compliance with legal and regulatory requirements, the
qualification and independence of our independent auditors and the performance of our internal
audit function and independent auditors. The Audit Committee also appoints, reviews the plans and
results of the audit engagement and compensates and oversees the engagement and provision of
services
14
by our independent auditors. The Audit Committee pre-approves all audit, audit-related,
tax and other services conducted by our independent auditors. The Audit Committee also coordinates
with our Regulatory Compliance Committee and Health Care Quality and Access Committee regarding
regulatory compliance and quality measurement matters that may have an effect on our business,
financial statements, compliance policies or internal audit function. The Audit Committee held 18
meetings during 2008.
Dr. Herzlinger, Mr. Hourani and Mr. Michalik currently serve as the members of the Audit
Committee, with Dr. Herzlinger serving as chairperson. The Board has determined that each of the
members of the Audit Committee is financially literate and that each of Dr. Herzlinger and Mr.
Michalik is an audit committee financial expert as such term is defined under Item 407(d) of SEC
Regulation S-K. All members of the Audit Committee meet the independence requirements prescribed
by the NYSE and the Audit Committee independence requirements prescribed by the SEC.
Nominating and Corporate Governance Committee
The Nominating Committee is responsible for developing our Corporate Governance Guidelines and
for recommending those guidelines to the Board for adoption. The Nominating Committee is also
responsible for periodically reviewing the composition of the full Board to determine whether
additional Board members with different qualifications or areas of expertise are needed and making
recommendations to the Board regarding the size, composition and functions of the Board and its
committees. The Nominating Committee identifies and reviews the qualifications of new Director
nominees consistent with selection criteria established by the Board and recommends the slate of
nominees for inclusion in the proxy statement. The Nominating Committees process for selecting
nominees to the Board is described in more detail below under Nominating and Corporate Governance
Committees Process for Selecting Nominees to the Board. The Nominating Committee is also
responsible for overseeing the periodic evaluation of the performance of the Board and its
committees, for considering questions of independence and possible conflicts of interest of members
of the Board and executive officers and for ensuring we are compliant with NYSE corporate
governance listing requirements. The Nominating Committee held two meetings during 2008.
Compensation Committee
The Compensation Committee provides oversight and guidance for compensation and benefit
programs for our associates, executive officers and Board of Directors, reviews and approves the
compensation, including base salary and incentive awards and other significant terms of employment,
for our executive officers and reviews and make recommendations with respect to incentive
compensation plans, equity-based plans and Board compensation. The Compensation Committee reviews
and discusses the Compensation Discussion and Analysis, or the CD&A, with management and makes a
recommendation to the Board for inclusion of the CD&A in our proxy statement. The Compensation
Committee also reviews and approves performance goals and objectives (both at the corporate and
individual level) applicable to our named executive officers compensation (including our Chief
Executive Officer), evaluates the named executive officers performance in light of those goals and
objectives and has sole authority to determine the named executive officers compensation based on
this evaluation. The Compensation Committee held 12 meetings during 2008.
Under its charter, the Compensation Committee has the authority to obtain advice and
assistance from any officer or employee of the Company or from any outside legal expert or other
advisor. Pursuant to this authority, the Compensation Committee has engaged Watson Wyatt
Worldwide, or Watson Wyatt, as its compensation consultant.
In connection with our annual associate review and evaluation process, incentive compensation
decisions for our executive officers, including the named executive officers, are generally made by
the Compensation Committee in early March and are largely based on prior fiscal year Company and
individual performance. For example, in March of a given year, the following decisions are
typically made by the Compensation Committee for our executive officers: base salary adjustments;
annual cash bonus awards related to prior fiscal year performance based on targets established in
the prior fiscal year; long-term incentive awards based on targets established in the prior fiscal
year; new annual cash bonus targets; and new long-term incentive targets. Annual cash bonuses and
long-term incentive awards are discretionary (except as might otherwise be required by an
executives employment agreement) and are based on targets that are increased or decreased for
overall Company performance and individual performance, each as subjectively determined by the
Compensation Committee after receiving recommendations from our Chief Executive Officer for his
direct reports.
The Compensation Committee generally reviews the compensation being paid to the members of the
Board of Directors on an annual basis. The Compensation Committee works closely with the Chief
Executive Officer as well as Watson Wyatt
15
when evaluating committee fees (both annual retainer and
meeting fees) as well as the value of equity awards, if any, to be awarded to our Board members.
Additional information on executive compensation programs, including the respective roles of
the Compensation Committee, the Chief Executive Officer and Watson Wyatt, is provided in the CD&A
in this proxy statement.
Regulatory Compliance Committee
The principal purpose of the Regulatory Compliance Committee is to assist the Board in
overseeing our regulatory compliance program, including: (i) compliance with federal and state
laws, rules and regulations applicable to our business; and (ii) compliance with our corporate
ethics and compliance program and related policies by our employees, officers and Directors. The
Regulatory Compliance Committee held one meeting during 2008.
Health Care Quality and Access Committee
The principal purpose of the Health Care Quality and Access Committee is to assist the Board
by providing general oversight of our policies and procedures governing health care quality and
access for our members. In furtherance of this purpose, the Health Care Quality and Access
Committees primary responsibilities are to (i) establish and maintain the corporate definition of
health care quality and access and (ii) develop, review and approve our health care quality and
access strategy. The Health Care Quality and Access Committee held three meetings during 2008.
Special Committee and Special Litigation Committee
In addition to the above-described standing committees, the Board has established a Special
Committee and a Special Litigation Committee. In connection with the previously disclosed
government investigations, the Special Committee was formed in October 2007 to investigate
independently and otherwise assess the facts and circumstances raised in any federal or state
regulatory or enforcement inquiries (including, without limitation, any matters relating to
accounting and operational issues) and in any private party proceedings, and to develop and
recommend remedial measures to the Board for its consideration. The members of the Special
Committee are Neal Moszkowski (Chair), Christian Michalik and Ruben King-Shaw, Jr. During 2008,
the Special Committee met 12 times. In addition, on April 29, 2009, upon the recommendation of the
Nominating Committee, the Board formed a Special Litigation Committee, comprised of a
newly-appointed independent Director, to investigate the facts and circumstances underlying the
claims asserted in the federal and state derivative suits and to take such action with respect to
such claims as the Special Litigation Committee determines to be in the best interests of the
Company. David Gallitano is the sole member of the Special Litigation Committee.
Nominating and Corporate Governance Committees Process for Selecting Nominees to the Board
The Nominating Committee considers candidates for Board membership who are suggested by its
members and other Board members, as well as by management, shareholders and other interested
parties. The Nominating Committee may also retain a third-party search firm to identify candidates
from time to time. For example, the Nominating Committee retained a search firm to assist in
identifying and assessing Mr. Gallitano as a candidate for our Board. Shareholders can recommend a
prospective nominee for the Board by writing to our corporate secretary at our corporate
headquarters and providing the information required by our bylaws, along with whatever additional
supporting material the shareholder considers appropriate.
The Nominating Committees assessment of a nominees qualification for Board membership
includes, among other things, the following criteria:
|
|
|
The diversity, age, background and experience of the candidate; |
|
|
|
|
The personal qualities and characteristics, accomplishments and reputation in the
community of the candidate; |
|
|
|
|
The knowledge and contacts of the candidate in the communities in which we conduct
business and in our business industry or other industries relevant to our business; |
|
|
|
|
The ability and expertise of the candidate in various activities deemed appropriate by
the Board; and |
|
|
|
|
The fit of the candidates skills, experience and personality with those of other
Directors in maintaining an effective, collegial and responsive Board. |
16
The initial determination to seek a Board candidate is usually based on the need for
additional Board members to fill vacancies or to expand the size of the Board, although the
decision can also be based on the need for certain skill sets or qualifications, such as financial
expertise. The Nominating Committees process for evaluating nominees for Director is the same no
matter who makes the recommendation.
Once the Nominating Committee has determined, in consultation with other Board members if
appropriate, that additional consideration of a candidate is warranted, the Nominating Committee
may, or it may request third parties to, gather additional information about the prospective
candidates background, experience and independence. Following review of this information, if the
Nominating Committee determines it is appropriate to proceed, the Nominating Committee or other
members of the Board will generally interview the prospective candidate. The Nominating Committee
then evaluates the prospective nominee against the standards and qualifications set forth above and
such other relevant factors that the Nominating Committee or the Board deems appropriate, including
the current composition of the Board and the candidates personal qualities, skills and
characteristics.
Following this evaluation, if the Nominating Committee believes that the prospective candidate
is qualified for nomination, generally the Nominating Committee will make a recommendation to the
full Board, and the full Board will make the final determination whether the candidate should be
appointed, or nominated for election, to the Board.
Related Person Transactions
We have a written policy for reviewing transactions between us and our executive officers,
Directors and certain of their immediate family members and other related persons, including those
required to be reported under Item 404 of Regulation S-K. Under this policy, the Nominating
Committee must approve any transaction in which we participate that involves more than $100,000 and
in which a related person has a direct or indirect interest. Furthermore, related person
transactions that involve executive compensation or compensation for the members of our Board must
be approved by the Compensation Committee. Pursuant to our policy, we enter into a transaction
with such related persons only if the transaction is on terms comparable to those that could be
obtained in arms length dealings with an unrelated third party and is otherwise fair to us.
As a member of our Board of Directors, Mr. King-Shaw is a related person under our policy. As
discussed above, in September 2008, Mr. King-Shaw became the Chief Executive Officer of All-Med, a
company with which two of our subsidiaries have contracted for the provision of durable medical
equipment to members of the Companys Florida health plans. These agreements have been in place
since 2002. Under these agreements, our subsidiaries paid All-Med an aggregate amount of
approximately $6.9 million in 2008. Because these agreements continued after Mr. King-Shaw became
the Chief Executive Officer of All-Med, the Nominating Committee reviewed the agreements under our
policy and ratified them after determining they were on terms comparable to those that could be
obtained in an arms length transaction and were fair to us. Mr. King-Shaws compensation as Chief
Executive Officer of All-Med is not conditioned on these agreements or otherwise directly related
to them.
The Corporate Compliance Program
Under the direction of our Chief Compliance Officer, our General Counsel and the Board, we
recently implemented a comprehensive new and enhanced corporate ethics and compliance program that
includes structural enhancements, improved communications with and reporting to our regulators, a
new employee training program, called iCare, a new Code of Conduct and Business Ethics (the Code
of Conduct) and improved policies and procedures. The corporate compliance program covers all
aspects of our company and is designed to assist us with conducting our business in accordance with
applicable federal and state laws and high standards of business ethics. The corporate compliance
program applies to members of our Board, our officers and all of our associates. The following are
several of the ways in which we have redesigned and enhanced our compliance program:
|
|
|
Formation of the Regulatory Compliance Committee. As discussed above, our Board formed
a Regulatory Compliance Committee to oversee our compliance activities and programs. This
committee receives periodic reports from our Chief Compliance Officer and is responsible
for oversight of managements corporate compliance committee, which is discussed below. |
|
|
|
|
Appointment of the Chief Compliance Officer. Our Chief Compliance Officer reports
directly to our Chief Executive Officer and the Regulatory Compliance Committee. The Chief
Compliance Officer is responsible for monitoring regulatory reporting and regulatory
communications, affiliated company arrangements, and political contributions and
fund-raising, among other things. |
17
|
|
|
Reorganization of the compliance department. We have separated the compliance function
from our legal department and created a standalone compliance department under the
supervision of our Chief Compliance Officer. In addition, under the leadership of our
Chief Compliance Officer, the compliance department has been reorganized into the following
units: Medicare, Medicaid, privacy and corporate compliance. |
|
|
|
|
Enhanced corporate compliance committee. Our corporate compliance committee operates
under a charter approved by the Boards Regulatory Compliance Committee. The reconstituted
corporate compliance committee is chaired by our Chief Compliance Officer and comprised of
other members of senior management, including our General Counsel, Chief Operating Officer
and leaders of our Medicare and Medicaid businesses. The corporate compliance committee
has recently introduced iCare, an improved corporate ethics and compliance program for all
of our lines of business and corporate functions. In addition, the corporate compliance
committee reviews areas of legal, regulatory and compliance risk throughout the Company
and, under the oversight of the Regulatory Compliance Committee, is responsible for
developing appropriate policies and procedures to address such risks. |
|
|
|
|
Communications with regulators. We are implementing a comprehensive program to help us
identify regulatory reporting issues and report such issues to the appropriate federal or
state regulator. The program, which is administered under the supervision of our Chief
Compliance Officer, is designed to ensure the reliability of the information we communicate
to regulators. As part of this program, we have established an internal certification
process relating to the data contained in, and preparation of, the reports that we file
with regulators. In addition, we will audit sample reports we have filed with state
regulators to confirm that they were prepared in compliance with applicable law and are
otherwise accurate and complete. |
|
|
|
|
Effective compliance training. iCare includes mandatory compliance training programs,
or training modules, for all associates. So far, we have implemented a general compliance
training module and a training module on fraud, waste and abuse, and intend to add new
training modules from time to time. These training modules are designed to strengthen our
associates competency, independent judgment and identification of potential violations of
applicable law or Company policy. |
|
|
|
|
Enhanced communication of non-retaliation policies and improved reporting channels. As
an integral part of the iCare program, we are re-emphasizing to all of our associates that
any form of employee retaliation or retribution is prohibited and will result in
disciplinary action, including possible termination. We are also continuing to encourage
our associates to express concerns or report violations of which they have become aware or
have observed. Associates may express concerns through a variety of channels, including an
anonymous telephonic hotline, the Companys compliance intranet, or by contacting directly
our Chief Compliance Officer or any member of our legal department. |
|
|
|
|
Enhancement of written policies and procedures. We have adopted new or revised written
policies and procedures to reflect a clear commitment to corporate integrity and compliance
and a duty to report. As part of this process, earlier this year the Board adopted a new
Code of Conduct, which replaced our previous standards of conduct. The Code of Conduct
applies to all of our Directors and associates, including our Chief Executive Officer,
Chief Financial Officer and Chief Accounting Officer. Collectively, these written policies
will serve as guiding principles that emphasize, among other things, our commitment to
financial reporting integrity. |
Our Code of Conduct is available on our website at www.wellcare.com. We intend to disclose
future amendments to, or waivers from, the provisions of the Code of Conduct, if any, made with
respect to any of our Directors and executive officers on our website.
Communications with Directors
The Board has adopted procedures relating to communications sent to Directors to ensure that
such communications are properly managed. Shareholders may contact our Lead Director,
non-management members of our Board as a group, the full Board or any individual member of the
Board, by writing to the following address:
[Name of Requested Recipient]
WellCare Health Plans, Inc.
8735 Henderson Road
Tampa, Florida 33634
Attn: Chief Compliance Officer
18
The communication should clearly identify the issue being raised, the name of the party
initiating the communication and contact information for potential follow-up by the recipient.
In addition, our Board and Audit Committee have established separate procedures for the
receipt, retention and treatment of communications related to accounting, internal accounting
controls or auditing matters. Both the Director and the Audit Committee communication procedures
are available on our website at www.wellcare.com. As described in more detail in the procedures as
posted on our website, we generally will not forward to the Directors a communication that is
primarily commercial in nature, relates to an improper or irrelevant topic, or requests general
information regarding WellCare.
The procedures regarding communicating with the Board and the Audit Committee supplement our
Code of Conduct, which is discussed above in the section titled The Corporate Compliance Program.
Section 16(a) Beneficial Ownership Reporting Compliance
Section 16(a) of the Exchange Act requires our officers and Directors, and persons who own
more than 10% of our common stock, to file reports of ownership and changes in ownership with the
SEC and NYSE. Officers, Directors and greater than 10% stockholders are required by the SEC to
furnish us with copies of all Section 16(a) forms that they file.
Based solely on our review of the copies of such forms, or written representations from
reporting persons that all reportable transactions were reported, we believe that all our executive
officers, Directors and greater than 10% beneficial owners timely filed all reports they were
required to file under Section 16(a) during the fiscal year 2008.
DIRECTOR COMPENSATION AND RELATED INFORMATION
2008 Director Compensation
In February 2008, the Board appointed Mr. Hickey as Lead Director. Further, in April 2008,
the Board established a Regulatory Compliance Committee and a Health Care Quality and Access
Committee. In recognition of these new committees and the appointment of a Lead Director, the
Board approved the payment of an additional fee of $10,000 per year to the Lead Director and the
payment of an additional fee of $2,500 per year for the chair, and $2,000 per year for each
non-chair member, of each of the Regulatory Compliance Committee and the Health Care Quality and
Access Committee. In addition, the Board approved the payment of an additional fee of $2,500 per
year for the chair, and $2,000 per year for each non-chair member of the Nominating Committee, the
members of which did not previously receive additional fees for service on this committee. Neither
Mr. Schiesser nor Mr. Berg, who are executive officers of the Company, receives additional
compensation for his Board service.
The following table summarizes the fees paid to our Board and committee members as of
April 2008:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Annual Fee |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
for Serving |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Annual |
|
Annual Fee |
|
as a Non- |
|
|
|
|
Annual |
|
Annual Audit |
|
Annual |
|
Special |
|
for Serving |
|
Chair |
|
Annual |
|
|
Audit |
|
Committee |
|
Special |
|
Committee |
|
As the Chair |
|
Member of |
|
Lead |
Annual |
|
Committee |
|
Non-Chair |
|
Committee |
|
Non-Chair |
|
of Other |
|
Other |
|
Director |
Board Fee |
|
Chair Fee |
|
Member Fee |
|
Chair Fee |
|
Fee |
|
Committees(1) |
|
Committees(1) |
|
Fee |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$37,500 |
|
$ |
10,000 |
|
|
$ |
5,000 |
|
|
$ |
90,000 |
|
|
$ |
60,000 |
|
|
$ |
2,500 |
|
|
$ |
2,000 |
|
|
$ |
10,000 |
|
|
|
|
(1) |
|
These fees are for the Compensation Committee, the Nominating and Corporate Governance
Committee, the Regulatory Compliance Committee and the Health Care Quality and Access
Committee. |
As discussed below under Compensation Discussion and Analysis Equity Award Process, in
July 2006, the Compensation Committee determined that all annual equity awards to Board members
will be issued effective as of the date of the annual meeting of shareholders. Historically, we
have granted equity awards to Board members upon their initial appointment or election to the Board
as well as annually although we have not had a standard plan or program as to the number or type of
equity awards granted to our non-employee Directors. We did not hold our 2008 annual meeting of
shareholders, and consequently, no equity awards were made to the Directors during fiscal year
2008.
19
2009 Director Compensation
On March 23, 2009, the Board approved a new Non-Employee Director Compensation Policy (the
Director Compensation Policy). The Director Compensation Policy is applicable to our
non-employee Directors effective for the fiscal quarter commencing April 1, 2009. Similar to the
compensation structure of our executives, our Boards historical compensation was heavily weighted
toward equity compensation. Following the commencement of the governmental investigations in
October 2007 and the subsequent decline in our stock price, our Board determined it was necessary
to analyze our Board compensation program. In addition to trying to balance the distribution of
Board compensation between cash and equity, the Board also felt it was necessary to review our
Board compensation practices in order to be able to attract new Board members and to bring such
practices in-line with market standards. The Compensation Committee retained Watson Wyatt to
conduct an analysis of compensation practices at comparable companies and make recommendations as
to how to structure our Board compensation policy. The Director Compensation Policy was adopted
based in part upon the Watson Wyatt analysis and recommendations.
Under the Director Compensation Policy, each non-employee Director earns an annual retainer
and Board and committee fees as set forth below, paid on a quarterly basis at the end of the
applicable quarter. Each non-employee member of the Board and its committees who serves during any
portion of a quarterly period, shall be paid the full quarterly retainer and applicable fees.
The following table summarizes the standing fees paid to our Board and committee members as of
April 2009:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Annual Fee |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
for Serving |
|
|
|
|
|
|
|
|
Annual |
|
|
|
|
|
Annual |
|
|
|
|
|
Annual Fee |
|
as a Non- |
|
|
|
|
Annual |
|
Audit |
|
Annual |
|
Special |
|
|
|
|
|
for Serving |
|
Chair |
|
Annual |
|
|
Audit |
|
Committee |
|
Special |
|
Committee |
|
Annual |
|
As the Chair |
|
Member of |
|
Lead |
Annual |
|
Committee |
|
Non-Chair |
|
Committee |
|
Non-Chair |
|
Special Litigation |
|
of Other |
|
Other |
|
Director |
Board Fee |
|
Chair Fee |
|
Member Fee |
|
Chair Fee |
|
Fee |
|
Committee Fee |
|
Committees(1) |
|
Committees(1) |
|
Fee |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$50,000 |
|
$ |
20,000 |
|
|
$ |
12,000 |
|
|
$ |
90,000 |
|
|
$ |
60,000 |
|
|
$ |
90,000 |
|
|
$ |
12,000 |
|
|
$ |
8,000 |
|
|
$ |
15,000 |
|
|
|
|
(1) |
|
These fees are for the Compensation Committee, the Nominating Committee, the Regulatory
Compliance Committee and the Health Care Quality and Access Committee. |
In addition to the cash retainers described above, each non-employee Director receives $2,000
for each meeting of the full Board attended in person, telephonically or by way of other remote or
electronic means. In addition, unless otherwise determined by the Compensation Committee and
subject to the Compensation Committees approval, each non-employee Director, other than a
non-employee Director joining the Board at the annual shareholders meeting, receives an annual
grant of restricted stock valued at approximately $100,000 (based on the closing price on the date
of grant), pursuant to and in accordance with the terms and provisions of a restricted stock
agreement and the 2004 Equity Incentive Plan (the 2004 Equity Plan). Unless otherwise determined
by the Compensation Committee, all such annual grants are granted on the date of the Companys
annual meeting of shareholders and vest in full on the earlier of the first anniversary of the date
of grant or the date of the next annual shareholder meeting. Further, unless otherwise determined
by the Compensation Committee and subject to the Compensation Committees approval, newly elected
or appointed non-employee members of the Board receive an initial grant of restricted stock valued
at approximately $150,000 (based on the closing price on the date of grant), pursuant to and in
accordance with the terms and provisions of a restricted stock agreement and the 2004 Equity Plan.
Such grants of restricted stock vest equally on the first, second and third anniversary of the date
of grant.
Other Components of Director Compensation
We pay all reasonable expenses incurred by Directors for attending Board and committee
meetings, for certain director continuing education programs and related expenses and maintain
directors and officers liability insurance. We do not provide a retirement plan or perquisites for
our non-employee Directors. We have entered into indemnification agreements with each of our
Directors in addition to the indemnification that is provided for in our certificate of
incorporation and bylaws. These agreements, among other things, provide for the indemnification of
expenses specified in the agreements, including attorneys fees, judgments, fines and settlement
amounts, incurred by the Directors in any action or proceeding arising out of their service as
Directors for us, any of our subsidiaries or any other entity to which the Directors provide
services at our request.
20
All of our Directors unvested restricted stock awards and unvested stock options were issued under
our 2004 Equity Plan, except for a portion of Mr. Michaliks stock options. The circumstances
under which the vesting of equity awards under the 2004 Equity Plan will accelerate are described
below under Potential Payments to Named Executive Officers upon Termination or Change in Control.
Under the provisions of the new Director Compensation Policy described above, we awarded
$150,000, or 14,354 shares, of restricted stock to Mr. Gallitano upon his appointment to the Board
and expect to award $100,000 worth of restricted stock to each of the non-employee members of the
Board on the date of our 2009 annual shareholders meeting.
Stock Ownership Guidelines
Under the new Director Compensation Policy, each non-employee Director is required to own
shares of our common stock (the Ownership Requirement) having a value (as described below) equal
to the sum of three times the base annual retainer payable to each non-employee Director.
For purposes of determining ownership, the following will be included in determining whether a
non-employee Director has satisfied the Ownership Requirement:
|
|
|
One hundred percent (100%) of the value of shares of our common stock owned
individually, either directly or indirectly, including vested and unvested restricted
stock or restricted stock unit awards or shares acquired upon exercise of stock
options; and |
|
|
|
|
Shares of our common stock owned jointly, or separately by a spouse, domestic
partner and/or minor children, directly or indirectly. |
No other rights to acquire shares of our common stock (including stock options or similar
rights) shall be considered shares of our common stock owned for purposes of meeting the Ownership
Requirements under the Director Compensation Policy.
For purposes hereof, the value of a share of the Companys common stock, including vested and
unvested restricted stock and restricted stock units, shall be calculated on the last trading day
of each calendar year based on the average closing price of our common stock during the prior year
(a Determination Date). Any subsequent change in the value of the shares of our common stock
during that year will not affect the amount of stock a non-employee Director should hold during
that year under the policy. If the value of the shares of our common stock increases from year to
year, each non-employee Director shall have one year in which to meet the Ownership Requirement.
In the event the annual retainer increases, each non-employee Director will have four years
from the time of the increase to acquire any additional shares needed to satisfy the Ownership
Requirement.
A non-employee Director shall have until the first Determination Date following the fourth
anniversary of such non-employee Directors election or appointment to the Board or upon otherwise
becoming a non-employee Director of the Board to satisfy the Ownership Requirement; provided,
however, that a non-employee Director who was a non-employee Director of the Company as of April 1,
2009, shall have until December 31, 2013 to meet the Ownership Requirement.
Director Compensation Table
The table below sets forth the compensation paid to each non-employee member of our Board of
Directors in fiscal year 2008.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fees Earned or |
|
Stock |
|
Option |
|
|
|
|
Paid in Cash |
|
Awards(1) |
|
Awards(1) |
|
Total |
Name |
|
($) |
|
($) |
|
($) |
|
($) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Robert Graham |
|
|
50,250 |
|
|
|
125,170 |
|
|
|
|
|
|
|
175,420 |
|
Regina Herzlinger |
|
|
59,875 |
|
|
|
|
|
|
|
1,189 |
|
|
|
61,064 |
|
Kevin Hickey |
|
|
57,375 |
|
|
|
|
|
|
|
594 |
|
|
|
57,969 |
|
Alif Hourani |
|
|
57,125 |
|
|
|
|
|
|
|
594 |
|
|
|
57,719 |
|
Ruben King-Shaw, Jr. |
|
|
123,750 |
|
|
|
|
|
|
|
594 |
|
|
|
124,344 |
|
Christian Michalik |
|
|
129,625 |
|
|
|
|
|
|
|
594 |
|
|
|
130,219 |
|
Neal Moszkowski |
|
|
164,375 |
|
|
|
125,180 |
|
|
|
|
|
|
|
289,555 |
|
David Gallitano(2) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
21
|
|
|
(1) |
|
The amounts included in the Stock Awards and Option Awards columns
are the amounts of compensation cost related to restricted stock and
stock option awards, respectively, recognized by us in our financial
statements during fiscal year 2008 in accordance with Statement of
Financial Accounting Standards No. 123R (FAS 123R). Pursuant to SEC
rules, the amounts shown exclude the impact of estimated forfeitures
related to service-based vesting conditions, as applicable. These
amounts reflect our accounting expense for these awards and do not
correspond to the actual value that will be realized by the Directors.
For a discussion of valuation assumptions and methodologies, see Note
2 to our 2008 consolidated financial statements included in our annual
report on Form 10-K for the year-ended December 31, 2008. |
|
(2) |
|
Mr. Gallitano was appointed to our Board of Directors in March 2009. |
The following table sets forth certain information regarding unexercised options and stock
that has not vested for each non-employee member of our Board of Directors outstanding as of
December 31, 2008.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Option Awards |
|
Stock Awards |
|
|
Number |
|
Number |
|
|
|
|
|
|
|
|
|
Number |
|
Market |
|
|
of |
|
of |
|
|
|
|
|
|
|
|
|
of Shares |
|
Value of |
|
|
Securities |
|
Securities |
|
|
|
|
|
|
|
|
|
or Units |
|
Shares or |
|
|
Underlying |
|
Underlying |
|
|
|
|
|
|
|
|
|
of Stock |
|
Units of |
|
|
Unexercised |
|
Unexercised |
|
Option |
|
|
|
|
|
That Have |
|
Stock |
|
|
Options |
|
Options |
|
Exercise |
|
Option |
|
Not |
|
That Have |
|
|
(#) |
|
(#) |
|
Price |
|
Expiration |
|
Vested |
|
Not Vested(1) |
Name |
|
Exercisable |
|
Unexercisable |
|
($) |
|
Date |
|
(#) |
|
($) |
|
Robert Graham |
|
|
10,693 |
|
|
|
|
|
|
|
90.05 |
|
|
|
10/26/11 |
|
|
|
1,389 |
(2) |
|
|
17,863 |
|
|
|
|
3,790 |
|
|
|
|
|
|
|
90.52 |
|
|
|
12/12/11 |
|
|
|
|
|
|
|
|
|
Regina Herzlinger |
|
|
10,000 |
|
|
|
|
|
|
|
17.00 |
|
|
|
07/07/14 |
|
|
|
|
|
|
|
|
|
|
|
|
7,000 |
|
|
|
|
|
|
|
36.45 |
|
|
|
07/27/12 |
|
|
|
|
|
|
|
|
|
|
|
|
6,500 |
|
|
|
|
|
|
|
47.40 |
|
|
|
06/07/13 |
|
|
|
|
|
|
|
|
|
|
|
|
5,128 |
|
|
|
|
|
|
|
90.52 |
|
|
|
12/12/11 |
|
|
|
|
|
|
|
|
|
Kevin Hickey |
|
|
5,000 |
|
|
|
|
|
|
|
17.00 |
|
|
|
07/07/14 |
|
|
|
|
|
|
|
|
|
|
|
|
4,500 |
|
|
|
|
|
|
|
36.45 |
|
|
|
07/27/12 |
|
|
|
|
|
|
|
|
|
|
|
|
5,000 |
|
|
|
|
|
|
|
47.40 |
|
|
|
06/07/13 |
|
|
|
|
|
|
|
|
|
|
|
|
3,790 |
|
|
|
|
|
|
|
90.52 |
|
|
|
12/12/11 |
|
|
|
|
|
|
|
|
|
Alif Hourani |
|
|
5,000 |
|
|
|
|
|
|
|
17.00 |
|
|
|
07/07/14 |
|
|
|
|
|
|
|
|
|
|
|
|
4,500 |
|
|
|
|
|
|
|
36.45 |
|
|
|
07/27/12 |
|
|
|
|
|
|
|
|
|
|
|
|
5,000 |
|
|
|
|
|
|
|
47.40 |
|
|
|
06/07/13 |
|
|
|
|
|
|
|
|
|
|
|
|
3,790 |
|
|
|
|
|
|
|
90.52 |
|
|
|
12/12/11 |
|
|
|
|
|
|
|
|
|
Ruben King-Shaw, Jr. |
|
|
1,875 |
|
|
|
|
|
|
|
17.00 |
|
|
|
07/07/14 |
|
|
|
|
|
|
|
|
|
|
|
|
5,000 |
|
|
|
|
|
|
|
47.40 |
|
|
|
06/07/13 |
|
|
|
|
|
|
|
|
|
|
|
|
3,790 |
|
|
|
|
|
|
|
90.52 |
|
|
|
12/12/11 |
|
|
|
|
|
|
|
|
|
Christian Michalik |
|
|
33,657 |
|
|
|
|
|
|
|
6.47 |
|
|
|
12/31/13 |
|
|
|
|
|
|
|
|
|
|
|
|
5,000 |
|
|
|
|
|
|
|
17.00 |
|
|
|
07/07/14 |
|
|
|
|
|
|
|
|
|
|
|
|
4,500 |
|
|
|
|
|
|
|
36.45 |
|
|
|
07/27/12 |
|
|
|
|
|
|
|
|
|
|
|
|
5,000 |
|
|
|
|
|
|
|
47.40 |
|
|
|
06/07/13 |
|
|
|
|
|
|
|
|
|
|
|
|
3,790 |
|
|
|
|
|
|
|
90.52 |
|
|
|
12/12/11 |
|
|
|
|
|
|
|
|
|
Neal Moszkowski |
|
|
10,495 |
|
|
|
|
|
|
|
91.64 |
|
|
|
10/20/11 |
|
|
|
1,364 |
(3) |
|
|
17,541 |
|
|
|
|
3,790 |
|
|
|
|
|
|
|
90.52 |
|
|
|
12/12/11 |
|
|
|
|
|
|
|
|
|
David Gallitano(4) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Value based on $12.86 per share which was the closing price of our common stock on the NYSE on December 31, 2008. |
|
(2) |
|
These shares vested on April 26, 2009. |
|
(3) |
|
These shares vested on April 20, 2009. |
|
(4) |
|
Mr. Gallitano was appointed to our Board of Directors in March 2009. |
22
The table below sets forth the number of stock options exercised and the value realized upon
exercise of the stock options, or the vesting of restricted stock and the value realized, for each
non-employee member of our Board of Directors in fiscal year 2008.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Option Awards |
|
Stock Awards |
|
|
Number of |
|
|
|
|
|
Number of |
|
|
|
|
Shares |
|
|
|
|
|
Shares |
|
|
|
|
Acquired |
|
Value Realized |
|
Acquired |
|
Value Realized |
|
|
on Exercise |
|
on Exercise(1) |
|
on Vesting |
|
on Vesting(2) |
Name |
|
(#) |
|
($) |
|
(#) |
|
($) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Robert Graham |
|
|
|
|
|
|
|
|
|
|
1,388 |
|
|
|
56,936 |
|
Regina Herzlinger |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Kevin Hickey |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Alif Hourani |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ruben King-Shaw, Jr. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Christian Michalik |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Neal Moszkowski |
|
|
|
|
|
|
|
|
|
|
1,364 |
|
|
|
58,106 |
|
David Gallitano(3) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
The value realized is calculated by multiplying the number of shares by the difference between the market price of our common stock at time of
exercise and the exercise price of the stock option. |
|
(2) |
|
The value realized is calculated by multiplying the number of shares vested by the closing market price of our common stock on the date of vesting. |
|
(3) |
|
Mr. Gallitano was appointed to our Board of Directors in March 2009. |
COMPENSATION DISCUSSION AND ANALYSIS
Overview
This Compensation Discussion and Analysis discusses our historical compensation philosophy and
program for fiscal year 2008 as it pertained to our named executive officers, and also addresses
compensation decisions that were made in early 2009 that relate to 2008 performance and, in some
cases, 2009 and beyond.
The following individuals constituted our named executive officers for 2008:
|
|
|
Heath G. Schiesser and Todd S. Farha, two individuals who served as our principal
executive officer during 2008; |
|
|
|
|
Thomas L. Tran and Paul L. Behrens, two individuals who served as our principal
financial officer during 2008; |
|
|
|
|
Charles G. Berg, Adam T. Miller and Thomas F. ONeil III, our three other most
highly compensated executive officers who were serving as executive officers at the end
of 2008; and |
|
|
|
|
Anil Kottoor, an individual who would have been one of our three other most highly
compensated executive officers if he had served as an executive officer at the end of
2008. |
Messrs. Schiesser, Tran, Berg and ONeil were each appointed to their respective positions
during 2008. Each of these executives negotiated employment agreements in connection with their
appointment. Consequently, compensation for 2008 for these executives was largely dictated by the
terms of their respective employment agreements, which included, among other things, base salary,
initial equity awards of restricted stock and stock options, and in some instances, sign-on bonuses
and minimum guaranteed bonuses for the first year of employment. Mr. ONeils employment agreement
was amended and restated on June 3, 2009. For information related to his amended and restated
agreement, see Executive Compensation Additional Information With Respect to the Summary
Compensation Table and Grants of Plan-Based Awards Employment Agreements with Named Executive
Officers and Executive Compensation Potential Payments to Named Executive Officers upon
Termination or Change in Control.
Decisions relating to 2008 compensation for Messrs. Miller and Kottoor were driven largely by
our desire to retain their services following the commencement of the governmental investigations
in October 2007 (as described under Legal Proceedings in our quarterly report on Form 10-Q for
the quarterly period ended March 31, 2009), and were also designed to increase their total
compensation to be in line with similarly-situated executives at companies in our peer group. In
the case of Mr. Kottoor, who terminated his employment in December 2008, his compensation was also
dictated in part by the terms of his separation agreement. See Separation Agreements below for a
description of Mr. Kottoors separation agreement.
23
Messrs. Farha and Behrens each resigned from their respective positions in January 2008, which
was before 2008 annual compensation decisions were determined by the Compensation Committee.
Consequently, virtually no decisions relating to 2008 compensation were made with regard to either
of these individuals; rather, their compensation was dictated by the terms of their separation
agreements. See Separation Agreements below for a description of Messrs. Farhas and Behrens
separation agreements.
Compensation Philosophy
We have not, and we currently do not, pre-establish performance goals with respect to our
performance-based compensation. Our executive compensation program, including decisions relating
to performance-based compensation, have been, and continue to be, based on the Compensation
Committees subjective and discretionary review of overall company and individual executive officer
performance, each as subjectively determined by the Compensation Committee after receiving
recommendations from our Chief Executive Officer for his direct reports.
We believe that, prior to 2008, our compensation philosophy and processes reflected those of a
newly-public company in many respects. Prior to 2008, our senior management team was in large part
the same team that built and helped bring the Company public in 2004. Following our Initial Public
Offering (IPO), we experienced significant growth which was reflected in the price of our stock,
which increased from our IPO price of $17.00 in July 2004 to $122.27 by October 23, 2007, the day
before the commencement of the government investigations. Due to the value that our stock
represented to our associates, including senior management, the focus of our compensation program
prior to 2008 was equity awards in the form of restricted stock and stock options, which were
granted on a discretionary basis. Conversely, our cash compensation, including base salaries and
annual cash bonuses, was typically less than other companies within the health care industry due to
our emphasis on, and success of, our equity compensation program. Accordingly, as a general
matter, prior to 2008 we were able to attract and retain our executives with compensation packages
providing for relatively low amounts of cash compensation and uncertain future equity awards in
exchange for an attractive initial equity grant.
However, following the commencement of the governmental investigations in October 2007, and
the subsequent significant decrease in our stock price, which decreased from $122.27 on October 23,
2007 to $22.87 on November 1, 2007, our ability to attract and retain our associates, including our
executives, became much more challenging. In light of this, our Compensation Committee determined
we could no longer rely solely on initial equity grants as our primary recruitment and retention
tool. To help address these concerns, our Compensation Committee retained Watson Wyatt Worldwide
in November 2007 to advise us with respect to how the amounts and composition of executive
compensation paid by us, including base salary and annual cash and long-term equity incentive
compensation targets, compared to market compensation levels (see Benchmarking below). As a
result of this review, and as discussed in more detail below, the Compensation Committee approved a
compensation package that it felt was more effective given the Companys maturation to a larger,
post-IPO company.
We anticipate that the Compensation Committee will continue to work with Watson Wyatt, the
Board and Mr. Schiesser to develop an evolving compensation program that reflects our continued
maturation as a public company and the need to attract and retain talented management during our
current challenges and beyond.
Although no significant changes were made in 2009 to the Companys overall compensation
philosophy and structure, we aggressively reduced administrative costs during 2008 in response to
various changes in our business and have and are implementing additional cost-cutting measures in
2009, including a salary freeze, management bonus reductions and the suspension of 401(k)
retirement plan Company matching contributions. As discussed below, these initiatives affected the
2008 compensation of some of the named executive officers.
Benchmarking
As discussed above, due to the decline in our stock price and the Compensation Committees
consequential focus on alternative retention mechanisms, the Compensation Committee engaged Watson
Wyatt to perform an analysis of the amounts and composition of executive compensation paid by
WellCare, including base salary, annual cash and long-term equity incentive targets, as compared to
amounts being paid to similarly-situated employees at companies we believed to be in our peer
group.
For purposes of determining our relevant peer group, Watson Wyatt prepared an analysis, based
on the then most recently filed proxy statements, of the compensation practices and levels of
publicly-traded comparable medical service and health plan providers. The companies were the
following:
24
2008 Peer Group
|
|
|
Aetna Inc. |
|
|
|
|
AMERIGROUP Corp. |
|
|
|
|
Centene Corp. |
|
|
|
|
Cigna Corp. |
|
|
|
|
Coventry Health Care, Inc. |
|
|
|
|
Express Scripts Inc. |
|
|
|
|
Health Net, Inc. |
|
|
|
|
HealthSpring Inc. |
|
|
|
|
Humana, Inc. |
|
|
|
|
Sierra Health Services, Inc. |
As of December 31, 2007, the market capitalization of these companies ranged from
approximately $1.0 billion to $28.9 billion, with a median of $7.2 billion, and revenues ranged
from approximately $1.6 billion to $27.6 billion, with a median of $14.1 billion. This compared to
our December 31, 2007 market capitalization of approximately $1.8 billion and revenues of
approximately $5.3 billion. While our market capitalization and revenues represented the lower end
of the peer group range, these companies were nevertheless selected principally because they are
representative of the pool of companies in which we compete for talent. These companies were also
selected based on their similarity of product offerings, and the size and growth rate of their
Medicare and Medicaid businesses.
In addition to peer group data, Watson Wyatt also analyzed comparable market data from the
following published survey sources:
|
|
|
Watson Wyatt 2007/08 Survey Report on Top Management Compensation; |
|
|
|
|
Watson Wyatt 2007/08 Survey Report on Health, Annuity, and Life Insurance Management Compensation; |
|
|
|
|
2007 U.S. Mercer Benchmark Database: Executive Survey Report; and |
|
|
|
|
2007 Mercer Integrated Health Networks (IHN): U.S. Integrated Health Networks
Compensation Survey Suite. |
While the Compensation Committee reviewed and considered the comparable market data provided
by these surveys, it did not consider or review the compensation paid to executives at the
component companies included within such surveys; however, the data from these surveys was scaled
to our size using either regression analysis based on revenues or corresponding revenue ranges as
provided by the various surveys.
The peer group data prepared by Watson Wyatt, as well as the comparable market data analyzed
by Watson Wyatt, is collectively referred to as the market data.
The fiscal year 2008 market data prepared by Watson Wyatt indicated the following:
|
|
|
cash compensation paid to our executives in the aggregate, consisting of base salary
and annual incentive cash compensation, was 16% below the median of the market data;
and |
|
|
|
|
ongoing equity awards to our executives in the aggregate was 40% above the 75th
percentile of the market data. |
This analysis, coupled with our revised retention mechanisms in light of the Companys
circumstances and decline in stock price, resulted in the Compensation Committees determination
that base salaries for certain of our associates, including Messrs. Kottoor and Miller, should be
increased to be competitive with the median of the market data. With respect to annual and
long-term incentive opportunities (consisting of cash and equity awards), the Compensation
Committee, upon the recommendation of Mr. Schiesser, determined to target the 50th to 75th
percentile of the market data. These changes resulted in our executives total direct compensation
to range from the 50th to 75th percentile of the market data. In addition to the decreased
efficacy of using initial equity awards as the primary retention tool due to our decreased stock
price, the Compensation Committee felt targeting this segment of the market data was appropriate
as, consistent with other post-IPO companies, base salary and annual cash bonuses would likely
begin to become a more significant element of executive compensation as the Company matures.
As discussed below, for 2008, each of Messrs. Kottoor and Millers base salary was increased
to bring each executive in line with the median of the market data. In addition, the targeted
total cash compensation for Messrs. Kottoor and Miller was at the 70th percentile of the market
data, which the Compensation Committee deemed necessary for retention purposes. As
25
discussed in more detail below, Mr. Millers base salary and annual cash incentive compensation was
subsequently adjusted for additional retention purposes in April 2008, resulting in his targeted
total cash compensation above the 75th percentile.
Negotiation of Employment Agreement Terms for 2008 Hires
We experienced a significant turnover in our senior management team during 2008. Messrs.
Schiesser, Tran, Berg and ONeil were all appointed to their respective positions during 2008.
Recruiting executives was challenging in light of our circumstances following the government
investigations. In framing the general compensation package for each of these named executive
officers, the Compensation Committee considered a number of quantitative and qualitative factors,
including the market data as described in Benchmarking above, the total cost of each compensation
package, the compensation packages developed for other senior executives in the Company and the
terms and conditions that other job candidates were seeking. However, the final terms of each
employment agreement were reached after arms-length negotiations between us and these executives
and were determined by the Compensation Committee, based in part on market data received from
Watson Wyatt, to be reasonable. The Compensation Committee also determined that the negotiated
terms were necessary to recruit these individuals in a relatively short time frame, and bring the
experience the Company needed in light of the challenges we were facing. See Employment
Agreements with Named Executive Officers below for a description of the employment agreements.
Compensation Program Process and Components
In connection with our annual associate review and evaluation process, incentive compensation
decisions for our executive officers, including the named executive officers, are generally made in
early March and are largely based on prior fiscal year company and individual performance. For
example, in March of a given year, the following decisions are typically made by the Compensation
Committee for our executive officers:
|
|
|
base salary adjustments; |
|
|
|
|
annual cash bonus awards related to prior fiscal year performance based on targets
established in the prior fiscal year; |
|
|
|
|
long-term incentive awards based on targets established in the prior fiscal year; |
|
|
|
|
new annual cash bonus targets; and |
|
|
|
|
new long-term incentive targets. |
Annual cash bonuses and long-term incentive awards are discretionary (except as might
otherwise be required by an executives employment agreement) and are based on targets that are
increased or decreased for overall company performance and individual performance, each as
subjectively determined by the Compensation Committee after receiving recommendations from our
Chief Executive Officer for his direct reports.
During fiscal year 2008, our executive compensation program consisted of the following four
elements:
|
|
|
base salary; |
|
|
|
|
an annual cash bonus; |
|
|
|
|
long-term incentive awards in the form of cash, restricted stock and stock options;
and |
|
|
|
|
retention-related incentive awards in the form of cash and stock options. |
Base Salary
We pay base salary to attract talented executives and to provide a fixed base of cash
compensation. Base salaries for executive officers are determined by the Compensation Committee,
after considering the market data (as described in Benchmarking above), the scope and
complexities of an individuals role, internal equity (in this context, meaning striving to ensure
that our executives with similar responsibilities, experience and historical performance are
rewarded comparably) and
26
individual performance. The Compensation Committee is mindful of setting the appropriate level of
base salary in order to ensure that total direct compensation is both competitive and reasonable.
In general, the Compensation Committee considers three factors when determining whether to
approve an increase to an executive officers base pay: annual merit increases, promotions or
changes in role, and market adjustments.
|
|
|
Annual merit increases. The Compensation Committee begins to review potential merit
increases in February and merit increases, if any, are usually effective in
mid-February or early March. Annual merit increases are not guaranteed and any
adjustments take into account the individuals performance, responsibilities and
experience. When making these determinations, the Compensation Committee relies to a
large extent on the Chief Executive Officers evaluation of the performance of
executive officers who report directly to him. |
|
|
|
|
Promotions or changes in role. The Compensation Committee may determine to increase
an executives base salary to recognize an increase in responsibilities resulting from
a change in an executives role or a promotion to a new position. The Compensation
Committee considers new responsibilities, market data and internal pay equity in
addition to past performance and experience when approving any such salary increases. |
|
|
|
|
Market adjustments. Market adjustments may be awarded to an executive when, in the
judgment of the Compensation Committee, a significant gap between the market data and
the individuals base salary is recognized. In general, market adjustments are
determined as part of the annual merit review process. |
Fiscal Year 2008 Salaries
In connection with the review of base salaries for fiscal year 2008, the Compensation
Committee determined to approve a base salary increase for Mr. Kottoor of $65,000, from $250,000 to
$315,000. The Compensation Committee also determined to approve a base salary increase for Mr.
Miller of $45,000, from $280,000 to $325,000. These increases represented market adjustments, and
brought each executives base salary in line with the median of the market data, while keeping
total cash compensation at the 70th percentile of the market data. Following the determination of
2008 base salaries, in April 2008 Messrs. Schiesser and Miller entered into further discussions
regarding an additional base salary increase for Mr. Miller. Due to concerns over retaining Mr.
Miller, and given the significant increase in our prescription drug plan and private
fee-for-service Medicare business and the resulting responsibilities of Mr. Miller since the time
of his hire during which time his overall compensation remained relatively static the
Compensation Committee approved an additional increase in Mr. Millers base salary of $75,000,
retroactive to February 2008 when other 2008 base salaries increases were effective, bringing his
base salary rate for 2008 to $400,000.
As discussed above, Messrs. Schiesser, Tran, Berg and ONeil each negotiated base salaries in
connection with being recruited by us in 2008. For 2008, the base salaries for Messrs. Schiesser,
Tran, Berg and ONeil were $400,000, $475,000, $500,000 and $500,000, respectively, and such
salaries were all included as a term of each executives employment agreement executed during 2008.
See Negotiation of Employment Agreement Terms for 2008 Hires above and Employment Agreements
with Named Executive Officers below for a description of these employment agreements.
Messrs. Farha and Behrens each resigned from their respective positions in January 2008, which
was before annual compensation decisions were determined by the Compensation Committee.
Consequently, no changes were made to their base salaries prior to their respective resignations.
See Separation Agreements below for a description of these separation agreements.
Fiscal Year 2009 Salaries
No salary adjustments for 2009 were made for Messrs. Schiesser, Tran, Berg, Miller or ONeil.
Incentive Awards
As a component of total compensation, the Compensation Committee may choose to pay
performance-based incentive awards with the intention of driving the achievement of key goals and
initiatives for the Company and recognizing individuals based on their contributions to those
results. Incentive awards consist of an annual cash bonus award, incentive cash awards that vest
over a long-term, restricted stock and/or stock options. Incentive awards are discretionary
(except as might otherwise be required by an executives employment agreement) and are generally
based on pre-established targets that are increased or decreased depending on overall company
performance (the company performance modifier) and individual performance (the individual
performance modifier), each as subjectively determined by the Compensation Committee.
27
In determining the company performance modifier for a fiscal year, the Compensation Committee
uses its discretion in considering a number of quantitative and qualitative factors it considers
relevant for that fiscal year. In a favorable or unfavorable year as determined by the
Compensation Committee, the company performance modifier could be above or below 100% respectively.
The individual performance modifier is based on an executives annual performance review and
ranges from 0% to 150%, with higher performing executives receiving higher performance multipliers.
Once the performance modifiers are determined by the Compensation Committee, the bonus payouts
are formulaic as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Bonus
Payout
|
|
=
|
|
Pre-
Established
Bonus Target
|
|
x
|
|
Company
Performance
Modifier
|
|
x
|
|
Individual
Performance
Modifier
|
|
|
For 2008, the Compensation Committee determined the company performance modifier to be 60%,
which was applied to all bonus-eligible associates across the Company equally, after considering
the following factors:
|
|
|
budgets that were achieved, including revenue, membership and selling, general and
administrative expenses (when adjusted to exclude investigation-related expenses); |
|
|
|
|
budgets that were not achieved, including earnings; |
|
|
|
|
expansion into the Hawaii market; |
|
|
|
|
Medicare growth versus our industrys growth rate; |
|
|
|
|
major projects, including the completion of CMS and NCQA audits and Medicaid
compliance; |
|
|
|
|
medical cost improvements in our Ohio market; |
|
|
|
|
improving regulatory relationships; and |
|
|
|
|
our stock price performance. |
Each executives individual performance modifier is also approved by the Compensation
Committee, largely based on the recommendations of Mr. Schiesser with respect to his direct
reports, including Messrs. Tran, Miller and ONeil. For fiscal year 2008 performance, the
Compensation Committee determined Mr. Trans individual performance modifier at 110%, Mr. Millers
individual performance modifier at 115% and Mr. ONeils individual performance modifier at 150%.
Mr. Trans individual performance modifier was based on success in managing the audit process and
our financial statement filings. Mr. Millers individual performance modifier was based on success
in growing and managing our Medicare products in 2008. Mr. ONeils individual performance
modifier was based on his leadership in managing the legal challenges facing the Company.
Messrs. Schiesser and Berg each requested they be paid no cash bonuses for 2008 and,
therefore, they did not receive any such bonuses. Messrs. Schiesser and Berg also requested that
the Compensation Committee make long-term incentive award determinations with respect to them at a
later date.
As discussed below under Separation Agreements and Potential Payments to Named Executive
Officers upon Termination or Change in Control, no bonuses were awarded to Messrs. Farha and
Behrens for 2008 and Mr. Kottoors bonus payment for 2008 was dictated by the terms of his July
2008 letter agreement.
Annual Cash Bonus Awards
As discussed above, annual cash bonus awards are discretionary (except as might otherwise be
required by an executives employment agreement) and generally based on pre-established targets
that are increased or decreased based on the company and individual performance modifiers.
28
Fiscal Year 2008
|
|
|
2008 Annual Cash Bonus Targets. For 2008, the Compensation Committee established
new annual cash bonus targets for Messrs. Kottoor and Miller for their annual cash
bonus to be paid in March 2009 (the annual cash bonus related to fiscal year 2008
performance is referred to as the 2008 Annual Cash Bonus Award). Mr. Kottoors
target was increased from 35% of base salary to 80% of base salary. Mr. Millers
target was increased from 50% of base salary to 80% of base salary. The new bonus
targets were largely based on the recommendation of Mr. Schiesser and reflected the
Compensation Committees desire to target total cash compensation of Messrs. Kottoor
and Miller at the 70th percentile of the market data. As a result of the further
discussions with Mr. Miller in April 2008, as discussed above under Base Salary
Fiscal Year 2008, the Compensation Committee approved increasing Mr. Millers fiscal
year 2008 bonus target from 80% to 100% of base salary. |
|
|
|
|
Messrs. Schiesser, Tran, Berg and ONeil were each hired for their respective positions
during 2008. Each of these executives, with the exception of Mr. Berg, negotiated
an annual cash incentive bonus target in connection with being recruited as
discussed above. Although Mr. Berg did not negotiate a specific target, his
employment agreement provides that he is eligible to receive an annual cash bonus as
determined in the discretion of the Compensation Committee. For 2008, and as set
forth in their respective employment agreements, the annual cash bonus targets for
Messrs. Schiesser, Tran and ONeil are 200%, 100% and 50% of base salary,
respectively. In addition, Messrs. Tran and ONeil negotiated guaranteed minimum
bonuses of $475,000 (pro rated for the portion of the calendar year employed) and
$250,000, respectively, for the initial calendar year of employment. See
Employment Agreements with Named Executive Officers below for a description of
these agreements. |
|
|
|
|
2008 Annual Cash Bonus Awards. Applying the company performance modifier of 60% and
Mr. Millers individual performance modifier of 115% to Mr. Millers annual cash bonus
target (100% of base salary) resulted in a payout of $276,000, or 69% of his base
salary, in 2009 related to 2008 performance. Messrs. Tran and ONeil received the
guaranteed minimum bonus payouts of $212,706 and $250,000, respectively, in 2009
related to 2008 performance, each in accordance with the terms of their respective
employment agreements. Pursuant to the terms of his severance agreement, Mr. Kottoor
was paid a bonus in the amount of $201,600, as discussed below under Separation
Agreements and Potential Payments to Named Executive Officers upon Termination or
Change in Control. As discussed above, Messrs. Schiesser and Berg requested that they
not be paid cash bonuses for 2008. As discussed below under Separation Agreements
and Potential Payments to Named Executive Officers upon Termination or Change in
Control, no bonuses were awarded to Messrs. Farha and Behrens for fiscal year 2008. |
Fiscal Year 2009
No changes were made to annual cash bonus targets for fiscal year 2009 for any of the named
executive officers. As discussed above, a specific target has not been established for Mr. Berg,
but he will continue to be eligible to receive an annual cash bonus as determined in the discretion
of the Compensation Committee.
Long-Term Incentive Awards
We issue both restricted stock and non-qualified stock options to our executives as long-term
incentives. We believe that a combination of restricted stock and stock options aligns our
executives interests with those of our shareholders and provides meaningful retention
compensation. When making equity awards, our practice is to determine the dollar amount of equity
compensation that we desire to provide to the executive and then grant a number of shares of
restricted stock or a number of stock options that have a fair value equal to that amount on the
date of grant. For additional information on our equity award process, see Equity Award Process
below.
Prior to 2008, our practice was to use equity awards both as a retention tool and reward for
each executives prior year performance (pursuant to an annual equity award) as well as a periodic
incentive and retention tool (typically pursuant to a mid-year equity award), as recommended by Mr.
Farha. However, such awards were discretionary and were not made pursuant to any pre-established
program or policy. In addition, there was no set allocation between restricted stock and option
awards; rather, award determinations were based primarily on the recommendations of Mr. Farha.
However, as discussed below, beginning in 2008, the Compensation Committee determined to provide
additional structure and
consistency to our long-term incentive compensation program by establishing long-term incentive
targets for our executives. The Compensation Committee also
determined, on a going forward basis, to
award 50% of an executives long-term incentive value in restricted
29
stock and 50% in stock options as the Compensation Committee values both types of awards to balance
retention needs with future incentive tied to share price.
This new structure was first implemented for awards made in March 2008. However, due to
securities law restrictions to which we were then subject as a result not being timely in our SEC
filings, we were not able to issue restricted stock at that time. In lieu of the restricted stock
component of an executives long-term incentive award in March 2008, the Compensation Committee
approved a special performance-based long-term potential cash incentive award, as discussed below.
Determinations made in March 2009 also represented a deviation from our goal of awarding 50% of an
executives long-term incentive value in restricted stock and 50% in stock options due to the
limitations on shares available for issuance under our 2004 Equity Plan and current volatile
economic conditions, as well as restrictions on our ability to grant restricted stock in March
2009. In lieu of an equity award in March 2009, the Compensation Committee determined to approve a
special long-term potential cash incentive representing 50% of an executives long-term incentive
value and defer making determinations with regard to the other half until a later time.
Fiscal Year 2008
|
|
|
2008 Long-Term Incentive Targets. In March 2008, in order to impose more structure
and consistency to our equity compensation program, the Compensation Committee set
long-term incentive targets for each of Messrs. Kottoor and Miller. Expressed as a
percentage of each officers fiscal year 2008 base salary, the long-term incentive
targets were established at 150% for each executive and were determined based on the
desire of the Compensation Committee to target annual and long-term incentive
compensation at the 50th to 75th percentile of the market data. Although the long-term
incentive targets were first established by the Compensation Committee and communicated
to the executives in March 2008, these targets were used to determine the long-term
incentive awards made in March 2008 and were also the basis for determining the
long-term incentive awards to be made in March 2009 (other than for Mr. Kottoor, whose
annual 2009 long-term incentive award was determined in connection with the termination
of his employment effective December 19, 2008) (the long-term incentive award related
to fiscal year 2008 performance is referred to as the 2008 Long-Term Incentive). |
|
|
|
|
2008 Long-Term Incentive Stock Option Award. As discussed above, each executives
long-term incentive award granted in March 2008 (related to fiscal year 2007
performance) was divided between a stock option award and a potential performance-based
long-term cash incentive award, each as described in more detail below. In March 2008,
based on the recommendation of Mr. Schiesser, the Compensation Committee approved a
stock option award to purchase 17,898 shares of common stock for Mr. Kottoor and a
stock option award to purchase 16,004 shares of common stock for Mr. Miller. The
options have an exercise price of $43.45 per share and will vest in equal annual
installments on each of the first through fourth anniversaries of the grant date of the
award. These stock option awards were determined based on 50% of each executives
long-term incentive target, adjusted based on each executives overall fiscal year 2007
performance. In determining the size of Mr. Kottoors award, the Compensation
Committee considered his progress in building our information technology team,
upgrading and stabilizing our information technology systems and building new
capabilities in our enrollment process. In determining the size of Mr. Millers award,
the Compensation Committee considered the growth in our private fee-for-service
business and Mr. Millers leadership in addressing compliance concerns with CMS. See
the table entitled Grants of Plan-Based Awards below for details regarding these
equity awards. |
|
|
|
|
2008 Special Performance-Based Long-Term Cash Incentive Award. As stated above, in
March 2008, each of Messrs. Kottoor and Miller received an annual equity award
consisting solely of stock options which represented half of their targeted long-term
incentive award opportunity related to fiscal year 2007 performance. Because we could
not issue restricted stock for the other half of their long-term incentive award
opportunity due to securities law restrictions we were then subject to as discussed
above, the Compensation Committee approved a special performance-based long-term cash
incentive opportunity (the 2008 Special Performance-Based Long-Term Cash Incentive
Award), payable in September 2009 (other than for Mr. Kottoor, as discussed below), in
lieu of a restricted stock award. All associates eligible to receive a long-term
incentive award in March 2008, including Messrs. Kottoor and Miller, are eligible to
participate in this special incentive program. |
|
|
|
|
The target amounts for each associate, including Messrs. Kottoor and Miller,
were determined by the Compensation Committee based on 50% of each executives
targeted long-term incentive award opportunity, as adjusted for individual
performance. The target amounts are subject to increase or decrease by the Board by
up |
30
|
|
|
to 50% at the conclusion of the period based on the Boards subjective review of
the Companys performance
during the period (that is, March 2008 through September 2009). Mr. Kottoor was awarded
a target amount of $354,375 and Mr. Miller was awarded a target amount of $316,875. As a
result of the termination of Mr. Kottoors employment, Mr. Kottoors bonus was paid at
target on December 29, 2008 pursuant to the terms of his severance agreement. See
Separation Agreements and Potential Payments to Named Executive Officers upon
Termination or Change in Control below for the 2008 Special Performance-Based Long-Term
Cash Incentive Award paid to Mr. Kottoor. |
|
|
|
|
2008 New Hire Equity Awards. As discussed above, Messrs. Schiesser, Tran, Berg and
ONeil each negotiated an initial equity award of restricted stock and non-qualified
stock options in connection with being recruited in 2008. For a description of their
initial equity awards, see Negotiation of Employment Agreement Terms for 2008 Hires
above and Employment Agreements with Named Executive Officers below. See also the
table entitled Grants of Plan-Based Awards below for details regarding these equity
awards. |
Fiscal Year 2009
|
|
|
2009 Long-Term Incentive Targets. Messrs. Schiesser, Tran, Berg and ONeil were
each hired for their respective positions during 2008. Only Mr. Tran negotiated a
long-term incentive target in connection with being hired, equal to 150% of base salary
and included a guaranteed minimum for the initial calendar year of employment.
Although Messrs. Schiesser, Berg and ONeil did not negotiate specific targets, their
respective employment agreements provide that each is eligible to receive an annual
equity award as determined in the discretion of the Compensation Committee. In March
2009, the Compensation Committee determined to establish a long-term incentive target
for Mr. ONeil at 150% of base salary, which was applied to awards related to fiscal
year 2008 performance and also will be the basis for determining his long-term
incentive awards in future years, unless otherwise adjusted by the Compensation
Committee. Mr. ONeils target was determined by the Compensation Committee to be
reasonable and in line with the other senior executives at Mr. ONeils level, based in
part on market data provided by Watson Wyatt. |
|
|
|
|
As discussed above, the Compensation Committee has not established long-term incentive
targets for Messrs. Schiesser or Berg. No changes were made to long-term incentive
targets for fiscal year 2009 for any of the named executive officers for their long-term
incentive awards to be granted, if at all, in March 2010. |
|
|
|
|
2009 Long-Term Cash Bonus Awards. As discussed above, due to the limitations on
shares available for issuance under our 2004 Equity Plan and current volatile economic
conditions as well as restrictions on our ability to grant restricted stock in March
2009, in lieu of awarding an executives long-term incentive related to fiscal year
2008 performance entirely in equity, the Compensation Committee determined to approve a
special long-term potential cash incentive representing 50% of an executives long-term
incentive award opportunity. All associates eligible to receive a long-term incentive
award in March 2009, other than Messrs. Schiesser and Berg, were granted a 2009
Long-Term Cash Bonus Award. In March 2009, at the request of Mr. Schiesser, Mr. Tran
agreed to an amendment to his employment agreement providing for a cash award in lieu
of 50% of the equity award that he would otherwise be entitled to receive under his
employment agreement. |
|
|
|
|
The target amounts for each associate, including Messrs. Tran, Miller and
ONeil, were determined by the Compensation Committee based on 50% of each
executives targeted long-term incentive award opportunity, as adjusted for
individual performance. Applying the company performance modifier of 60% and each
executives individual performance modifier as discussed above to 50% of each
executives long-term incentive target results in awards of $159,530, $207,000 and
$254,052 to Messrs. Tran, Miller and ONeil respectively. As provided under the
2009 Long-Term Cash Bonus Plan, 50% of each executives award will be paid in
September 2010 and 50% will be paid in September 2011, each payment subject to
continued employment. The 2009 Long-Term Cash Bonus Plan also provides for
acceleration of any unpaid amounts in the event an executives employment is
terminated without cause within one year following a change in control. As stated
above, no long-term cash awards were made to Messrs. Schiesser or Berg. |
|
|
|
|
2009 Equity Awards. As discussed above, due to the limitations on shares available
for issuance under our 2004 Equity Plan and current volatile economic conditions as
well as restrictions on our ability to grant restricted stock in March 2009, the
Compensation Committee has deferred making determinations with regard to the other half
of long-term incentive awards related to 2008 performance until a later date. The
Compensation Committee has not determined when, if at all, equity awards will be
granted in 2009. |
31
Retention-Related Incentive Awards
Special Retention Bonus
In light of our concerns relating to retention of our associates, as well as the concerns of
our associates relating to job security, in November 2007 the Compensation Committee approved a
one-time special cash retention bonus (the Special Retention Bonus), payable in January 2009, to
bonus-eligible associates who were employed on October 31, 2007 assuming each associate remained
with the Company through December 31, 2008. Messrs. Kottoor and Miller were eligible to
participate in this program; Mr. Schiesser was not in a bonus-eligible position on October 31,
2007; Messrs. Tran, Berg and ONeil were not employed by the Company on October 31, 2007; and
Messrs. Farha and Behrens were specifically excluded from participating in the program.
Pursuant to the terms of the special retention bonus plan, all eligible associates in the
level of vice president or above, including Messrs. Kottoor and Miller, were eligible to earn a
retention bonus equal to 50% of their base salaries as of December 31, 2008. Accordingly, Mr.
Kottoor was eligible to earn a special retention bonus in the amount of $157,500. With respect to
Mr. Miller, although his base salary was increased to $400,000 in April 2008 (see Base Salary
Fiscal Year 2008 above), Mr. Millers special retention bonus of $162,500 was based on 50% of his
initial base salary increase for fiscal year 2008. For the amount of the Special Retention Bonus
paid to Mr. Kottoor upon the termination of his employment, see Potential Payments to Named
Executive Officers upon Termination or Change in Control below.
Equity Retention Stock Option Award
In addition to the special retention bonus discussed above, and due to the retention risk and
the significant drop in our stock price which reduced financial ties to our Company, in March 2008
the Compensation Committee approved the grant of additional stock option retention awards (the
Equity Retention Stock Option Award) to all members of our senior management team, other than
Messrs. Schiesser and Berg. At the time this award was granted, neither Mr. Tran nor Mr. ONeil
had been hired yet. The grants were determined based on the Compensation Committees review of an
internally-prepared analysis which showed, for each of Messrs. Kottoor and Miller, the decrease in
value of the equity awards held by each executive as a result of our significant stock price
decline in October 2007. The analysis showed that the stock options then-held by each such officer
were below the exercise price of the options (that is, the options were underwater). Because the
Compensation Committee and the Board believed it to be imperative that each executive be retained
and provided with an incentive to remain with the Company, the Compensation Committee approved a
stock option award to purchase 55,000 shares of common stock for Mr. Kottoor and a stock option
awards to purchase 40,000 shares of common stock for Mr. Miller as an additional retention
incentive. The options have an exercise price of $45.25 per share and vest in full, based on the
continued employment of the executive, in November 2009. See the table entitled Grants of
Plan-Based Awards below for details regarding these equity awards.
As a result of termination of Mr. Kottoors employment, Mr. Kottoors equity retention stock
option award accelerated in full, effective December 19, 2008. See Separation Agreements and
Potential Payments to Named Executive Officers upon Termination or Change in Control below.
Clawback Policies for Special Retention Bonus and Equity Retention Stock Option Awards
The terms of the special retention bonus and the equity retention stock option awards each
provide that, if it is determined by the Board, in its sole and absolute discretion, that an
associate receiving such award, including Messrs. Kottoor and Miller, has committed any:
|
|
|
wrongdoing that contributed to (i) any material misstatement or omission from any
report or statement filed by WellCare with the SEC, or (ii) any statement,
certification, cost report, claim for payment or other filing made under Medicare or
Medicaid that was false, fraudulent, or for an item or service not provided as claimed; |
|
|
|
|
gross misconduct; |
|
|
|
|
breach of fiduciary duty to the Company; or |
|
|
|
|
fraud, |
32
then, in the case of the special retention bonus, the associate will be required to pay back to
WellCare any payments the associate has received pursuant to the special retention bonus plan. In
the case of the equity retention stock option award, the option will be immediately forfeited and
cancelled. If the option has been exercised prior to the Boards determination, the associate is
required to pay to WellCare an amount equal to the difference between the aggregate value of the
shares acquired upon exercise of the option at the date of the Board determination and the
aggregate exercise price paid by the associate.
Equity Award Process
We maintain an equity award process to ensure that the authorization, timing and pricing of
all equity awards are processed, recorded, disclosed and accounted for in full compliance with all
applicable laws and regulations. For equity awards issued to existing executive officers and
associates, the awards are effective and, in the case of options, the exercise price is set, as of
the date of the approval. For equity awards issued to newly-hired executive officers, the awards
are effective and, in the case of options, the exercise price is set, as of the later of the
individuals first date of employment or the date of approval. For equity awards to new Board
members, the awards are effective and, in the case of options, the exercise price is set, as of the
first date of service as a Board member. In July 2006, the Compensation Committee also developed a
policy whereby annual equity awards to incumbent Board members will be effective, and in the case
of stock options, the exercise price will be set, as of the date of our annual shareholders
meeting. Approval for all equity awards is obtained in advance of or on the date of grant. The
exercise price for all stock option awards is the officially-quoted closing selling price of our
common stock on the NYSE on the date of grant (or the officially-quoted closing selling price of
our common stock on the next trading day if the NYSE is closed on the date in question).
Commencing in April 2009, the Board adopted a Non-Employee Director Compensation Policy. See
Director Compensation 2009 Director Compensation above for a description of this new policy.
Because we hold our Board and committee meetings shortly before we announce our quarterly and
annual financial results, there are times when equity awards for our executive officers are
approved and, according to our process, are effective, shortly before we announce earnings.
However, we do not have a program, plan or practice to time our equity awards in coordination with
the release of material, non-public information.
Perquisites
Pursuant to the terms of their respective employment agreements, Mr. Farha was entitled to a
monthly allowance of $4,000 to maintain an apartment in New York, and each of Messrs. Farha and
Behrens were entitled to an annual allowance of $5,000 and $3,000, respectively, to be applied
toward supplemental life and disability insurance policies, although Mr. Behrens decided not to
renew his disability policy since fiscal year 2006. Because we believed that these executives
should receive the total amount of their benefit, we grossed up these allowance payments to cover
any income taxes attributed to the payments.
Messrs. Tran and ONeil are entitled to monthly allowances of $6,000 and $4,600, respectively,
from their respective dates of hire through December 2009 to cover housing and automobile expenses
in Tampa, Florida. Mr. ONeil is also entitled to be reimbursed for expenses incurred in traveling
between Baltimore, Maryland and Tampa, Florida; however, beginning in February 2009, in order to
reduce administrative burdens and also limit expenses, Mr. ONeil agreed to accept a monthly
allowance of $1,800 to cover these expenses. Although we grossed up certain reimbursement payments
related to commuting expenses, we discontinued this practice in February 2009.
In addition, as negotiated with Messrs. Tran, Kottoor and Miller upon their hire, we agreed to
pay reasonable expenses incurred by each of them to relocate to Tampa, Florida. We also reimbursed
Messrs. Schiesser, Tran, Berg and ONeil for legal fees and expenses in connection with the
negotiation of their employment agreements upon hire.
We own a corporate aircraft that is used primarily for business travel. Families and invited
guests of Directors and executives occasionally fly on our corporate aircraft as additional
passengers on business flights, which is treated as a personal benefit to the Director or
executive. In those cases, the aggregate incremental cost to us is a de minimis amount. For tax
reporting purposes, when family members or guests of a Director or executive travel on business
flights, the value of such personal use, determined using a method based on the Standard Industry
Fair Level (SIFL) rates as published by the Internal Revenue Service, is imputed as income to
such Director or executive. Such imputed income would be included in taxable income for the
Director or executive and reflected in compensation tables herein to the extent the SIFL rate
exceeds the amount reimbursed by the Director or executive. None of our Directors or executives
were attributed any such income in fiscal year 2008.
33
Overall, we view the cost to the Company of these perquisites as de minimis as compared to the
goodwill established between the Company and the executives.
Tax and Accounting Implications
Tax deductibility
Section 162(m) of the Internal Revenue Code limits deductibility to any publicly-held
corporation of certain compensation for a covered employee, consisting of our Chief Executive
Officer and three most highly paid executive officers who are employed on the last day of our
fiscal year (other than the Chief Financial Officer), in excess of $1 million per year. If certain
conditions are met, performance-based compensation may be excluded from this limitation. While we
do not design our compensation programs for tax purposes, we do design our plans to be tax
efficient for the Company where possible. However, if following the requirements of Section 162(m)
would not be in the best interests of the Company and our shareholders, the Compensation Committee
may conclude that the payment of non-deductible compensation is appropriate under the circumstances
to allow us to pay competitive compensation to our executive officers. During 2008, certain
compensation paid to Messrs. Schiesser and Berg was non-deductible under Section 162(m).
Accounting for stock-based compensation
Beginning on January 1, 2006, we began accounting for stock-based payments, including stock
options, performance shares and restricted stock awards, in accordance with FAS 123R. The
Compensation Committee and the Chief Executive Officer take into consideration the accounting
treatment under FAS 123R of alternative award proposals when determining the form and amount of
equity compensation awards. Because our determinations regarding equity awards are generally based
on a dollar value, as discussed above, FAS 123R has impacted the size and terms of our equity
awards.
Compensation Committee Report
The Compensation Committee, comprised solely of independent Directors, has reviewed and
discussed the Compensation Discussion and Analysis with the Companys management. Based on this
review and discussion, the Compensation Committee recommended to the Board that the Compensation
Discussion and Analysis be included in this proxy statement on Schedule 14A.
The Compensation Committee
Neal Moszkowski (Chairperson)*
Alif Hourani
Kevin Hickey
|
|
|
* |
|
Mr. Gallitano was recently appointed the Chairperson of the Compensation Committee. |
COMPENSATION COMMITTEE INTERLOCKS AND INSIDER PARTICIPATION
During fiscal year 2008, Messrs. Hickey, Hourani and Moszkowski served as the members of the
Compensation Committee, with Mr. Moszkowski serving as the chairperson. None of these members has
ever been an officer or employee of the Company or any of its subsidiaries or had any relationship
during fiscal year 2008 that would require disclosure under Item 404 of SEC Regulation S-K. During
fiscal year 2008, none of our executive officers served on the Compensation Committee (or its
equivalent) or Board of Directors of another entity, one of whose executive officers served on our
Board or Compensation Committee.
EXECUTIVE COMPENSATION
Summary Compensation Table
The following table and footnotes discuss the compensation of Heath G. Schiesser and Todd S.
Farha, the two individuals who served as our principal executive officer during 2008; Thomas L.
Tran and Paul L. Behrens, the two individuals who served as our principal financial officer during
2008; Charles G. Berg, Adam T. Miller and Thomas F. ONeil III, our three other most highly
compensated executive officers who were serving as executive officers at the end of 2008; and Anil
Kottoor, an individual who would have been one of our three other most highly compensated executive
officers if he had served as an executive officer at the end of 2008.
34
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-Equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock |
|
Option |
|
Incentive Plan |
|
All Other |
|
Name and |
|
|
|
|
|
Salary(9) |
|
Bonus(10) |
|
Awards(11) |
|
Awards(11) |
|
Compensation(12) |
|
Compensation(13) |
|
Total |
Principal Position |
|
Year |
|
($) |
|
($) |
|
($) |
|
($) |
|
($) |
|
($) |
|
($) |
Heath G. Schiesser
President and Chief
Executive Officer(1) |
|
|
2008 |
|
|
|
365,292 |
|
|
|
|
|
|
|
2,609,963 |
|
|
|
2,379,614 |
|
|
|
|
|
|
|
2,722,849 |
|
|
|
8,077,718 |
|
Todd S. Farha Chairman, President and Chief Executive Officer(2) |
|
|
2008 |
|
|
|
109,231 |
|
|
|
|
|
|
|
551,132 |
|
|
|
511,894 |
|
|
|
|
|
|
|
43,079 |
|
|
|
1,215,336 |
|
|
|
2007 |
|
|
|
400,000 |
|
|
|
|
|
|
|
3,383,307 |
|
|
|
2,224,015 |
|
|
|
|
|
|
|
86,790 |
|
|
|
6,094,112 |
|
|
|
2006 |
|
|
|
400,000 |
|
|
|
400,000 |
|
|
|
2,758,269 |
|
|
|
1,635,495 |
|
|
|
|
|
|
|
77,061 |
|
|
|
5,270,825 |
|
Thomas L. Tran
Senior Vice President and
Chief Financial Officer(3) |
|
|
2008 |
|
|
|
200,962 |
|
|
|
287,706 |
|
|
|
163,717 |
|
|
|
139,165 |
|
|
|
|
|
|
|
41,309 |
|
|
|
832,859 |
|
Paul L. Behrens Senior Vice President and Chief Financial Officer(4) |
|
|
2008 |
|
|
|
83,462 |
|
|
|
|
|
|
|
80,002 |
|
|
|
39,369 |
|
|
|
|
|
|
|
662 |
|
|
|
203,495 |
|
|
|
2007 |
|
|
|
305,000 |
|
|
|
|
|
|
|
341,438 |
|
|
|
382,134 |
|
|
|
|
|
|
|
|
|
|
|
1,028,572 |
|
|
|
2006 |
|
|
|
282,269 |
|
|
|
200,000 |
|
|
|
361,232 |
|
|
|
136,597 |
|
|
|
|
|
|
|
4,079 |
|
|
|
984,177 |
|
Charles G. Berg
Executive Chairman(5) |
|
|
2008 |
|
|
|
453,846 |
|
|
|
|
|
|
|
4,019,086 |
|
|
|
2,582,640 |
|
|
|
|
|
|
|
118,162 |
|
|
|
7,173,734 |
|
Anil Kottoor
Senior Vice President and
Chief Information Officer(6) |
|
|
2008 |
|
|
|
305,000 |
|
|
|
|
|
|
|
1,094,079 |
|
|
|
962,027 |
|
|
|
|
|
|
|
718,855 |
|
|
|
3,079,961 |
|
|
|
2007 |
|
|
|
244,231 |
|
|
|
131,250 |
|
|
|
206,013 |
|
|
|
204,504 |
|
|
|
|
|
|
|
20,031 |
|
|
|
806,029 |
|
Adam T. Miller
Senior Vice President,
National Medicare and Government Relations(7) |
|
|
2008 |
|
|
|
381,539 |
|
|
|
276,000 |
|
|
|
295,596 |
|
|
|
538,071 |
|
|
|
162,500 |
|
|
|
6,673 |
|
|
|
1,660,379 |
|
|
|
2007 |
|
|
|
278,077 |
|
|
|
182,000 |
|
|
|
249,320 |
|
|
|
262,261 |
|
|
|
|
|
|
|
10,687 |
|
|
|
982,345 |
|
|
Thomas F. ONeil III
Vice Chairman(8) |
|
|
2008 |
|
|
|
365,385 |
|
|
|
350,000 |
|
|
|
372,862 |
|
|
|
335,826 |
|
|
|
|
|
|
|
57,113 |
|
|
|
1,481,186 |
|
|
|
|
(1) |
|
Mr. Schiesser began his service as principal executive officer in January 2008. Compensation for Mr. Schiesser is provided only for
2008 because he was not a named executive officer for 2006 or 2007. |
|
(2) |
|
Mr. Farhas service as principal executive officer terminated in January 2008. |
|
(3) |
|
Mr. Tran began his service as principal financial officer in July 2008. Mr. Tran was not employed by the Company prior to July 2008. |
|
(4) |
|
Mr. Behrens service as principal financial officer terminated in January 2008. |
|
(5) |
|
Mr. Berg began his service as an executive officer in January 2008. Mr. Berg was not employed by the Company prior to January 2008. |
|
(6) |
|
Mr. Kottoors service as an executive officer terminated in December 2008. Compensation for Mr. Kottoor is provided only for 2007
and 2008 because he was not employed by the Company in 2006. |
|
(7) |
|
Compensation for Mr. Miller is provided only for 2007 and 2008 because he was not a named executive officer for 2006. |
|
(8) |
|
Mr. ONeil began his service as an executive officer in April 2008. Mr. ONeil was not employed by the Company prior to April 2008.
On June 3, 2009, Mr. ONeil ceased serving as our Senior Vice President, General Counsel and Secretary and was appointed our
executive Vice Chairman. |
|
(9) |
|
Represents total salary earned by these named executive officers and includes amounts of compensation contributed by the named
executive officers to our 401(k) savings plan for each respective fiscal year. |
|
(10) |
|
Represents discretionary bonuses earned by the named executive officers during each respective fiscal year. Mr. Trans bonus for
2008 consists of a signing bonus in the amount of $75,000 and a minimum guaranteed bonus for 2008 in the amount of $212,706. Mr.
ONeils bonus for 2008 consists of a signing bonus in the amount of $100,000 and a minimum guaranteed bonus for 2008 in the amount
of $250,000. See Employment Agreements with Named Executive Officers below. |
|
(11) |
|
The amounts included in the Stock Awards and Option Awards columns are the amounts of compensation cost related to performance
shares (with respect to Mr. Farha only), restricted stock awards and stock option awards, respectively, recognized by us in our
financial statements during fiscal years 2008, 2007 and 2006, respectively, in accordance with FAS 123R. Pursuant to SEC rules, the
amounts shown exclude the impact of estimated forfeitures related to service-based vesting conditions. These amounts reflect our
accounting expense for these awards and do not correspond to the actual value that will be realized by the executives. For a
discussion of valuation assumptions and methodologies, see Note 2 to our 2008 consolidated financial statements included in our
annual report on Form 10-K for the year-ended December 31, 2008; Note 2 to our 2007 consolidated financial statements included in
our annual report on Form 10-K for the year-ended December 31, 2007; Note 2 to our 2006 consolidated financial statements included
in our annual report on Form 10-K for the year-ended December 31, 2006; and Note 14 to our 2005 consolidated financial statements
included in our annual report on Form 10-K for the year-ended December 31, 2005. |
|
(12) |
|
Represents bonus earned by Mr. Miller in 2008 under the WellCare Health Plans, Inc. Special Retention Bonus Plan. See
Retention-Related Incentive Awards Special Retention Bonus above. |
|
(13) |
|
The following table shows the components of the All Other Compensation for fiscal year 2008: |
35
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Housing & |
|
|
|
|
|
|
|
|
|
Legal |
|
|
|
|
|
|
|
|
|
|
Separation |
|
Automobile |
|
Commuting |
|
|
|
|
|
401(k) |
|
Fees and |
|
Tax |
|
All Other |
|
|
|
|
|
|
Payments(1) |
|
Allowance(2) |
|
Reimbursements(3) |
|
Relocation(4) |
|
Match |
|
Expenses(5) |
|
Gross-Ups(6) |
|
Compensation |
Name |
|
Year |
|
($) |
|
($) |
|
($) |
|
($) |
|
($) |
|
($) |
|
($) |
|
($) |
Heath G. Schiesser |
|
|
2008 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,266 |
|
|
|
240,591 |
|
|
|
2,480,992 |
|
|
|
2,722,849 |
|
Todd S. Farha |
|
|
2008 |
|
|
|
17,223 |
|
|
|
16,000 |
|
|
|
|
|
|
|
|
|
|
|
2,100 |
|
|
|
|
|
|
|
7,756 |
|
|
|
43,079 |
|
Thomas L. Tran |
|
|
2008 |
|
|
|
|
|
|
|
30,000 |
|
|
|
3,516 |
|
|
|
538 |
|
|
|
4,925 |
|
|
|
1,380 |
|
|
|
950 |
|
|
|
41,309 |
|
Paul L. Behrens |
|
|
2008 |
|
|
|
662 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
662 |
|
Charles G. Berg |
|
|
2008 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
118,162 |
|
|
|
|
|
|
|
118,162 |
|
Anil Kottoor |
|
|
2008 |
|
|
|
713,475 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5,380 |
|
|
|
|
|
|
|
|
|
|
|
718,855 |
|
Adam T. Miller |
|
|
2008 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6,673 |
|
|
|
|
|
|
|
|
|
|
|
6,673 |
|
Thomas F. ONeil III |
|
|
2008 |
|
|
|
|
|
|
|
41,400 |
|
|
|
4,369 |
|
|
|
44 |
|
|
|
5,768 |
|
|
|
3,318 |
|
|
|
2,214 |
|
|
|
57,113 |
|
|
|
|
(1) |
|
Represents amounts paid upon separation of employment. With respect
to Messrs. Farha and Behrens, the amounts represent the value of
accrued but unused vacation days as of their respective dates of
termination of employment. With respect to Mr. Kottoor, the amount
represents the payment made in 2008 pursuant to his separation
agreement and general release. Subject to Mr. Kottoors compliance
with non-competition, non-solicitation, confidentiality and
non-disparagement covenants, he is also entitled to additional
payments during 2009 and 2010 totaling $666,346. See Potential
Payments to Named Executive Officers upon Termination or Change in
Control below. |
|
(2) |
|
Represents cash allowances to cover housing and automobile expenses in
New York, New York with respect to Mr. Farha and in Tampa, Florida
with respect to Messrs. Tran and ONeil. See Employment Agreements
with Named Executive Officers below. |
|
(3) |
|
Represents amounts paid by the Company or reimbursed to the executive
for travel between executives home and the Companys headquarters in
Tampa, Florida. |
|
(4) |
|
Represents amounts paid by the Company for the relocation of Messrs.
Tran and ONeil to Tampa, Florida in connection with their hire. See
Employment Agreements with Named Executive Officers below. |
|
(5) |
|
Represents amounts paid by the Company for legal fees and expenses in
connection with the negotiation of executives employment agreement
and related agreements, including, in the case of Messrs. Schiesser
and Berg, legal diligence with regard to the pending governmental
investigations and civil actions. See Employment Agreements with
Named Executive Officers below. |
|
(6) |
|
With respect to Mr. Schiesser, the amount represents the payment to
cover income taxes in connection with Mr. Schiesser making an election
under Section 83(b) of the Internal Revenue Code of 1986, as amended,
with respect to 100,000 shares of restricted stock granted in January
2008. See Employment Agreements below. With respect to Mr. Farha,
the amount represents the payment to cover income taxes attributed to
his housing and automobile allowance. With respect to Messrs. Tran
and ONeil, the amounts represent the payments to cover income taxes
attributed to their respective commuting reimbursements. See
Employment Agreements with Named Executive Officers below. |
Grants of Plan-Based Awards
The following table sets forth information regarding each grant of a plan-based award made to
a named executive officer during fiscal year 2008.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
All Other |
|
All Other |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock |
|
Option |
|
|
|
|
|
Grant |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Awards: |
|
Awards: |
|
Exercise |
|
Date Fair |
|
|
|
|
|
|
|
|
|
|
Estimated Future Payouts |
|
Number |
|
Number |
|
or Base |
|
Value of |
|
|
|
|
|
|
|
|
|
|
Under Non-Equity |
|
of Shares |
|
of Securities |
|
Price of |
|
Stock and |
|
|
|
|
|
|
|
|
|
|
Incentive Plan Awards(2) |
|
of Stock |
|
Underlying |
|
Option |
|
Option |
|
|
Grant |
|
Approval |
|
Threshold |
|
Target |
|
Maximum |
|
or Units(3) |
|
Options(4) |
|
Awards(5) |
|
Awards(6) |
Name |
|
Date(1) |
|
Date(1) |
|
($) |
|
($) |
|
($) |
|
(#) |
|
(#) |
|
($/Sh) |
|
($) |
Heath G. Schiesser |
|
|
01/25/08 |
|
|
|
01/25/08 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
250,000 |
(7) |
|
|
|
|
|
|
|
|
|
|
10,780,000 |
|
|
|
|
01/25/08 |
|
|
|
01/25/08 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
500,000 |
(8) |
|
|
43.12 |
|
|
|
9,599,450 |
|
Thomas L. Tran |
|
|
07/21/08 |
|
|
|
07/14/08 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
50,000 |
(9) |
|
|
|
|
|
|
|
|
|
|
1,461,500 |
|
|
|
|
07/21/08 |
|
|
|
07/14/08 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
100,000 |
(9) |
|
|
29.23 |
|
|
|
1,242,320 |
|
Charles G. Berg |
|
|
01/25/08 |
|
|
|
01/25/08 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
200,000 |
(10) |
|
|
|
|
|
|
|
|
|
|
8,624,000 |
|
|
|
|
01/25/08 |
|
|
|
01/25/08 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
300,000 |
(11) |
|
|
43.12 |
|
|
|
5,541,750 |
|
Anil Kottoor |
|
|
|
|
|
|
|
|
|
|
177,188 |
|
|
|
354,375 |
|
|
|
531,563 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
03/05/08 |
|
|
|
03/05/08 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
55,000 |
(12) |
|
|
45.25 |
|
|
|
737,088 |
|
|
|
|
03/06/08 |
|
|
|
03/06/08 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
17,898 |
(9) |
|
|
43.45 |
|
|
|
304,568 |
|
Adam T. Miller |
|
|
|
|
|
|
|
|
|
|
158,438 |
|
|
|
316,875 |
|
|
|
475,313 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
03/05/08 |
|
|
|
03/05/08 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
40,000 |
(13) |
|
|
45.25 |
|
|
|
536,064 |
|
|
|
|
03/06/08 |
|
|
|
03/06/08 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
16,004 |
(9) |
|
|
43.45 |
|
|
|
272,338 |
|
Thomas F. ONeil III |
|
|
04/01/08 |
|
|
|
03/03/08 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
50,000 |
(9) |
|
|
|
|
|
|
|
|
|
|
1,985,000 |
|
|
|
|
04/01/08 |
|
|
|
03/03/08 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
100,000 |
(9) |
|
|
39.70 |
|
|
|
1,787,830 |
|
|
|
|
(1) |
|
Our equity award process is described in more detail under Equity Award Process above. |
|
(2) |
|
This column shows the 2008 Special Performance-Based Long-Term Cash Incentive Awards made in March 2008 and payable in September 2009. See 2008 Special
Performance-Based Long-Term Cash Incentive Award above for a description of these awards. With regard to Mr. Kottoor, his award was paid at target
pursuant to his separation agreement and general release. See Separation Agreements and Potential Payments to Named Executive Officers upon Termination
or Change in Control below. |
|
(3) |
|
This column shows the number of shares of restricted stock granted to our named executive officers in fiscal year 2008. All grants were made under |
36
|
|
|
|
|
our 2004
Equity Incentive Plan, except the grant to Mr. ONeil which was a non-plan grant. These awards are subject to continued service through the applicable
vesting dates, and are not subject to pre-established performance goals. Acceleration of vesting of awards is described in more detail below under
Potential Payments to Named Executive Officers upon Termination or Change in Control. |
|
(4) |
|
This column shows the number of stock options granted to our named executive officers in fiscal year 2008. All grants were made under our 2004 Equity
Incentive Plan, except the grant to Mr. ONeil which was a non-plan grant. These awards are subject to continued service through the applicable vesting
dates, and are not subject to pre-established performance goals. Acceleration of vesting of awards is described in more detail below under Potential
Payments to Named Executive Officers upon Termination or Change in Control. |
|
(5) |
|
This column shows the exercise price for the stock options granted, which was the closing market price of our stock on the date of grant. |
|
(6) |
|
This column shows the full grant date fair value of stock options and restricted stock granted to our named executive officers in fiscal year 2008
calculated in accordance with FAS 123R. These amounts reflect the accounting expense that we will recognize over the vesting term for these awards and do
not correspond to the actual value that will be realized by the executives. |
|
(7) |
|
Award vests in equal quarterly installments on the 25th day of every third calendar month for forty-eight months, commencing on the date of grant. |
|
(8) |
|
Award vests in approximately equal monthly installments on the 25th day of each calendar month following the date of grant for forty-eight
consecutive months. |
|
(9) |
|
Award vests in equal annual installments on each of the first through fourth anniversaries of the date of grant. |
|
(10) |
|
Award vests as to twenty-five percent (25%) on the 25th day of the sixth calendar month following the date of grant and the remaining balance
vest in equal quarterly installments on the 25th day of every third calendar month for eighteen months. |
|
(11) |
|
Award vests in equal quarterly installments on the 25th day of every third calendar month for twenty-four months, commencing on the date of
grant. The original terms of this award were amended in 2008 to accurately reflect the intent of the parties as expressed in Mr. Bergs employment
agreement that, in the event of any termination of employment by Mr. Berg without good reason (as defined in the employment agreement) on or after January
25, 2010, the option would remain exercisable for its full ten-year term. See Employment Agreements with Named Executive Officers below. |
|
(12) |
|
Award originally scheduled to vest in full in November 2009. However, this award was amended in 2008 and vested in full in December 2008 in connection with
Mr. Kottoors termination of employment. See Potential Payments to Named Executive Officers upon Termination or Change in Control below. |
|
(13) |
|
Award vests in full in November 2009. |
Additional Information With Respect to the Summary Compensation Table and Grants of Plan-Based
Awards
In addition to the information provided below, see Compensation Discussion and Analysis
above for a discussion of certain named executive officers amount of salary and bonus compared to
total compensation.
Employment Agreements with Named Executive Officers
Heath G. Schiesser
Pursuant to an employment agreement with Mr. Schiesser, dated January 25, 2008, Mr. Schiesser
agreed to serve as our President and Chief Executive Officer, with an initial base salary of
$400,000. He is also entitled to receive an annual cash bonus based on his achievement of
performance objectives set by the Compensation Committee, after consultation with Mr. Schiesser,
with a targeted bonus of 200% of his annual salary for each fiscal year, as well as special bonuses
at the discretion of the Compensation Committee. Mr. Schiesser is also entitled to participate in
all Company benefit plans on the most favorable basis available to any senior executive of the
Company. The employment agreement provides that the Company will reimburse Mr. Schiesser for legal
fees and expenses in connection with the negotiation of his employment agreement. The employment
agreement also includes confidentiality and non-competition provisions, including a requirement
that Mr. Schiesser not seek employment with, or ownership in, a company in direct competition with
the Company and its subsidiaries for a period of one year after the termination of his employment.
The employment agreement has an initial term of four years and will automatically renew for
successive one-year periods thereafter unless either party notifies the other that the term will
not be extended. As noted above under Proposal Number One Election of Directors Class I
Director Nominees, on June 26, 2009, Mr. Schiesser informed the Board of Directors that he intends
to resign from his current officer and Director positions upon the appointment of a new President
and Chief Executive Officer. It is currently uncertain when Mr. Schiessers employment will
terminate.
Pursuant to the employment agreement, Mr. Schiesser also received (i) a non-qualified stock
option to purchase 500,000 shares of the Companys common stock and (ii) 250,000 restricted shares
of the Companys common stock, each of which was granted pursuant to our 2004 Equity Plan. See
Grants of Plan-Based Awards above. The non-qualified stock options have a ten year term and a
per share exercise price of $43.12, which was based on the closing price of our common stock on the
date of grant. The non-qualified stock options vest in equal monthly installments on the
25th day of each calendar month following January 25, 2008 for forty-eight consecutive
months. The restricted shares vest in equal quarterly installments on the 25th day of
every third calendar month for forty-eight months, commencing on January 25, 2008. The employment
agreement also provides that we will pay, on a fully-grossed up basis, all federal, state, and
local income taxes incurred by Mr. Schiesser on compensation resulting from Mr. Schiesser making an
election under Section 83(b) of the Code on the 100,000 restricted shares that are scheduled to
vest first. See footnote 13 in the Summary Compensation Table above. In addition, Mr. Schiesser
is entitled to earn future equity compensation awards and/or other long term incentive compensation
as determined in the discretion of the Compensation Committee.
37
Pursuant to the employment agreement described above, Mr. Schiesser is also entitled to
certain additional payments and benefits in the event of a change in control or his employment is
terminated under certain circumstances. For a description of these payments and benefits, see
Potential Payments to Named Executive Officers upon Termination or Change in Control.
Todd S. Farha
Mr. Farha terminated his employment as our President and Chief Executive Officer in January
2008; however, Mr. Farha served as our President and Chief Executive Officer pursuant to an amended
and restated employment agreement dated June 6, 2005, pursuant to which he was entitled to certain
payments and benefits upon termination of employment or a change in control. For a description of
each of these provisions and payments, as well as the separation agreement entered into between the
Company and Mr. Farha, see Separation Agreements and Potential Payments to Named Executive
Officers upon Termination or Change in Control.
Thomas L. Tran
Pursuant to an employment agreement with Mr. Tran, dated July 21, 2008, Mr. Tran agreed to
serve as our Senior Vice President and Chief Financial Officer, with an initial annual base salary
of $475,000 and an initial annual cash bonus target of 100% of his base salary, with a minimum
guaranteed bonus of $475,000 for fiscal year 2008, pro rated for the portion of the calendar year
Mr. Tran is employed. In addition, the employment agreement provided for a one-time cash signing
bonus of $75,000 and that we will pay Mr. Tran an allowance of $6,000 per month through December
2009 as an allowance for housing in the Tampa area and as an automobile allowance. In addition,
the employment agreement provided that we would pay reasonable relocation expenses, up to $25,000,
for him to relocate to Tampa, Florida in connection with his employment by us, and that the Company
will reimburse Mr. Tran for legal fees and expenses in connection with the negotiation of his
employment agreement. The employment agreement also includes confidentiality and non-competition
provisions, including a requirement that Mr. Tran not seek employment with, or ownership in, a
company in direct competition with the Company and its subsidiaries for a period of one year after
the termination of his employment. The employment agreement has an initial term of four years and
will automatically renew for successive one-year periods thereafter unless either party notifies
the other that the term will not be extended.
Pursuant to the employment agreement, Mr. Tran also received (i) a non-qualified stock option
to purchase 100,000 shares of the Companys common stock and (ii) 50,000 restricted shares of the
Companys common stock, each of which was granted pursuant to our 2004 Equity Plan. See Grants of
Plan-Based Awards above. The non-qualified stock options have a ten year term and a per share
exercise price of $29.23, which was based on the closing price of our common stock on the date of
grant. Both the non-qualified stock options and the restricted shares of common stock will vest in
equal annual installments on each of the first through fourth anniversaries of the grant date of
the award. In addition, Mr. Tran will be entitled to earn equity compensation awards based upon
Mr. Trans achievement of specified performance objectives, with an annual equity compensation
award target of 150% of Mr. Trans annual salary for each fiscal year (with a minimum guaranteed
annual equity compensation award in 2009 (related to fiscal year 2008 performance) of 100% of Mr.
Trans annual salary for fiscal year 2008, pro-rated for the portion of the calendar year Mr. Tran
is employed).
The employment agreement described above was amended on March 10, 2009 to provide that 50% of
Mr. Trans minimum guaranteed equity compensation award in 2009 would be paid in the form of a cash
award under the 2009 Long Term Cash Bonus Plan.
Pursuant to the employment agreement described above, Mr. Tran is also entitled to certain
additional payments and benefits in the event his employment is terminated under certain
circumstances. For a description of these payments and benefits, see Potential Payments to Named
Executive Officers upon Termination or Change in Control.
Paul L. Behrens
Mr. Behrens terminated his employment as our Senior Vice President and Chief Financial Officer
in January 2008; however, Mr. Behrens served as our Senior Vice President and Chief Financial
Officer pursuant to an employment agreement dated September 15, 2003, pursuant to which he was
entitled to certain payments and benefits upon termination. For a description of each of these
provisions and payments, as well as the separation agreement entered into between the Company and
Mr. Behrens, see Separation Agreements and Potential Payments to Named Executive Officers upon
Termination or Change in Control.
38
Charles G. Berg
Pursuant to a letter agreement with Mr. Berg, dated January 25, 2008, Mr. Berg agreed to serve
as our Executive Chairman, with an initial base salary of $500,000. Mr. Berg will be eligible to
participate in the employee benefit plans maintained by the Company and its subsidiaries for senior
executives on the same basis as other executive officers. He will also be eligible to receive, in
the sole discretion of the Compensation Committee, an annual bonus based on his individual
performance and the performance of the Company. The letter agreement provides that the Company
will reimburse Mr. Berg for legal fees and expenses in connection with the negotiation of his
letter agreement. The letter agreement provides that Mr. Berg not seek employment with, or
ownership in, a company in direct competition with the Company and its subsidiaries during any
period in which he is receiving severance payments. The letter agreement has a term of two years.
Pursuant to the letter agreement, Mr. Berg also received (i) a non-qualified stock option to
purchase 300,000 shares of the Companys common stock and (ii) 200,000 restricted shares of the
Companys common stock, each of which was granted pursuant to our 2004 Equity Plan. See Grants of
Plan-Based Awards above. The non-qualified stock options have a ten year term and a per share
exercise price of $43.12, which was based on the closing price of the Companys common stock on the
date of grant. The non-qualified stock options vest and become exercisable in eight quarterly
installments beginning three months after January 25, 2008 and continuing quarterly thereafter.
Twenty-five percent (25%) of the restricted shares vested six months after January 25, 2008 and the
remaining restricted shares vest quarterly thereafter.
Pursuant to the letter agreement, Mr. Berg is also entitled to certain additional payments and
benefits in the event of a change in control or his employment is terminated under certain
circumstances. For a description of these payments and benefits, see Potential Payments to Named
Executive Officers upon Termination or Change in Control.
Anil Kottoor
Mr. Kottoors service as our Senior Vice President and Chief Information Officer terminated in
December 2008; however, Mr. Kottoor served as our Senior Vice President and Chief Information
Officer pursuant to an offer letter dated December 18, 2006 and a letter agreement dated July 2,
2008, pursuant to which he was entitled to certain payments and benefits upon termination. For a
description of each of these provisions and payments, as well as the separation agreement entered
into between the Company and Mr. Kottoor, see Separation Agreements and Potential Payments to
Named Executive Officers upon Termination or Change in Control.
Adam T. Miller
Pursuant to an offer letter with Mr. Miller, dated January 17, 2006, Mr. Miller agreed to
serve as our Chief Operating Officer, PDP with an initial annual base salary of $270,000 and an
initial annual cash bonus target of 50% of his base salary, with a guaranteed cash bonus of 35% of
his base salary during fiscal year 2006. Mr. Miller also received a grant of (i) 25,000 shares of
restricted stock and (ii) a stock option to purchase 60,000 shares of common stock, each of which
vest over a five-year period and was granted pursuant to our 2004 Equity Plan. See Grants of
Plan-Based Awards above.
Pursuant to the offer letter described above, Mr. Miller is also entitled to certain
additional payments and benefits in the event his employment is terminated under certain
circumstances. For a description of these payments and benefits, see Potential Payments to Named
Executive Officers upon Termination or Change in Control.
As discussed in the Compensation Discussion and Analysis above, since the execution of his
2006 offer letter, Mr. Miller has received, among other things, increases in his base salary and
bonus targets, as well as additional equity awards.
Thomas F. ONeil III
Pursuant to an employment agreement with Mr. ONeil, dated April 1, 2008, Mr. ONeil agreed to
serve as our Senior Vice President, General Counsel and Secretary, with an initial annual base
salary of $500,000 and an initial annual cash bonus target of 50% of his base salary, with a
minimum guaranteed cash bonus of $250,000 for fiscal year 2008. In addition, the employment
agreement provided for a one-time cash signing bonus of $100,000 and that we will pay Mr. ONeil an
allowance of $4,600 per month through December 2009 to cover expenses incurred in connection with
his housing and car allowance. The employment agreement also provides that we will pay or
reimburse Mr. ONeil for expenses incurred in traveling between Baltimore, Maryland and Tampa,
Florida (although, as discussed below, this
provision was amended in 2009), and that the Company will reimburse Mr. ONeil for legal fees and
expenses in connection with the negotiation of his employment agreement. The employment agreement
also includes confidentiality and non-competition provisions, including a requirement
39
that Mr. ONeil not seek employment with, or ownership in, a company in direct competition with the
Company and its subsidiaries for a period of one-year after the termination of his employment. The
employment agreement has an initial term of four years and will automatically renew for successive
one-year periods thereafter unless either party notifies the other that the term will not be
extended.
Pursuant to the employment agreement, Mr. ONeil also received (i) a non-qualified stock
option to purchase 100,000 shares of the Companys common stock and (ii) 50,000 restricted shares
of the Companys common stock. See Grants of Plan-Based Awards above. The non-qualified stock
options have a ten year term and a per share exercise price of $39.70, which was based on the
closing price of our common stock on the date of grant. Both the non-qualified stock options and
the restricted shares of common stock vest in equal annual installments on each of the first
through fourth anniversaries of the grant date of the award. In addition, Mr. ONeil is entitled
to earn future equity compensation awards and/or other long term incentive compensation as
determined in the discretion of the Compensation Committee.
The employment agreement was amended on February 23, 2009 to provide that commencing in
February 2009, Mr. ONeil will receive an allowance of $1,800 per month to cover expenses incurred
in traveling between Baltimore, Maryland and Tampa, Florida in lieu of what the employment
agreement originally provided with regard to travel between Baltimore and Tampa.
Mr. ONeils employment agreement was further amended and restated on June 3, 2009 in
connection with his appointment as our executive Vice Chairman. Pursuant to the amended and
restated agreement, Mr. ONeil ceased serving as our Senior Vice President, General Counsel and
Secretary. The amended and restated employment agreement provides for the continuation of Mr.
ONeils current base salary of not less than $41,667 per month and a cash bonus opportunity for
calendar year 2009 to be paid based on the achievement of certain performance objectives to be
agreed to by us and Mr. ONeil, with a bonus target of 50% of his annual base salary. So long as
Mr. ONeil remains employed by us through December 31, 2009, he also will be entitled to receive an
additional amount in cash equal to the sum of (i) $500,000 and (ii) the higher of his (x) annual
cash bonus for calendar year 2008 (which was $250,000) or (y) annual cash bonus for calendar year
2009 (which is expected to be determined in 2010). Of this additional amount, $500,000 is required
to be paid on December 31, 2009 and the remainder not later than March 15, 2010. Mr. ONeil will
receive all group insurance, pension plan and other fringe benefits offered by us to other senior
executives, and he will continue to receive an allowance of $4,600 per month to cover certain
living expenses through September 11, 2009 (prorated for the partial month of September 2009).
Pursuant to the employment agreement described above, Mr. ONeil is also entitled to certain
additional payments and benefits in the event his employment is terminated under certain
circumstances. For a description of these payments and benefits, see Potential Payments to Named
Executive Officers upon Termination or Change in Control.
Separation Agreements
Messrs. Farha and Behrens
On January 25, 2008, we entered into separation agreements with each of Messrs. Farha and
Behrens providing for their respective resignations from the Company and its subsidiaries.
Pursuant to the separation agreements, each officer agreed that his resignation would be a
voluntary termination pursuant to his respective employment agreement. The separation agreements
provided for no new severance or other payments or benefits. Accordingly, each officer received
only a cash amount equal to his accrued but unpaid vacation as provided for in their respective
employment agreements. In addition, Mr. Farha may potentially earn a portion of his 2005
performance share award, in a maximum amount of 130,000 shares. For a discussion of the
circumstances pursuant to which Mr. Farha may earn these shares, as well as each officers
separation agreement, see Potential Payments to Named Executive Officers upon Termination or
Change in Control below.
Mr. Kottoor
In July 2008, we entered into a letter agreement with Mr. Kottoor. Except as set forth
immediately below, the letter agreement did not provide Mr. Kottoor with any additional
compensatory awards. Instead, the letter agreement provided for the acceleration of the Special
Retention Bonus, 2008 Special Performance-Based Long-Term Cash Incentive Award and the 2008 Annual
Cash Bonus Award (each as defined above in Compensation Discussion and Analysis) in the event Mr.
Kottoors employment was terminated under certain circumstances.
In addition, the letter agreement provided for the following additional compensation and/or
acceleration of awards if Mr. Kottoor was terminated under the circumstances described below:
40
|
|
|
A potential additional retention bonus (the Additional Retention Bonus) in the
amount of $236,250, which such amount represented 50% of Mr. Kottoors target 2008
Long-Term Incentive opportunity, as described above. The Additional Retention Bonus
was payable in the event Mr. Kottoors employment terminated prior to vesting of the
equity awards, if any, awarded pursuant to his 2008 Long-Term Incentive opportunity, as
described above, or in the event his employment terminated for any reason prior to June
1, 2009. |
|
|
|
|
Continuation of Mr. Kottoors base salary as in effect on the date of termination of
employment from the date of termination through May 1, 2010 (the Severance Payment). |
|
|
|
|
Accelerated vesting of all of his unvested restricted stock grants, as of July 2,
2008, or a total of 13,934 shares, to the extent not already vested on his termination
date. |
|
|
|
|
Accelerated vesting of his Equity Retention Stock Option Award, exercisable for
55,000 shares. |
Mr. Kottoors employment was terminated in December 2008. Consistent with the terms of the
letter agreement described above, we entered into a separation agreement with Mr. Kottoor on
December 19, 2008 providing for the following:
|
|
|
lump-sum payment of $713,475 on December 29, 2008, consisting of his (i)
Special Retention Bonus in the amount of $157,500, (ii) 2008 Special Performance-Based
Long-Term Cash Incentive Award in the amount of $354,375 and (iii) 2008 Annual Cash
Bonus in the amount of $201,600 (representing 80% of his target) (See Summary
Compensation Table above); |
|
|
|
|
Continuation of Mr. Kottoors base salary from December 19, 2008 through May 1,
2010, in the aggregate amount of $430,096; and |
|
|
|
|
A lump-sum payment of $236,250 due May 1, 2010. |
The separation agreement also includes confidentiality and non-competition provisions,
including a requirement that Mr. Kottoor not seek employment with, or ownership in, a company in
direct competition with the Company and its subsidiaries for a period beginning on the date of his
termination of employment and ending on May 1, 2010.
For a discussion of the payments made to Mr. Kottoor based upon the letter agreement and the
termination of his employment effective December 19, 2008, see Potential Payments to Named
Executive Officers upon Termination or Change in Control below. See also Summary Compensation
Table for the payments made to Mr. Kottoor in 2008 in connection with this agreement.
41
Outstanding Equity Awards at Fiscal Year-End
The following table sets forth certain information regarding unexercised options, stock that
has not vested and, with respect to Mr. Farha only, performance share awards for the named
executive officers outstanding as of December 31, 2008. Unless otherwise noted, all vesting is
based upon the continued service of the executive.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock Awards |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Incentive |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Plan Awards: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity |
|
Market or |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Incentive |
|
Payout |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Plan Awards: |
|
Value |
|
|
|
|
|
|
|
|
|
|
|
|
Number |
|
of |
|
|
Option Awards |
|
|
|
|
|
Market |
|
of |
|
Unearned |
|
|
Number |
|
Number |
|
|
|
|
|
|
|
|
|
Number |
|
Value of |
|
Unearned |
|
Shares, |
|
|
of |
|
of |
|
|
|
|
|
|
|
|
|
of Shares |
|
Shares or |
|
Shares, |
|
Units or |
|
|
Securities |
|
Securities |
|
|
|
|
|
|
|
|
|
or Units |
|
Units of |
|
Units or |
|
Other |
|
|
Underlying |
|
Underlying |
|
|
|
|
|
|
|
|
|
of Stock |
|
Stock |
|
Other Rights |
|
Rights |
|
|
Unexercised |
|
Unexercised |
|
Option |
|
|
|
|
|
That Have |
|
That Have |
|
That Have |
|
That Have |
|
|
Options |
|
Options |
|
Exercise |
|
Option |
|
Not |
|
Not |
|
Not |
|
Not |
|
|
(#) |
|
(#) |
|
Price |
|
Expiration |
|
Vested |
|
Vested(1) |
|
Vested |
|
Vested(1) |
Name |
|
Exercisable |
|
Unexercisable |
|
($) |
|
Date |
|
(#) |
|
($) |
|
(#) |
|
($) |
Heath G. Schiesser |
|
|
1,186 |
|
|
|
|
|
|
|
8.33 |
|
|
|
02/06/14 |
|
|
|
600 |
(6) |
|
|
7,716 |
|
|
|
|
|
|
|
|
|
|
|
|
10,740 |
|
|
|
7,160 |
(2) |
|
|
36.45 |
|
|
|
07/27/12 |
|
|
|
5,751 |
(7) |
|
|
73,958 |
|
|
|
|
|
|
|
|
|
|
|
|
28,600 |
|
|
|
|
|
|
|
48.50 |
|
|
|
06/08/13 |
|
|
|
203,125 |
(8) |
|
|
2,612,188 |
|
|
|
|
|
|
|
|
|
|
|
|
4,582 |
|
|
|
4,230 |
(3) |
|
|
50.16 |
|
|
|
07/27/13 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,885 |
|
|
|
8,658 |
(4) |
|
|
85.53 |
|
|
|
09/13/11 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
114,581 |
|
|
|
385,419 |
(5) |
|
|
43.12 |
|
|
|
01/25/18 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Todd S. Farha |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
130,000 |
(9) |
|
|
1,671,800 |
|
Thomas L. Tran |
|
|
|
|
|
|
100,000 |
(10) |
|
|
29.23 |
|
|
|
07/21/15 |
|
|
|
50,000 |
(11) |
|
|
643,000 |
|
|
|
|
|
|
|
|
|
Charles G. Berg |
|
|
112,500 |
|
|
|
187,500 |
(12) |
|
|
43.12 |
|
|
|
01/25/18 |
|
|
|
125,000 |
(13) |
|
|
1,607,500 |
|
|
|
|
|
|
|
|
|
Anil Kottoor |
|
|
5,903 |
(14) |
|
|
|
|
|
|
69.14 |
|
|
|
04/15/09 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
981 |
(14) |
|
|
|
|
|
|
85.53 |
|
|
|
04/15/09 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,121 |
(14) |
|
|
|
|
|
|
85.53 |
|
|
|
04/15/09 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
55,000 |
(14) |
|
|
|
|
|
|
45.25 |
|
|
|
04/15/09 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adam T. Miller |
|
|
12,000 |
|
|
|
36,000 |
(15) |
|
|
38.11 |
|
|
|
01/18/13 |
|
|
|
15,000 |
(20) |
|
|
192,900 |
|
|
|
|
|
|
|
|
|
|
|
|
3,172 |
|
|
|
4,230 |
(16) |
|
|
50.16 |
|
|
|
07/27/13 |
|
|
|
720 |
(21) |
|
|
9,259 |
|
|
|
|
|
|
|
|
|
|
|
|
817 |
|
|
|
2,453 |
(17) |
|
|
85.53 |
|
|
|
09/13/11 |
|
|
|
1,169 |
(22) |
|
|
15,033 |
|
|
|
|
|
|
|
|
|
|
|
|
2,601 |
|
|
|
|
|
|
|
85.53 |
|
|
|
09/13/11 |
|
|
|
2,696 |
(23) |
|
|
34,671 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
40,000 |
(18) |
|
|
45.25 |
|
|
|
11/28/12 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
16,004 |
(19) |
|
|
43.45 |
|
|
|
03/06/15 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Thomas F. ONeil III |
|
|
|
|
|
|
100,000 |
(24) |
|
|
39.70 |
|
|
|
04/01/18 |
|
|
|
50,000 |
(25) |
|
|
643,000 |
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Value based on $12.86 per share which was the closing price of our common stock on the NYSE on December 31, 2008. |
|
(2) |
|
Of this amount, 3,580 options vest on July 27, 2009 and 3,580 options vest on July 27, 2010. |
|
(3) |
|
Of this amount, 1,140 options vest on July 27, 2009; 1,140 options vest on July 27, 2010; and 1,140 options vest on July 27, 2011. |
|
(4) |
|
Of this amount, 2,886 options vested on March 13, 2009; 2,886 options vest on march 13, 2010; and 2,886 options vest on March 13, 2011. |
|
(5) |
|
Of this amount, 10,417 options vested on January 1, 2009; 10,416 options vested on February 25, 2009; 10,417 vested on March 25, 2009;
10,416 options vested on April 25, 2009; and approximately 10,417 options vest on the 25th day of each calendar month
thereafter until fully vested. |
|
(6) |
|
These shares vested on March 15, 2009. |
|
(7) |
|
Of this amount, 1,917 shares vested on March 13, 2009; 1,917 shares vest on March 13, 2010; and 1,917 shares vest on March 13, 2011. |
|
(8) |
|
Of this amount, 15,625 shares vested on January 1, 2009; 15,625 shares vested on April 25, 2009; 15,625 shares vest on July 25, 2009;
15,625 shares vest on October 25, 2009; 15,625 shares vest on January 1, 2010; 15,625 shares vest on April 25, 2010; 15,625 shares vest
on July 25, 2010; 15,625 shares vest on October 25, 2010; 15,625 shares vest on January 1, 2011; 15,625 shares vest on April 25, 2011;
15,625 shares vest on July 25, 2011; 15,625 shares vest on October 25, 2011; and 15,625 shares vest on January 1, 2012. |
|
(9) |
|
Pursuant to an award agreement dated June 6, 2005, Mr. Farha was eligible to receive a maximum of 240,279 shares of our common stock
based upon the achievement of certain performance criteria. Specifically, Mr. Farha was eligible to earn a (i) threshold of 32,500
shares, (ii) target of 65,000 shares, or (iii) a maximum of 130,000 shares subject to the award (the maximum of 130,000 shares are
referred to as the First Tranche Shares) on June 6, 2008 based on achievement of compounded annual percentage increases in diluted net
income per share (EPS) over the three-year period measured from January 1, 2005 through December 31, 2007. Any portion of the First
Tranche Shares not earned as of June 6, 2008 were to be available for issuance on June 6, 2010 (together with the remaining 110,279
shares) based on achievement of cumulative EPS goals for the five-year period measured from January 1, 2005 through December 31, 2010
(the Second Tranche Shares). Due to his termination of employment in January 2008, Mr. Farha forfeited the Second Tranche Shares. As
of December 31, 2008, our cumulative EPS growth over the three-year performance period applicable to the First Tranche Shares exceeded
the maximum cumulative EPS goal of $5.59 per share. Accordingly, pursuant to SEC disclosure requirements, we have included the maximum
number of shares subject to the First Tranche Shares in the table above; however, Mr. Farhas ability to receive these shares is subject
in entirety to the additional conditions and terms of his separation agreement with us, as discussed under Potential Payments to Named
Executive Officers upon Termination or Change in Control below. |
|
(10) |
|
Of this amount, 25,000 options vest on July 21, 2009; 25,000 options vest on July 21, 2010; 25,000 options vest on July 21, 2011; and
25,000 options vest on July 21, 2012. |
|
(11) |
|
Of this amount, 25,000 shares vest on July 21, 2009; 25,000 shares vest on July 21, 2010; 25,000 shares vest on July 21, 2011; and 25,000
shares vest |
42
|
|
|
|
|
on July 21, 2012. |
|
(12) |
|
Of this amount, 37,500 options vested on January 25, 2009; 37,500 options vest on April 25, 2009; 37,500 options vest on July 25, 2009;
37,500 options vest on October 25, 2009; and 37,500 options vest on January 25, 2010. |
|
(13) |
|
Of this amount, 25,000 shares vested on January 25, 2009; 25,000 shares vest on April 25, 2009; 25,000 shares vest on July 25, 2009;
25,000 shares vest on October 25, 2009; and 25,000 shares vest on January 25, 2010. |
|
(14) |
|
These options expired unexercised on April 15, 2009. |
|
(15) |
|
Of this amount, 12,000 options vested on January 18, 2009; 12,000 options vest on January 18, 2010; and 12,000 options vest on January
18, 2011. |
|
(16) |
|
Of this amount, 1,140 options vest on July 27, 2009; 1,140 options vest on July 27, 2010; and 1,140 options vest on July 27, 2011. |
|
(17) |
|
Of this amount, 818 options vested on March 13, 2009; 817 options vest on march 13, 2010; and 818 options vest on March 13, 2011. |
|
(18) |
|
These options vest on November 28, 2009. |
|
(19) |
|
Of this amount, 4,001 options vested on March 6, 2009; 4,001 options vest on March 6, 2010; 4,001 options vest on March 6, 2011; and
4,001 options vest on March 6, 2012. |
|
(20) |
|
Of this amount, 5,000 shares vested on January 18, 2009; 5,000 shares vest on January 18, 2010; and 5,000 shares vest on January 18, 2011. |
|
(21) |
|
Of this amount, 239 shares vested on March 13, 2009; 240 shares vest on March 13, 2010; and 241 shares vest on March 13, 2011. |
|
(22) |
|
Of this amount, 292 shares vested on March 13, 2009; 293 shares vest on March 13, 2010; 292 shares vest on March 13, 2011; and 292 shares
vest on March 13, 2012. |
|
(23) |
|
Of this amount, 674 shares vest on August 3, 2009; 674 shares vest on August 3, 2010; 674 shares vest on August 3, 2011; and 674 shares
vest on August 3, 2012. |
|
(24) |
|
Of this amount, 25,000 options vested on April 1, 2009; 25,000 options vest on April 1, 2010; 25,000 options vest on April 1, 2011; and
25,000 options vest on April 1, 2012. |
|
(25) |
|
Of this amount, 25,000 shares vested on April 1, 2009; 25,000 shares vest on April 1, 2010; 25,000 shares vest on April 1, 2011; and
25,000 shares vest on April 1, 2012. |
Option Exercises and Stock Vested
The table below sets forth the number of stock options exercised and the value realized upon
exercise of the stock options, or the vesting of restricted stock and the value realized, for the
named executive officers during fiscal year 2008.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Option Awards |
|
Stock Awards |
|
|
Number of |
|
|
|
|
|
Number of |
|
|
|
|
Shares |
|
|
|
|
|
Shares |
|
|
|
|
Acquired |
|
Value Realized |
|
Acquired |
|
Value Realized |
|
|
on Exercise |
|
on Exercise(1) |
|
on Vesting |
|
on Vesting(2) |
Name |
|
(#) |
|
($) |
|
(#) |
|
($) |
Heath G. Schiesser |
|
|
|
|
|
|
|
|
|
|
49,392 |
|
|
|
1,625,754 |
|
Todd S. Farha |
|
|
191,315 |
|
|
|
2,864,286 |
|
|
|
4,000 |
|
|
|
149,720 |
|
Thomas L. Tran |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Paul L. Behrens |
|
|
8,131 |
|
|
|
278,162 |
|
|
|
3,978 |
|
|
|
148,289 |
|
Charles G. Berg |
|
|
|
|
|
|
|
|
|
|
75,000 |
|
|
|
2,309,250 |
|
Anil Kottoor |
|
|
|
|
|
|
|
|
|
|
16,453 |
|
|
|
299,715 |
|
Adam Miller |
|
|
|
|
|
|
|
|
|
|
6,206 |
|
|
|
315,605 |
|
Thomas F. ONeil III |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
The value realized is calculated by multiplying the number of shares by the difference between the market price of our common stock at time of
exercise and the exercise price of the stock option. |
|
(2) |
|
The value realized is calculated by multiplying the number of shares vested by the closing market price of our common stock on the date of vesting. |
Pension Benefits and Nonqualified Deferred Compensation
We did not maintain a pension or nonqualified deferred compensation plan during fiscal year
2008.
Potential Payments to Named Executive Officers upon Termination or Change in Control
Overview
Messrs. Schiesser, Tran and ONeil serve as executive officers pursuant to employment
agreements. Mr. Berg serves as an executive officer pursuant to a letter agreement and Mr. Miller
serves as an executive officer pursuant to an offer letter. The employment agreements, letter
agreement and offer letter include provisions providing for certain payments and benefits upon
certain terminations of employment with us, as discussed under Termination Benefits below. In
addition, as discussed under Treatment of Equity Awards below, each executives equity award
agreements provide for accelerated vesting of awards upon certain terminations of employment, and
in the case of Messrs. Schiesser and Berg, upon a change in control of the Company without
termination of employment. Below are descriptions of the circumstances under which Messrs.
Schiesser, Tran, Berg and ONeil would be entitled to payments and benefits upon the occurrence of
a change in control or termination of employment, as applicable, as of December 31, 2008, and a
quantification of such payments and benefits under the terms of the
43
applicable agreements between us and each named executive officer. All of the descriptions are
qualified by reference to the applicable agreements between us and each named executive officer and
the quantification of the hypothetical payments are subject to the assumptions described below.
The actual amounts to be paid to Messrs. Schiesser, Tran, Berg and ONeil will only be determined
at the time of their actual termination.
As discussed above, Messrs. Farha and Behrens resigned from their respective executive officer
and Director positions on January 25, 2008, and Mr. Kottoors employment was terminated effective
December 19, 2008. Below are descriptions of the actual payments and benefits received by these
individuals upon their actual termination of employment.
Definitions
For the purpose of the following discussion, the following terms generally have the following
meanings:
|
|
|
A change in control generally occurs upon: (i) certain persons acquiring more
than 50% of our outstanding voting shares or more than 50% of the fair market value of
such shares; (ii) a majority of our incumbent Directors being replaced under certain
circumstances; (iii) the consummation of a merger, consolidation or other business
combination in which more than 50% of the outstanding common stock of the Company is no
longer held by the shareholders of the Company prior to such transaction; or (iv) or a
liquidation or sale of all or substantially all of our assets under certain
circumstances. |
|
|
|
|
termination for good reason generally means that the executive terminated as the
result of: (i) a material diminution in authority, duties and responsibilities or
change in title; (ii) any material diminution of executives base salary or bonus
opportunity; (iii) any material breach by the Company of the terms of the respective
agreement; (iv) a change in the executives office location by more than 50 miles from
the executives offices in Tampa, Florida; or (v) with respect to Messrs. Schiesser and
Berg only, removal from the Board other than pursuant to cause, pursuant to shareholder
vote or due to executives resignation from the Board, in each case, subject to notice
and the Companys right to a reasonable opportunity to cure. |
|
|
|
|
termination for cause generally means that we terminate the executive as the
result of: (i) any willful act or omission by the executive representing a material
breach of the respective agreement; (ii) the executive being convicted of, or pleading
guilty to, a felony or other crime that involves fraud, conversion, misappropriation or
embezzlement under any federal or state law; or (iii) the executives bad faith,
willful acts in the performance of executives duties, to the material detriment of the
Company; in each case, subject to notice and the executives right to a reasonable
opportunity to cure. |
|
|
|
|
termination for disability generally means the executives employment is
terminated as of result of the executive being unable to engage in any substantial
gainful business activity, by reason of any medically determinable physical or mental
impairment, that has caused the executive to be unable to carry out his duties for
specified time periods. |
Termination Benefits Under Employment Arrangements
|
|
|
Mr. Schiesser. As noted above under Proposal Number One Election of Directors
Class I Director Nominees, on June 26, 2009, Mr. Schiesser informed the Board of
Directors that he intends to resign from his current officer and Director positions
upon the appointment of a new President and Chief Executive Officer. The Board of
Directors has formed a Committee on Leadership and Executive Succession, comprised of
certain Directors and a non-Director executive officer, to focus on leadership
transition at our Company. As of the date hereof, it is uncertain when Mr.
Schiessers employment will terminate. We currently anticipate engaging in discussions
with Mr. Schiesser in the near future regarding potential compensation and benefits
payable to him in connection with his services during the transition period and the
termination of his employment. The timing and possible terms of any agreement with Mr.
Schiesser are uncertain. |
Mr. Schiessers employment agreement currently provides for severance benefits in certain
circumstances as follows: Upon a termination by the Company without cause or by Mr.
Schiesser for good reason, he would be entitled to severance benefits including: (i) a
lump sum cash payment equal to two times (or if the termination date occurs on or after
January 25, 2009, one times) the sum of Mr. Schiessers annual salary as in effect on the
termination date and the greater of Mr. Schiessers target bonus for the fiscal year
during which the termination date occurs or the highest performance bonus earned by Mr.
Schiesser with respect to any preceding fiscal year;
44
and (ii) for a period of twenty-four months (or, if the termination date occurs on or
after January 25, 2009, twelve months) after the termination date, reimbursement on an
after-tax basis for the cost of continued participation in the medical, dental and vision
care and life insurance benefits in which Mr. Schiesser and his family participated prior
to the termination date. In the event of Mr. Schiessers death or disability, he (or his
estate, as the case may be) will be entitled to severance benefits including: (i) a lump
sum cash payment equal to the sum of Mr. Schiessers annual salary as in effect on the
termination date and the greater of Mr. Schiessers target bonus for the fiscal year
during which the termination date occurs or the highest performance bonus earned by Mr.
Schiesser with respect to any preceding fiscal year; and (ii) for a period of twelve
months after the termination date, reimbursement on an after-tax basis for the cost of
continued participation in the medical, dental and vision care and life insurance
benefits in which Mr. Schiesser and his family participated prior to the termination
date. If Mr. Schiessers employment is terminated by the Company for cause or by Mr.
Schiesser without good reason, Mr. Schiesser will be entitled to receive the value of his
accrued vacation time as of the time of termination of his employment. For a discussion
of the treatment of Mr. Schiessers equity awards upon certain termination benefits, see
Treatment of Equity Awards below.
|
|
|
Mr. Tran. If Mr. Trans employment is terminated by the Company without cause or by
Mr. Tran for good reason, he will be entitled to severance benefits that include: (i) a
lump sum cash payment equal to one times (or if the termination date occurs within one
year of a change in control, one-and-a-half times) the sum of Mr. Trans annual salary
as in effect on the termination date and the average of the two highest cash bonuses
earned by Mr. Tran over the three prior years or, if Mr. Tran has not been employed for
three years, the target cash bonus for the year in which the termination occurs, and
(ii) for the duration of the applicable COBRA period (generally 18 months, but under
certain circumstances up to 36 months following termination), reimbursement on an
after-tax basis for the cost of continued participation in the medical, dental and
vision care and life insurance benefits in which Mr. Tran and his family participated
prior to the termination date. In the event of Mr. Trans death or disability, or if
his employment is terminated by the Company for cause or by Mr. Tran without good
reason, Mr. Tran (or his estate, as the case may be) will be entitled to receive the
value of his accrued vacation time as of the time of termination of his employment.
For a discussion of the treatment of Mr. Trans equity awards upon certain termination
benefits, see Treatment of Equity Awards below. |
|
|
|
|
Mr. Berg. If Mr. Bergs employment is terminated prior to the end of the term of his
letter agreement on January 25, 2010 (i) by the Company without cause; (ii) by Mr. Berg
for good reason; or (iii) by reason of Mr. Bergs death or disability, Mr. Berg will
receive an amount equal to his base salary for the remainder of the term. For a
discussion of the treatment of Mr. Bergs equity awards upon certain termination
benefits, see Treatment of Equity Awards below. |
|
|
|
|
Mr. Miller. If Mr. Millers employment is terminated by the Company without cause or
by Mr. Miller for good reason, he will be entitled to severance benefits that include:
(i) continuation of his base salary in effect immediately prior to such termination for
twelve months following the date of termination; (ii) continuation of medical benefits
for twelve months following the date of termination; and (iii) an outplacement service
provided by us. For a discussion of the treatment of Mr. Millers equity awards upon
certain termination benefits, see Treatment of Equity Awards below. |
|
|
|
|
Mr. ONeil. If Mr. ONeils employment is terminated by the Company without cause or
by Mr. ONeil for good reason, he will be entitled to severance benefits that include:
(i) a lump sum cash payment equal to one times (or if the termination date occurs
within one year of a change in control, two times) the sum of Mr. ONeils annual
salary as in effect on the termination date and the average of the two highest cash
bonuses earned by Mr. ONeil over the three prior years or, if Mr. ONeil has not been
employed for three years, the target cash bonus for the year in which the termination
occurs, and (ii) for the duration of the applicable COBRA period (generally 18 months,
but under certain circumstances up to 36 months following termination), reimbursement
on an after-tax basis for the cost of continued participation in the medical, dental
and vision care and life insurance benefits in which Mr. ONeil and his family
participated prior to the termination date. In the event of Mr. ONeils death or
disability, or if his employment is terminated by the Company for cause or by Mr.
ONeil without good reason, Mr. ONeil (or his estate, as the case may be) will be
entitled to receive the value of his accrued vacation time as of the time of
termination of his employment. For a discussion of the treatment of Mr. ONeils
equity awards upon certain termination benefits, see Treatment of Equity Awards
below. Mr. ONeils employment agreement was amended and restated on June 3, 2009.
The amended and restated employment agreement provides some terms that differ from his
employment agreement in effect as of December 31, 2008 as relating to his termination
under certain circumstances. See below under Amended and Restated Employment
Agreement. |
45
In addition, to the extent that any payment or benefit received or to be received by Messrs.
Schiesser, Tran, Berg or ONeil (including any benefits upon a change in control) would be subject
to an excise tax under the Internal Revenue Code of 1986, as amended (the Code), the Company is
required to pay to such executive an additional amount such that the net amount received by such
executive is equal to what he would have received if none of his payments or benefits were subject
to an excise tax, provided that if the amount of payments subject to an excise tax exceeds the safe
harbor under Section 280G of the Code by less than ten percent of such executives base salary in
the case of Messrs. Schiesser, Tran and ONeil or $50,000 in the case of Mr. Berg, then such
executives payment will be reduced so that no amounts are subject to an excise tax.
Treatment of Equity Awards
|
|
|
Mr. Schiesser. Mr. Schiessers unvested stock options and shares of restricted stock
will immediately vest: (i) in the event of a change of control of the Company or (ii)
in the event of Mr. Schiessers death or disability. If Mr. Schiessers employment is
terminated by the Company without cause or by Mr. Schiesser for good reason, Mr.
Schiessers unvested stock options and shares of restricted stock will vest to the same
extent, and over the same period, that such awards would have vested had Mr.
Schiessers employment continued for 24 months (or, if the termination date occurs on
or after January 25, 2009, twelve months) after the termination date. In addition to
the foregoing, unvested shares of restricted stock issued to Mr. Schiesser prior to
January 25, 2008 will immediately vest in the event of Mr. Schiessers retirement. |
|
|
|
|
Mr. Tran. Mr. Trans unvested stock options and shares of restricted stock will
immediately vest: (i) in the event of Mr. Trans death or disability; or (ii) if there
is a change in control of the Company and Mr. Trans employment is terminated within
one year following the change in control by the Company without cause or by Mr. Tran
for good reason. |
|
|
|
|
Mr. Berg. Mr. Bergs unvested stock options and shares of restricted stock will
immediately vest: (i) in the event of a change in control of the Company; (ii) in the
event Mr. Bergs death or disability; or (iii) in the event Mr. Bergs employment is
terminated by the Company without cause or by Mr. Berg for good reason. |
|
|
|
|
Mr. Miller. Mr. Millers unvested awards of restricted stock will immediately vest:
(i) in the event of Mr. Millers death, disability or retirement; or (ii) if there is a
change in control of the Company and Mr. Millers employment is terminated within one
year of the change in control by the Company without cause or by Mr. Miller for good
reason. Unvested awards of stock options will immediately vest if there is a change in
control of the Company and Mr. Millers employment is terminated within one year of the
change in control: (i) by the Company without cause; (ii) by Mr. Miller for good
reason; or (iii) by reason of Mr. Millers death, disability or retirement. |
|
|
|
|
Mr. ONeil. Mr. ONeils unvested stock options and shares of restricted stock will
vest: (i) in the event of Mr. ONeils death or disability; or (ii) if there is a
change in control of the Company and Mr ONeils employment is terminated within one
year following the change in control by the Company without cause or by Mr. ONeil for
good reason. |
Assumptions and Certain Conditions
For purposes of quantifying any payments to be made to the executives in the event of
termination of employment or upon a change in control, other than as set forth below with respect
to Messrs. Farha, Behrens and Kottoor, it is assumed that the hypothetical termination event
occurred on December 31, 2008. For purposes of valuing the acceleration of vesting of equity
awards, restricted stock award values are equal to the number of restricted shares multiplied by
$12.86, which was the closing price of our common stock on the NYSE on December 31, 2008. No value
is attributed to options because in each case the exercise price of the stock option exceeded
$12.86, and therefore each stock option was underwater.
In calculating the amounts estimated to be paid to Messrs. Schiesser, Tran, Berg and ONeil
upon a change in control of the Company pursuant to Section 4999 of the Internal Revenue Code, it
was assumed that: (i) the change in control and the executives termination occurred on December
31, 2008; (ii) all equity awards vested and were sold on December 31, 2008; (iii) the executives
fiscal year 2008 base salary rate was used to calculate his salary severance payments; and (iv) the
Social Security Wage Base was reached prior to the executives termination date. In addition,
the following tax rates were assumed to apply: excise tax rate of 20%; Medicare tax rate of 1.45%;
applicable state tax rate of 5% in Connecticut for Messrs. Tran and
46
Berg, 0% in Florida for Mr. Schiesser and 5.5% in Maryland for Mr. ONeil; and a Federal tax rate
of 35%.
As noted above under Proposal Number One Election of Directors Class I Director
Nominees, on June 26, 2009, Mr. Schiesser informed the Board of Directors that he intends to
resign from his current officer and Director positions upon the appointment of a new President and
Chief Executive Officer. The Board of Directors has formed a Committee on Leadership and Executive
Succession, comprised of certain Directors and a non-Director executive officer, to focus on
leadership transition at our Company. As of the date hereof, it is uncertain when Mr. Schiessers
employment will terminate. We currently anticipate engaging in discussions with Mr. Schiesser in
the near future regarding potential compensation and benefits payable to him in connection with his
services during the transition period and the termination of his employment. The timing and
possible terms of any agreement with Mr. Schiesser are uncertain.
In order for named executive officers to be eligible to receive severance payments pursuant to
their respective agreements with us, they are each generally required to execute and deliver a
waiver and release of claims agreement within 30 days after the applicable termination date.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Termination by Executive for Good Reason or by the Company without Cause |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Acceleration |
|
Acceleration |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Acceleration |
|
Acceleration |
|
of Vesting |
|
of Vesting |
|
|
|
|
|
|
|
|
|
|
|
|
|
Excise |
|
|
|
|
|
|
|
|
of Vesting |
|
of Vesting |
|
of |
|
of |
|
|
|
|
|
|
|
|
|
Out- |
|
Taxes |
|
|
|
|
Severance |
|
of Stock |
|
of Stock |
|
Restricted |
|
Restricted |
|
Accrued |
|
Welfare |
|
placement |
|
and |
|
|
|
|
Payment |
|
Options |
|
Options |
|
Stock |
|
Stock |
|
Vacation |
|
Benefits |
|
Services |
|
Gross-Ups |
|
Total |
Name |
|
($) |
|
(#) |
|
($) |
|
(#) |
|
($) |
|
($) |
|
($) |
|
($) |
|
($) |
|
($) |
Heath G. Schiesser |
|
|
2,400,000 |
|
|
|
265,748 |
|
|
|
|
|
|
|
129,434 |
|
|
|
1,664,521 |
|
|
|
7,692 |
|
|
|
13,951 |
|
|
|
|
|
|
|
8,002 |
|
|
|
4,094,166 |
|
Thomas L. Tran |
|
|
950,000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
9,135 |
|
|
|
12,237 |
|
|
|
|
|
|
|
8,663 |
|
|
|
980,035 |
|
Charles G. Berg |
|
|
541,667 |
|
|
|
187,500 |
|
|
|
|
|
|
|
125,000 |
|
|
|
1,607,500 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,149,167 |
|
Adam T. Miller |
|
|
400,000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
7,061 |
|
|
|
7,000 |
|
|
|
|
|
|
|
414,061 |
|
Thomas F. ONeil III |
|
|
750,000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
25,481 |
|
|
|
6,698 |
|
|
|
|
|
|
|
5,041 |
|
|
|
787,220 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Termination upon Death or Disability |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Acceleration |
|
Acceleration |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Acceleration |
|
Acceleration |
|
of Vesting |
|
of Vesting |
|
|
|
|
|
|
|
|
|
|
|
|
|
Excise |
|
|
|
|
|
|
|
|
of Vesting |
|
of Vesting |
|
of |
|
of |
|
|
|
|
|
|
|
|
|
Out- |
|
Taxes |
|
|
|
|
Severance |
|
of Stock |
|
of Stock |
|
Restricted |
|
Restricted |
|
Accrued |
|
Welfare |
|
placement |
|
and |
|
|
|
|
Payment |
|
Options |
|
Options |
|
Stock |
|
Stock |
|
Vacation |
|
Benefits |
|
Services |
|
Gross-Ups |
|
Total |
Name |
|
($) |
|
(#) |
|
($) |
|
(#) |
|
($) |
|
($) |
|
($) |
|
($) |
|
($) |
|
($) |
Heath G. Schiesser |
|
|
1,200,000 |
|
|
|
405,467 |
|
|
|
|
|
|
|
209,476 |
|
|
|
2,693,861 |
|
|
|
7,692 |
|
|
|
6,975 |
|
|
|
|
|
|
|
4,001 |
|
|
|
3,912,529 |
|
Thomas L. Tran |
|
|
|
|
|
|
100,000 |
|
|
|
|
|
|
|
50,000 |
|
|
|
643,000 |
|
|
|
9,135 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
652,135 |
|
Charles G. Berg |
|
|
541,667 |
|
|
|
187,500 |
|
|
|
|
|
|
|
125,000 |
|
|
|
1,607,500 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,149,167 |
|
Adam T. Miller |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
19,585 |
|
|
|
251,863 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
251,863 |
|
Thomas F. ONeil III |
|
|
|
|
|
|
100,000 |
|
|
|
|
|
|
|
50,000 |
|
|
|
643,000 |
|
|
|
25,481 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
668,481 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Termination upon Retirement |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Acceleration |
|
Acceleration |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Acceleration |
|
of Vesting |
|
of Vesting |
|
|
|
|
|
|
|
|
|
|
|
|
|
Excise |
|
|
|
|
|
|
|
|
Acceleration |
|
of Vesting |
|
of |
|
of |
|
|
|
|
|
|
|
|
|
Out- |
|
Taxes |
|
|
|
|
Severance |
|
of Vesting |
|
of Stock |
|
Restricted |
|
Restricted |
|
Accrued |
|
Welfare |
|
placement |
|
and |
|
|
|
|
Payment |
|
of Stock Options |
|
Options |
|
Stock |
|
Stock |
|
Vacation |
|
Benefits |
|
Services |
|
Gross-Ups |
|
Total |
Name |
|
($) |
|
(#) |
|
($) |
|
(#) |
|
($) |
|
($) |
|
($) |
|
($) |
|
($) |
|
($) |
Heath G. Schiesser |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6,351 |
|
|
|
81,674 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
81,674 |
|
Thomas L. Tran |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Charles G. Berg |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adam T. Miller |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
19,585 |
|
|
|
251,863 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
251,863 |
|
Thomas F. ONeil III |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
47
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Termination by Executive for Good Reason or by the Company without Cause within twelve (12) months following a Change in Control |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Acceleration |
|
Acceleration |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Acceleration |
|
Acceleration |
|
of Vesting |
|
of Vesting |
|
|
|
|
|
|
|
|
|
|
|
|
|
Excise |
|
|
|
|
|
|
|
|
of Vesting |
|
of Vesting |
|
of |
|
of |
|
|
|
|
|
|
|
|
|
Out- |
|
Taxes |
|
|
|
|
Severance |
|
of Stock |
|
of Stock |
|
Restricted |
|
Restricted |
|
Accrued |
|
Welfare |
|
placement |
|
and |
|
|
|
|
Payment |
|
Options |
|
Options |
|
Stock |
|
Stock |
|
Vacation |
|
Benefits |
|
Services |
|
Gross-Ups |
|
Total |
Name |
|
($) |
|
(#) |
|
($) |
|
(#) |
|
($) |
|
($) |
|
($) |
|
($) |
|
($) |
|
($) |
Heath G. Schiesser |
|
|
2,400,000 |
|
|
|
405,467 |
|
|
|
|
|
|
|
209,476 |
|
|
|
2,693,861 |
|
|
|
7,692 |
|
|
|
13,951 |
|
|
|
|
|
|
|
1,153,788 |
|
|
|
6,269,292 |
|
Thomas L. Tran |
|
|
1,425,000 |
|
|
|
100,000 |
|
|
|
|
|
|
|
50,000 |
|
|
|
643,000 |
|
|
|
9,135 |
|
|
|
12,237 |
|
|
|
|
|
|
|
8,663 |
|
|
|
2,098,035 |
|
Charles G. Berg |
|
|
541,667 |
|
|
|
187,500 |
|
|
|
|
|
|
|
125,000 |
|
|
|
1,607,500 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,149,167 |
|
Adam T. Miller |
|
|
400,000 |
|
|
|
98,687 |
|
|
|
|
|
|
|
19,585 |
|
|
|
251,863 |
|
|
|
|
|
|
|
7,061 |
|
|
|
7,000 |
|
|
|
|
|
|
|
665,924 |
|
Thomas F. ONeil III |
|
|
1,500,000 |
|
|
|
100,000 |
|
|
|
|
|
|
|
50,000 |
|
|
|
643,000 |
|
|
|
25,481 |
|
|
|
6,698 |
|
|
|
|
|
|
|
5,041 |
|
|
|
2,180,220 |
|
|
Change in Control |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Acceleration |
|
Acceleration |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Acceleration |
|
Acceleration |
|
of Vesting |
|
of Vesting |
|
|
|
|
|
|
|
|
|
|
|
|
|
Excise |
|
|
|
|
|
|
|
|
of Vesting |
|
of Vesting |
|
of |
|
of |
|
|
|
|
|
|
|
|
|
Out- |
|
Taxes |
|
|
|
|
Severance |
|
of Stock |
|
of Stock |
|
Restricted |
|
Restricted |
|
Accrued |
|
Welfare |
|
placement |
|
and |
|
|
|
|
Payment |
|
Options |
|
Options |
|
Stock |
|
Stock |
|
Vacation |
|
Benefits |
|
Services |
|
Gross-Ups |
|
Total |
Name |
|
($) |
|
(#) |
|
($) |
|
(#) |
|
($) |
|
($) |
|
($) |
|
($) |
|
($) |
|
($) |
Heath G. Schiesser |
|
|
|
|
|
|
405,467 |
|
|
|
|
|
|
|
209,476 |
|
|
|
2,693,861 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,693,861 |
|
Thomas L. Tran |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Charles G. Berg |
|
|
|
|
|
|
187,500 |
|
|
|
|
|
|
|
125,000 |
|
|
|
1,607,500 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,607,500 |
|
Adam T. Miller |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Thomas F. ONeil III |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Termination by Executive without Good Reason or by the Company with Cause |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Acceleration |
|
Acceleration |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Acceleration |
|
Acceleration |
|
of Vesting |
|
of Vesting |
|
|
|
|
|
|
|
|
|
|
|
|
|
Excise |
|
|
|
|
|
|
|
|
of Vesting |
|
of Vesting |
|
of |
|
of |
|
|
|
|
|
|
|
|
|
Out- |
|
Taxes |
|
|
|
|
Severance |
|
of Stock |
|
of Stock |
|
Restricted |
|
Restricted |
|
Accrued |
|
Welfare |
|
placement |
|
and |
|
|
|
|
Payment |
|
Options |
|
Options |
|
Stock |
|
Stock |
|
Vacation |
|
Benefits |
|
Services |
|
Gross-Ups |
|
Total |
Name |
|
($) |
|
(#) |
|
($) |
|
(#) |
|
($) |
|
($) |
|
($) |
|
($) |
|
($) |
|
($) |
Heath G. Schiesser |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
7,692 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
7,692 |
|
Thomas L. Tran |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
9,135 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
9,135 |
|
Charles G. Berg |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adam T. Miller |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Thomas F. ONeil III |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
25,481 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
25,481 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Actual Benefits Received upon Termination of Employment During 2008 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Acceleration |
|
Acceleration |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Acceleration |
|
of Vesting |
|
of Vesting |
|
|
|
|
|
|
|
|
|
|
|
|
Salary |
|
of Bonus |
|
of Stock |
|
of Restricted |
|
Performance |
|
Accrued |
|
|
|
|
Termination |
|
Continuation |
|
Payments |
|
Options |
|
Stock |
|
Shares |
|
Vacation |
|
Total |
Name |
|
Date |
|
($) |
|
($) |
|
($) |
|
($) |
|
($) |
|
($) |
|
($) |
Todd S. Farha |
|
|
03/31/08 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(5) |
|
|
17,223 |
|
|
|
17,223 |
|
Paul L. Behrens |
|
|
03/31/08 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
662 |
|
|
|
662 |
|
Anil Kottoor |
|
|
12/19/08 |
|
|
|
430,096 |
(1) |
|
|
949,725 |
(2) |
|
|
|
(3) |
|
|
165,340 |
(4) |
|
|
|
|
|
|
|
|
|
|
1,545,161 |
|
48
|
|
|
(1) |
|
Represents the aggregate payments to be paid during the period from December 19, 2008 through May 1, 2010. |
|
(2) |
|
$713,475 was paid on December 29, 2008 and the remaining amount of $236,250 will be paid on May 1, 2010
subject to Mr. Kottoors compliance with non-competition, non-solicitation, confidentiality and
non-disparagement covenants. |
|
(3) |
|
A stock option to purchase 55,000 shares of common stock vested in full upon termination of employment.
In addition, Mr. Kottoors post-termination exercise period was extended for options to purchase up to
10,005 shares of our common stock until 30 days after the date on which the exercise of such options will
no longer violate applicable Federal, state, local and foreign laws, including securities laws. The
exercise prices of Mr. Kottoors stock options discussed above exceeded the closing price of our common
stock on the NYSE on Mr. Kottoors date of termination, and therefore such options expired unexercised. |
|
(4) |
|
13,164 shares of restricted stock vested in full upon Mr. Kottoors termination of employment. The
amount represents the value of such shares based on the closing price of our stock on the NYSE on Mr.
Kottoors date of termination. |
|
(5) |
|
Mr. Farhas performance share award agreement was amended so that he is eligible to vest in up to 130,000
of his unvested performance shares if certain specified conditions have been satisfied prior to June 6,
2010, and the value of shares that vest, if any, will be based on the closing price of our common stock
on the vesting date. Specifically, Mr. Farhas rights to receive up to 130,000 of the shares subject to
the performance award are to be extinguished and will lapse unless all of the following conditions have
been met by June 6, 2010: |
|
|
|
the Company has achieved the maximum cumulative adjusted EPS goal for the vesting of the full
130,000 shares, the target cumulative adjusted EPS goal for the vesting of 65,000 shares, or the
threshold cumulative adjusted EPS goal for the vesting of 32,500 shares, as applicable, for the
measurement period of January 1, 2005 through December 31, 2007; |
|
|
|
|
no loss contingencies have been identified for subsequent periods which, had they been identified
and accrued in such measurement period, would have resulted in the cumulative adjusted EPS not meeting
the relevant cumulative adjusted EPS described above; |
|
|
|
|
Mr. Farha has not become subject to any legal proceeding brought or threatened, or that could be
but has not yet been brought, by any governmental entity in connection with the ongoing investigations;
and |
|
|
|
|
we have not been required to have entered into or become subject to any criminal or civil order
of any court or agency relating to the ongoing investigations, or any agreement with any governmental
agency, by which there has been found to have been violations of laws, rules or regulation by us during
the measurement period for such shares, or the period prior thereto. |
Amended and Restated Employment Agreement
As described above under Additional Information With Respect to the Summary Compensation
Table and Grants of Plan-Based Awards Thomas F. ONeil III, Mr. ONeils employment agreement
was amended and restated on June 3, 2009 in connection with his appointment as our executive Vice
Chairman. Pursuant to the amended and restated agreement, Mr. ONeil is entitled to certain
payments and benefits in the event his employment is terminated prior to December 31, 2009 under
certain circumstances. If Mr. ONeils employment is terminated by us without cause (as defined
in the agreement) or by Mr. ONeil for good reason (as defined in the agreement), following his
execution of a release of claims he will be entitled to the following amounts: (i) a lump sum cash
payment equal to the sum of (x) his base salary from his termination date through December 31,
2009; (y) $750,000; and (z) his target annual bonus for calendar year 2009, (ii) continued
participation in our medical, dental and vision care and life insurance benefit plans for up to
eighteen months following termination, and (iii) any earned but unpaid base salary, incentive
compensation and other cash compensation, the value of his accrued but unused vacation time as of
the time of termination and any outstanding expense reimbursements.
In addition, to the extent that any payment or benefit received or to be received by Mr.
ONeil pursuant to the agreement would be subject to an excise tax under Section 4999 of the
Internal Revenue Code, we are required to pay to him an additional amount such that the net amount
received by him is equal to what he would have received if none of his payments or benefits were
subject to the excise tax; provided that if the amount of payments subject to the excise tax
exceeds the safe harbor under Section 280G of the Internal Revenue Code by less than ten percent of
his base salary, then Mr. ONeils payments will be reduced so that no amounts are subject to the
excise tax. The agreement also includes confidentiality, non-competition and non-solicitation
provisions, including a requirement that Mr. ONeil not seek employment with, or ownership in, a
company in direct competition with us and/or our subsidiaries for a period of one year after the
termination of his employment.
PROPOSAL NUMBER TWO AMENDMENT OF CERTIFICATE OF INCORPORATION TO PROVIDE FOR ANNUAL ELECTION OF
ALL DIRECTORS
Our Amended and Restated Certificate of Incorporation (the Restated Certificate of
Incorporation) currently provides that the Board will be divided into three classes, as nearly
equal in size as practicable, with one class to be elected by the shareholders every year, thereby
making the term of each class of Directors three years. Upon the recommendation of the
Nominating Committee, the Board has approved, and hereby recommends to the shareholders for
approval, an amendment to the Restated Certificate of Incorporation to provide for the annual
election of all Directors each year, thereby declassifying the Board.
If approved by the shareholders, the amendment will become effective upon the filing of a
Certificate of Amendment of the Restated Certificate of Incorporation containing this amendment
with the Secretary of State of the State of Delaware, which we intend to file promptly after
shareholder approval is obtained. Directors elected prior to the effectiveness of the amendment
(which include all of our current Directors) will stand for election for one-year terms once their
then-current terms expire. As
49
discussed below, because the transition to annual election of
Directors will be phased-in over time, the Board would not be fully declassified until after the
2010 Annual Meeting.
The term of the current Class I Directors (comprised of Messrs. Gallitano, Hickey and
Schiesser and Dr. Herzlinger) was to expire at the 2008 Annual Meeting; the term of the Class II
Directors (comprised of Messrs. Graham, King-Shaw and Michalik) will expire at the 2009 Annual
Meeting; and the term of the Class III Directors (comprised of Messrs. Berg, Hourani and
Moszkowski) will expire at the 2010 Annual Meeting. Because we did not hold the 2008 Annual
Meeting, Class I Directors were not elected in 2008 and, accordingly, the successors to the Class I
Directors will be elected and qualified at the 2009 Annual Meeting. Thus, if the proposed
amendment to the Restated Certificate of Incorporation is approved, the Class I and Class II
Directors will be up for election for one-year terms at the 2009 Annual Meeting. At the 2010
Annual Meeting when the term of Class III Directors will expire and every subsequent annual
meeting of shareholders thereafter, all Directors will be up for election for one-year terms and
the Board will be fully declassified. Any Director chosen as a result of a newly created
directorship or to fill a vacancy on the Board after the 2009 Annual Meeting will hold office for a
term expiring at the next annual meeting of shareholders.
This proposal would not change the present number of Directors or the Boards authority to
change that number and to fill any vacancies or newly created directorships.
Paragraphs (D) and (H) of Article V of our Restated Certificate of Incorporation contains the
provisions that will be affected if this proposal and Proposal Three below are adopted.
Appendix B to this proxy statement shows the proposed changes to paragraphs (D) and (H) of
Article V with deletions indicated by strikethroughs and additions indicated by underlining.
Reasons for the Proposal
The proposal is a result of our ongoing review of corporate governance matters by the
Nominating Committee and the Board. The Board, assisted by the Nominating Committee, considered
the advantages and disadvantages of maintaining the current classified board structure. The Board
considered the view of proponents of a classified board structure that it promotes continuity and
stability in the management of the business and affairs of the Company because a majority of
Directors always have prior experience as Directors of the Company, and because a classified
structure encourages a long-term perspective on the part of the Directors. However, the Board also
considered the view of proponents of a de-classified board structure and their belief that a
classified board has the effect of reducing accountability of directors to shareholders because
classified boards limit the ability of shareholders to evaluate and elect all directors on an
annual basis.
After considering these different views, the Board concluded that eliminating the classified
structure to provide for the annual election of all Directors would increase the Boards
accountability to shareholders by providing shareholders with a means for evaluating each Director
each year. Therefore, on the recommendation of the Nominating Committee, the Board approved the
amendments, and now recommends that the shareholders approve them.
For the reasons described above, the Board recommends that shareholders vote FOR Proposal Two,
which is a proposal to amend our existing Restated Certificate of Incorporation in order to provide
for annual elections of all directors, as described above. In order for the proposed Amended and
Restated Certificate of Incorporation to be approved and adopted, shareholders must approve both
this Proposal Two and Proposal Three below, and by approving both proposals, shareholders will be
approving and adopting the proposed Amended and Restated Certificate of Incorporation in the form
attached as Appendix B to this proxy statement.
The affirmative vote of the holders of at least 662/3 percent of the
voting power of all shares entitled to vote generally in the election of Directors, voting together
as a single class, is required to approve this proposal.
THE BOARD RECOMMENDS THAT YOU VOTE FOR AMENDING THE COMPANYS RESTATED CERTIFICATE OF INCORPORATION
TO PROVIDE FOR ANNUAL ELECTION OF ALL DIRECTORS.
50
PROPOSAL NUMBER THREE AMENDMENT OF CERTIFICATE OF INCORPORATION TO PROVIDE THAT DIRECTORS MAY BE
REMOVED WITH OR WITHOUT CAUSE
In accordance with Delaware law, unless a corporations certificate of incorporation provides
otherwise, directors of a corporation with a classified board may only be removed for cause.
Currently, the Restated Certificate of Incorporation provides that Directors may be removed only
for cause. Accordingly, together with our proposal to declassify our Board, the Board believes it
is appropriate to amend our Restated Certificate of Incorporation to provide that Directors may be
removed with or without cause. Thus, if the amendments to our Restated Certificate of
Incorporation are approved, Directors may be removed with or without cause at a meeting of
shareholders duly called for such purpose; provided, however, that prior to the 2010 Annual
Meeting, no current Class III Director serving the remaining portion of a multi-year term may be
removed during any part of his or her remaining multi-year term except for cause. After the 2010
Annual Meeting, all Directors may be removed with or without cause at a meeting of shareholders
duly called for such purpose.
Paragraphs (D) and (H) of Article V of our Restated Certificate of Incorporation contains the
provisions that will be affected if this proposal and Proposal Two above are adopted. Appendix
B to this proxy statement shows the proposed changes to paragraphs (D) and (H) of Article V
with deletions indicated by strikethroughs and additions indicated by underlining.
For the reasons described above, and for the reasons set forth under Proposal Number Two
Amendment Of Certificate Of Incorporation To Provide For Annual Election Of All Directors
Reasons For The Proposal, the Board recommends that shareholders vote FOR Proposal Three, which is
a proposal to amend our existing Restated Certificate of Incorporation in order to provide that
directors may be removed with or without cause (except for Class III Directors serving the
remaining portion of a multi-year term, who, if the amendment is approved and adopted, could not be
removed without cause prior to the end of their current multi-year term). In order for the
proposed Amended and Restated Certificate of Incorporation to be approved and adopted, shareholders
must approve both this Proposal Three and Proposal Two above, and by approving both proposals,
shareholders will be approving and adopting the proposed Amended and Restated Certificate of
Incorporation in the form attached as Appendix B to this proxy statement.
The affirmative vote of the holders of at least 662/3 percent of the
voting power of all shares entitled to vote generally in the election of Directors, voting together
as a single class, is required to approve this proposal.
THE BOARD RECOMMENDS THAT YOU VOTE FOR AMENDING THE COMPANYS RESTATED CERTIFICATE OF INCORPORATION
TO PROVIDE THAT DIRECTORS MAY BE REMOVED WITH OR WITHOUT CAUSE (EXCEPT FOR ANY CLASS III DIRECTOR
SERVING THE REMAINING PORTION OF A MULTI-YEAR TERM, WHO, IF THE AMENDMENT IS APPROVED AND ADOPTED,
COULD NOT BE REMOVED WITHOUT CAUSE UNTIL PRIOR TO THE END OF SUCH CURRENT MULTI-YEAR TERM).
51
AUDIT MATTERS
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
Independent Registered Public Accounting Firm
The table below presents fees for professional audit services billed by Deloitte & Touche LLP
for the years ended December 31, 2008 and 2007 and fees billed for other services rendered by
Deloitte & Touche LLP during those periods.
Audit, Audit-Related, Tax and Other Fees
|
|
|
|
|
|
|
|
|
Services |
|
2008 |
|
2007 |
Audit Fees |
|
$ |
12,018,500 |
(1) |
|
$ |
3,164,500 |
(1) |
Audit-related Fees |
|
$ |
129,104 |
(2) |
|
$ |
271,621 |
(2) |
Tax Fees |
|
|
|
|
|
|
|
|
All Other Fees |
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
The audit services billed by Deloitte & Touche LLP in 2008 and 2007
include services rendered for the audit of our annual consolidated
financial statements, managements assessment on internal control over
financial reporting, the effectiveness of internal control over
financial reporting and review of the interim financial statements
included in our quarterly reports on Form 10-Q. This amount also
includes fees billed for services normally provided by an independent
auditor in connection with subsidiary audits, statutory requirements,
regulatory filings and similar engagements. The 2008 audit fees
include services provided to expand the audit scope relating to the
investigation of the Company by certain federal and state agencies in
connection with the audit of the 2007 financial statements and the
restatement of the Companys 2004, 2005 and 2006 financial statements. |
|
(2) |
|
The audit-related services billed by Deloitte & Touche LLP in 2008 and
2007 related to consultations regarding financial accounting and
reporting standards, information systems audits and other attest
services. |
Audit and Non-Audit Services Pre-Approval Policy
The Audit Committee has adopted an Audit and Non-Audit Services Pre-Approval Policy which is
designed to assure that the services performed for us by the independent registered public
accounting firm do not impair its independence from the Company. This policy sets forth guidelines
and procedures the Audit Committee must follow when retaining the independent registered public
accounting firm to perform audit, audit-related, tax and other services. The policy provides
detailed descriptions of the types of services that may be provided under these four categories and
also sets forth a list of services that the independent registered public accounting firm may not
perform for us.
Prior to engagement, the Audit Committee pre-approves the services and fees of the independent
registered public accounting firm within each of the above categories. During the year, it may
become necessary to engage the independent registered public accounting firm for additional
services not previously contemplated as part of the engagement. In those instances, the Audit and
Non-Audit Services Pre-Approval Policy requires that the Audit Committee specifically approve the
services prior to the independent registered public accounting firms commencement of those
additional services. Under the Audit and Non-Audit Services Pre-Approval Policy, the Audit
Committee has delegated the ability to pre-approve audit and non-audit services to the Audit
Committee chairperson provided the chairperson reports any pre-approval decision to the Audit
Committee at its next scheduled meeting. The policy does not provide for a de minimis exception to
the pre-approval requirements. Accordingly, all of the 2008 and 2007 fees described above were
pre-approved by the Audit Committee in accordance with the Audit and Non-Audit Services
Pre-Approval Policy.
REPORT OF THE AUDIT COMMITTEE
The role of the Audit Committee is to assist the Board of Directors in the oversight of the
integrity of our financial statements, our compliance with legal, financial and regulatory
requirements, the qualification and independence of our independent auditors, and the performance
of our internal audit function and independent auditors. The Audit Committee operates pursuant to
a charter that is available on our website at www.wellcare.com and which sets forth the specific
duties and responsibilities of the Audit Committee. As set forth in the charter, the planning and
conduct of the audit is the responsibility of the independent auditors and the financial statements
are the responsibility of our management. The Audit Committee has the authority and responsibility
to retain and terminate our independent auditors.
52
In performance of this oversight function, the Audit Committee has considered and discussed
the audited financial statements included in our annual report on Form 10-K for the year ended
December 31, 2008 with management and the independent auditors. The Audit Committee has discussed
with Deloitte & Touche LLP, our independent registered public accounting firm, the matters required
to be discussed by Auditing Standards No. 61, as amended and replaced by SAS 114 (AICPA,
Professional Standards, Vol 1. AU section 380), as adopted by the Public Accounting
Oversight Board in Rule 3200T. The Audit Committee has also received the written disclosures and
the letter from Deloitte & Touche LLP required by applicable requirements of the Public Company
Accounting Oversight Board regarding the independent accountants communications with the Audit
Committee concerning independence, and has discussed with Deloitte & Touche LLP their independence.
The members of the Audit Committee are advised by the independent auditors. The independent
auditors are experts in the fields of accounting and auditing, including in respect of auditor
independence. Members of the Audit Committee rely without independent verification on the
information provided to them and on the representations made by management and the independent
auditors. Accordingly, management is solely responsible for maintaining appropriate accounting and
financial reporting principles and policies and internal control and procedures designed to assure
compliance with accounting standards and applicable laws and regulations. Furthermore, the Audit
Committees considerations and discussions referred to above do not assure that the audit of our
financial statements has been carried out in accordance with generally accepted auditing standards.
Based upon the reports and discussions described in this report, and subject to the
limitations on the role and responsibilities of the Audit Committee referred to above and in the
charter, the Audit Committee recommended to the Board that the audited financial statements be
included in our annual report on Form 10-K for the year ended December 31, 2008, as filed with the
SEC. In addition, the Audit Committee has approved the appointment of Deloitte & Touche LLP as our
independent registered public accounting firm for the fiscal year ending December 31, 2009.
The Audit Committee
Regina Herzlinger (Chairperson)
Alif Hourani
Christian Michalik
PROPOSAL NUMBER FOUR RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
The Audit Committee has appointed the firm of Deloitte & Touche LLP as our independent
registered public accounting firm for fiscal year 2009, and has directed that such appointment be
submitted to our shareholders for ratification at the annual meeting. Our organizational documents
do not require that our shareholders ratify the appointment of our independent registered public
accounting firm. We are submitting the appointment of Deloitte & Touche LLP to our shareholders
for ratification because we believe it is a matter of good corporate governance. In the event of a
negative vote on such ratification, the Audit Committee will reconsider its selection, but may
still retain Deloitte & Touche LLP. We anticipate that a representative of Deloitte & Touche LLP
will be present at the annual meeting to respond to appropriate questions and to make such
statements as they may desire.
The affirmative vote of the holders of a majority of the shares of common stock represented in
person or by proxy and entitled to vote at the meeting is required to approve this proposal.
THE BOARD OF DIRECTORS RECOMMENDS THAT YOU VOTE FOR THIS PROPOSAL.
* * * * *
53
ADDITIONAL INFORMATION
Shareholder Proposals
We expect that our 2010 annual meeting of shareholders will be more than 30 days from the date
of the 2009 annual meeting of shareholders. Shareholders who intend to submit a proposal at the
2010 annual meeting of shareholders and desire that such proposal be included in the proxy
materials for such meeting must follow the procedures prescribed in Rule 14a-8 under the Exchange
Act.
To be eligible for inclusion in the proxy materials, shareholder proposals must be received by
our secretary at our principal offices in Tampa, Florida, on or before December 1, 2009, which we
believe is a reasonable time before we will begin to print and send our proxy materials for the
2010 annual meeting. Nothing in this paragraph shall be deemed to require us to include in our
proxy statement and proxy relating to the 2010 annual meeting any shareholder proposal which may be
omitted from our proxy materials under applicable regulations of the SEC in effect at the time such
proposal is received.
In addition, under the advance notice provisions of our bylaws (Section 11), any shareholder
proposal for consideration at the 2010 annual meeting of shareholders submitted outside the
processes of Rule 14a-8 of the Exchange Act, including any shareholder nominations for the Board of
Directors, will be untimely unless it is received by our secretary not less than 90 days nor more
than 120 days prior to the date of the one-year anniversary of the 2009 annual meeting; provided
that if our 2010 annual meeting is held on a date more than 30 days prior to or delayed by more
than 60 days after such anniversary date, notice by the shareholder in order to be timely must be
received not earlier than 120 prior to such annual meeting, and not later than the later of the
close of business 90 days prior to such annual meeting or the 10th day following the day
on which such notice of the date of the annual meeting was mailed or such public disclosure of the
date of the annual meeting was made.
Because our 2009 annual meeting is being held on July 30, 2009, under our bylaws we would
normally have to receive written notice of a shareholder proposal submitted other than pursuant to
Rule 14a-8 by May 1, 2010, but no earlier than April 1, 2010, to be considered at the 2010 annual
meeting of shareholders. However, as noted above, we currently expect that our 2010 annual meeting
will be held on a date more than 30 days prior to the 2009 annual meeting and, as such, please
refer to the description of the advance notice requirements under Section 11 of our bylaws under
these circumstances.
Multiple Shareholders Having the Same Address
We have adopted a process called householding for mailing proxy materials in order to reduce
costs. Householding means that shareholders who share the same last name and address will receive
only one copy of our proxy materials, unless we receive contrary instructions. We will continue to
mail a proxy card to each shareholder of record. If you prefer to receive multiple copies of the
proxy materials at the same address, additional copies will be provided to you promptly upon
request. If you hold your shares in street name, you should direct your request to your bank or
broker. If you are a registered holder, you should direct your request to WellCare Health Plans,
Inc., C/O Computershare Investor Services, P.O Box 43078, Providence, RI 02940-3078, telephone
number (781) 575-2879. You may also request copies of our proxy materials by writing to Investor
Relations Department, WellCare Health Plans, Inc., P.O. Box 31379, Tampa, Florida 33631-3379, or by
calling (813) 865-1284. The Companys 2008 annual report to shareholders, annual report on Form
10-K for the year ended December 31, 2008 and this proxy statement are also available on our
website at http://wellcare.com/2009shareholder meeting.
Committee Reports
The information contained in the Report of the Compensation Committee and the Report of the
Audit Committee does not constitute soliciting material and should not be deemed filed or
incorporated by reference into any other of our filings under the Securities Act of 1933 or the
Exchange Act, except to the extent the filing specifically incorporates such information by
reference therein.
Solicitation
All costs and expenses associated with soliciting proxies will be borne by us. In addition to
the use of the mails, the Directors, officers and our associates by personal interview, telephone
or telegram may solicit proxies. Such Directors, officers and associates will not be additionally
compensated for such solicitation but may be reimbursed for out-of-pocket expenses incurred in
connection therewith. Arrangements will also be made with custodians, nominees and fiduciaries for
the forwarding of solicitation material to the beneficial owners of our common stock held of record
by such persons, and we will
54
reimburse such custodians, nominees and fiduciaries for their reasonable out-of-pocket expenses
incurred in connection therewith. We have retained Georgeson Inc., a proxy soliciting firm, to
assist with the solicitation of proxies for a fee not to exceed $8,500 plus reimbursement for
out-of-pocket expenses and shareholder outreach services.
Other Matters for Consideration
As of the date of this proxy statement, the Board of Directors is not aware of any other
business or matters to be presented for consideration at the meeting other than as set forth in the
notice of meeting attached to this proxy statement. However, if any other business shall come
before the meeting or any adjournment or postponement thereof and be voted upon, the enclosed proxy
shall be deemed to confer discretionary authority on the individuals named to vote the shares
represented by such proxy as to any such matters.
Requests for More Information
We will provide without charge to each beneficial holder of our common stock on the record
date, upon the written request of any such person, a copy of our 2008 annual report to shareholders
and annual report on Form 10-K (without exhibits) for the fiscal year ended December 31, 2008, as
filed with the SEC. We will also provide to any person without charge, upon request, a copy of our
Code of Conduct and Business Ethics our corporate governance guidelines and our Board committee
charters. Any such requests should be made in writing to the Investor Relations Department,
WellCare Health Plans, Inc., P.O. Box 31379, Tampa, Florida 33631-3379. A copy of these documents
and our other SEC filings are also available on our website at
http://wellcare.com/2009shareholdermeeting. We intend to disclose future amendments to, or waivers
from, the provisions of the Code of Conduct and Business Ethics, if any, made with respect to any
of our Directors and executive officers on our website.
55
APPENDIX A
AUDIT COMMITTEE CHARTER
WellCare Health Plans, Inc.
Audit Committee Charter
Purpose
The principal purposes of the audit committee (the audit committee or committee) of the board
of directors (the board) of WellCare Health Plans, Inc. (the Corporation) are to (A) assist the
board of directors in the oversight of (i) the integrity of the financial statements of the
Corporation, (ii) the compliance by the Corporation with legal, financial and regulatory
requirements, (iii) the qualification and independence of the Corporations outside auditors, and
(iv) the performance of the Corporations internal audit function and independent auditors, and (B)
prepare an audit committee report as required by the Securities and Exchange Commission to be
included in the Corporations annual proxy statement.
While the audit committee has the responsibilities and powers set forth in this Charter, its
function is one of oversight, and it is not the duty of the committee to plan or conduct audits or
to determine that the Corporations financial statements are complete and accurate and are in
accordance with accounting principles generally accepted in the United States of America. The
planning and conduct of the audit is the responsibility of the independent auditors and the
financial statements are the responsibility of management. Except as otherwise provided herein, it
is not the duty of the audit committee to conduct investigations or to assure compliance with laws
and regulations and the Corporations internal policies.
Authority
The audit committee has authority to conduct or authorize investigations into any matters within
its scope of responsibility. It shall be directly responsible for:
|
|
|
The appointment, compensation, retention and oversight of the work of any registered
public accounting firm engaged by the Corporation for the purpose of preparing or issuing
an audit report or performing other audit, review or attest services for the Corporation,
and such firm shall report directly to the audit committee. |
|
|
|
|
The resolution of any disagreements between management and the independent auditors
regarding the Corporations financial reporting. |
|
|
|
|
Seeking any information it requires from employees providing services for the
Corporation or its affiliatesall of whom are directed to cooperate with the committees
requestsor external parties. |
|
|
|
|
Meeting with the Corporations officers, independent auditors, or outside counsel, as
necessary. |
The audit committee may form, and to the extent legally permissible may delegate authority to,
subcommittees when the committee deems it appropriate or desirable.
The committee shall have the sole authority, to the extent it deems necessary or appropriate, to
retain and engage financial, legal or other advisors, including any independent counsel,
accountants, or others, to advise the committee or assist in the conduct of an investigation within
its scope of responsibility that it initiates, and shall have the sole authority to approve the
advisors fees and other retention terms.
The committee shall have the sole authority to, and shall, review and pre-approve, either pursuant
to a policy adopted by the committee or through a separate pre-approval by the committee, any
engagement of the Corporations independent auditors to provide any audit services and/or any
permitted non-audit services to the Corporation that are not prohibited by law. The committee
shall have the ability to delegate the authority to pre-approve audit and non-audit services to one
or more designated members of the committee. If such authority is delegated, the delegated
member(s) of the committee shall report to the full committee, at the next committee meeting, all
items pre-approved by the designated member(s).
The committee shall advise the Corporation of the funding requirements necessary to pay (i) the
independent auditors for the purpose of rendering the audit report or performing other audit,
review or attestation services, (ii) any other advisors employed
A-1
by the committee, and (iii)
ordinary administrative expenses of the committee that are necessary or appropriate in carrying out
its duties.
Composition and Qualification
The audit committee will consist of at least three independent members of the board of directors.
Each member of the committee will serve until such members successor is duly appointed and
qualified or until such members earlier resignation or removal. Committee members will be
appointed by the board based on nominations recommended by the Corporations nominating and
corporate governance committee. The nominating and corporate governance committee will recommend,
and the board will appoint, one member of the audit committee to serve as chairperson of the audit
committee. The committee chairperson will preside, when present, at all meetings of the committee.
In the event the committee chairperson is not present at a meeting, the committee members present
at the meeting will designate one such member as the acting chairperson of the meeting. Committee
members may be removed by the board of directors.
Each committee member will be both independent of management and financially literate pursuant to
the applicable rules and regulations of the federal securities laws and the New York Stock
Exchange, all as in effect from time to time and as interpreted by the board in its business
judgment. At least one member shall be designated as an audit committee financial expert, as
defined by applicable regulations of the Securities and Exchange Commission, and at least one
member shall have accounting or related financial management expertise (which member also may be
the audit committee financial expert). Because of the committees demanding role and
responsibilities, and the time commitment of each attendant to committee membership, no member of
the committee, including the chairman, shall serve on the audit committee of more than two other
public companies (aside from the Corporations audit committee) at any one time, unless it is
determined, based on the individual facts, that such other service will not interfere with service
on the Corporations audit committee.
To ensure independence and to otherwise avoid any potential conflicts of interest, members of the
committee may not (other than fees and equity received as compensation for serving as a director)
accept or receive, directly or indirectly, any consulting, advisory or other compensatory fee from
the Corporation or any of its subsidiaries, or be an affiliated person of the Corporation or any of
its subsidiaries, of an amount or in a manner that would disqualify them from being deemed
independent in accordance with Rule 10A-3 of the Securities Exchange Act of 1934, as amended.
Meetings
The committee will meet at least four times a year, with authority to convene additional meetings
as circumstances require. Notice of such meetings will be given in a manner consistent with the
procedure for giving notice of special meetings of the Corporations board of directors as set
forth in the Corporations bylaws, as amended. All committee members are expected to attend each
meeting, in person or via tele- or video-conference, and the committee may take action by written
consent. The committee will invite members of management, auditors, outside counsel or others to
attend meetings and provide pertinent information, as necessary. It will hold private meetings
with auditors (see below) and executive sessions, as necessary. Meeting agendas will be prepared
and provided in advance to members, along with appropriate briefing materials. Minutes of each
meeting will be prepared and distributed to all members of the Committee.
Responsibilities
The committee will carry out the following responsibilities:
Financial Statements
|
|
|
Review significant accounting and reporting issues, including complex or unusual
transactions and critical accounting policies, including matters that involve or
require significant judgments or estimates, and recent professional and regulatory
pronouncements, and understand their impact on the financial statements. The committee
shall review regular periodic reports from the independent auditors on the critical
policies and practices of the Corporation, and all alternative treatments of financial
information within generally accepted accounting principles that have been discussed
with management. |
|
|
|
|
Review with the independent auditors the results of the audit, any audit problems or
difficulties encountered and managements response to such problems or difficulties,
including any restrictions on the scope of the |
A-2
|
|
|
independent auditors activities or on
access to requested information, and any significant disagreements with management.
Such review may also include a discussion of: |
|
|
|
any accounting adjustments that were noted or proposed by the independent
auditors but were passed (as immaterial or otherwise); |
|
|
|
|
any communications between the independent auditors and its national office
respecting auditing or accounting issues presented by the engagement; |
|
|
|
|
any management or internal control letters issued, or proposed to be issued,
by the independent auditors to the Corporation, including any required attestation
reports; and |
|
|
|
|
the responsibilities, budget and staffing of the internal audit function. |
|
|
|
Review and discuss earnings press releases (paying particular attention to any use
of pro forma or adjusted financial measures and any other non-GAAP information), as
well as other financial information and earnings guidance provided to analysts and
rating agencies. |
|
|
|
|
Review with management and the independent auditors the annual audited financial
statements and disclosures contained in drafts of the Corporations annual reports on
Form 10-K, including without limitation under Managements Discussion and Analysis of
Financial Condition and Results of Operations, including their judgment about the
quality, not just the acceptability, of accounting principles, the reasonableness of
significant accounting and actuarial judgments and estimates, and the clarity of the
disclosures in the financial statements. Also, the committee shall discuss the results
of the annual audit and any other matters required to be communicated to the committee
by the independent auditors under generally accepted auditing standards. |
|
|
|
|
Review the interim financial statements and disclosures under Managements
Discussion and Analysis of Financial Condition and Results of Operations with
management and the independent auditors prior to the filing of the Corporations
Quarterly Report on Form 10-Q with the Securities and Exchange Commission. Also, the
committee shall discuss the results of the quarterly review and any other matters
required to be communicated to the committee by the independent auditors under
generally accepted auditing standards. |
|
|
|
|
In connection with the committees review of the Corporations annual audited and/or
quarterly unaudited financial statements, review and discuss the following: |
|
|
|
Major issues regarding accounting principles and financial statement
presentations, including any significant changes in the Corporations selection or
application of accounting principles, and any major issues as to the adequacy of the
Corporations internal controls and any special audit steps adopted in light of any
identified significant deficiencies or material weaknesses; |
|
|
|
|
Analyses prepared by management and/or the independent auditors setting forth
significant financial reporting issues and accounting and actuarial judgments and
estimates made in connection with the preparation of the financial statements,
including analyses of the effects of alternative generally accepted accounting
principle methods on the financial statements; and |
|
|
|
|
The effect of regulatory and accounting initiatives, as well as off-balance sheet
structures, on the Corporations financial statements. |
|
|
|
Review the following matters with the independent auditors (such matters shall be
timely reported to the committee by the independent auditors): |
|
|
|
All critical accounting policies and practices to be used, including without
limitation, significant accounting and actuarial judgments and estimates; |
|
|
|
|
All alternative treatments of financial information within generally accepted
accounting principles that have been discussed with management, ramifications of the
use of such alternative disclosures and treatments, and the preferred treatment of
the auditor; and |
|
|
|
|
Other material written communications between the independent auditors and
management, including any management letter or schedule of unadjusted differences. |
Internal Control
|
|
|
Consider the effectiveness of the Corporations internal control system, including
information technology security and control. |
|
|
|
|
Understand the scope of internal and independent auditors review of internal
control over financial reporting, and obtain reports on significant findings and
recommendations, together with managements responses. |
A-3
Internal Audit
|
|
|
Review with management and the head of internal audit the charter, plans,
activities, staffing, and organizational structure of the internal audit function. |
|
|
|
|
Ensure there are no unjustified restrictions or limitations on internal auditing
activities, and review and concur in the appointment, replacement, or dismissal of the
head of internal audit. |
|
|
|
|
Review the effectiveness of the internal audit function. |
|
|
|
|
On a regular basis, meet separately with the head of internal audit to discuss any
matters that the committee or internal audit believes should be discussed privately. |
|
|
|
|
Review managements annual report on internal control over financial reporting prior
to the Corporations inclusion of such annual report in the Corporations Annual Report
on Form 10-K. |
|
|
|
|
Review and discuss with the independent auditors the independent auditors
attestation report regarding managements assessment of the Corporations internal
control over financial reporting prior to the inclusion of such attestation report in
the Corporations Annual Report on Form 10-K. |
|
|
|
|
Review with management any changes in the Corporations internal control over
financial reporting that occurred during the most recently completed fiscal quarter
that have materially affected, or are reasonably likely to materially affect, the
Corporations internal control over financial reporting. |
|
|
|
|
Review any significant deficiencies or material weaknesses identified in the
Corporations internal control over financial reporting, and any special steps taken as
a result thereof. |
Independent Auditors
|
|
|
Review the independent auditors proposed audit scope and approach, including
coordination of audit effort with internal audit. |
|
|
|
|
Review the performance and qualifications of the independent auditors, and exercise
final approval on the appointment or discharge of the auditors. |
|
|
|
|
Review and confirm the independence of the independent auditors by obtaining
statements from the auditors on relationships between the auditors and the Corporation,
including any non-audit services, and discussing the relationships with the auditors. |
|
|
|
|
Review a report, at least annually, by the independent auditors describing the
auditors internal quality control procedures, and any material issues raised by the
most recent internal quality control review, or peer review, of the firm, or by any
inquiry or investigation by governmental or professional authorities, within the
preceding five years, respecting one or more independent audits carried out by the
firm, and any steps taken to deal with any such issues. |
|
|
|
|
Discuss with the independent auditors the matters required to be discussed by
Statement on Auditing Standards No. 61, as amended, relating to the conduct of the
audit. |
|
|
|
|
Request a representation letter from the Corporations independent auditors prior to
the commencement of the audit engagement confirming that (i) the lead (or coordinating)
audit partner and the reviewing audit partner have not performed audit services for the
Corporation for more than five (5) consecutive years, and (ii) if either of such
persons performed audit services for the Corporation for five (5) consecutive years,
the last year of such period was more than five (5) years ago. |
|
|
|
|
Consider whether, in order to assure continuing auditor independence, it is
appropriate to adopt a policy of rotating the lead audit partner or even the
independent auditing firm itself on a regular basis. |
|
|
|
|
Set polices regarding hiring by the Corporation of employees or former employees of
the independent auditors. |
|
|
|
|
On a regular basis, meet separately with the independent auditors to discuss any
matters that the committee or auditors believe should be discussed privately. |
Compliance
|
|
|
Establish and periodically review procedures for the receipt, retention, and
treatment of complaints received by the Corporation regarding accounting, internal
accounting controls, or auditing matters, and the confidential, anonymous submission by
employees providing services for the Corporation or its affiliates of concerns
regarding questionable accounting or auditing matters. |
A-4
|
|
|
Receive reports from, and coordinate with, the Regulatory Compliance Committee
regarding regulatory compliance matters that may affect the Corporations business,
financial statements or related compliance policies, including any material reports or
inquiries from regulatory or governmental agencies as necessary. |
|
|
|
|
Report to, and coordinate with, the Regulatory Compliance Committee regarding
regulatory compliance issues arising as a result of the Corporations internal audit
function as necessary. |
Reporting Responsibilities
|
|
|
Regularly report to the board of directors about committee activities, issues, and
related recommendations. |
|
|
|
|
Provide an open avenue of communication between internal auditors, the independent
auditors, and the board of directors. |
|
|
|
|
Report annually to the shareholders, describing the committees composition,
responsibilities and how they were discharged, and any other information required by
rule, including approval of non-audit services. |
|
|
|
|
Review any other reports the Corporation issues that relate to committee
responsibilities. |
Other Responsibilities
|
|
On a regular basis, meet separately with management to discuss any matters that the
committee or management believe should be discussed privately. |
|
|
|
Perform other activities related to this Charter as requested by the board of directors. |
|
|
|
Discuss the Corporations policies with respect to risk assessment and risk management,
including the Corporations major financial risk exposures and the steps management has taken
to monitor and control such exposures. |
|
|
|
Review and assess the adequacy of the committee charter annually, requesting board approval
for proposed changes, and ensure appropriate disclosure as may be required by law or
regulation. |
|
|
|
Confirm annually that all responsibilities outlined in this Charter have been carried out. |
|
|
|
Self-evaluate the committees performance on an annual basis. |
Disclosure
Publish this Charter to the Corporations website
A-5
APPENDIX B
PROPOSED AMENDED AND RESTATED CERTIFICATE OF INCORPORATION
AMENDED AND RESTATED
CERTIFICATE OF INCORPORATION OF
WELLCARE HEALTH PLANS, INC.
WellCare Health Plans, Inc., a corporation organized and existing under the General
Corporation Law of the State of Delaware, hereby certifies as follows:
1. The corporation was incorporated on February 5, 2004, under the name WellCare Group, Inc.,
pursuant to the General Corporation Law of the State of Delaware.
2. Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware,
this Amended and Restated Certificate of Incorporation restates and integrates and further amends
the provisions of the Certificate of Incorporation of the corporation.
3. The text of the Certificate of Incorporation is hereby amended and restated in its entirety
as follows:
ARTICLE I
NAME
The name of the Corporation is WellCare Health Plans, Inc. (the Corporation).
ARTICLE II
REGISTERED OFFICE AND AGENT
The address of the Corporations registered office in the State of Delaware is 2711
Centerville Road, Suite 400, City of Wilmington, County of New Castle. The name of its registered
agent at such address is Corporation Service Company.
ARTICLE III
PURPOSE
The purpose of the Corporation is to engage in any lawful act or activity for which
corporations may be organized under the General Corporation Law of the State of Delaware (the
DGCL).
ARTICLE IV
CAPITAL STOCK
The total number of shares of all classes of capital stock which the Corporation shall have
authority to issue is One Hundred Twenty Million (120,000,000) shares, of which:
One Hundred Million (100,000,000) shares, par value $0.01 per share, shall be shares of common
stock (the Common Stock); and
Twenty Million (20,000,000) shares, par value $0.01 per share, shall be shares of preferred
stock (the Preferred Stock).
(A) Common Stock. Except as (1) otherwise required by law or (2) expressly provided in
this Amended and Restated Certificate of Incorporation (as amended from time to time), each share
of Common Stock shall have the same powers, rights and privileges and shall rank equally, share
ratably and be identical in all respects as to all matters.
(1) Dividends. Subject to the rights of the holders of Preferred Stock, and to the
other provisions of this Amended and Restated Certificate of Incorporation (as amended from time to
time), holders of Common Stock shall be entitled to receive equally, on a per share basis, such
dividends and other distributions in cash, securities or other property of the Corporation as may
be declared thereon by the Board of Directors from time to time out of assets or funds of the
Corporation legally available therefore.
B-1
(2) Voting Rights. At every annual or special meeting of stockholders of the
Corporation, each holder of Common Stock shall be entitled to cast one (1) vote for each share of
Common Stock standing in such holders name on the stock transfer records of the Corporation.
(3) Liquidation Rights. In the event of any liquidation, dissolution or winding up of
the affairs of the Corporation, whether voluntary or involuntary, after payment or provision for
payment of the Corporations debts and amounts payable upon shares of Preferred Stock entitled to a
preference, if any, over holders of Common Stock upon such dissolution, liquidation or winding up,
the remaining net assets of the Corporation shall be distributed among holders of shares of Common
Stock equally on a per share basis. A merger or consolidation of the Corporation with or into any
other corporation or other entity, or a sale or conveyance of all or any part of the assets of the
Corporation (which shall not in fact result in the liquidation of the Corporation and the
distribution of assets to its stockholders) shall not be deemed to be a voluntary or involuntary
liquidation or dissolution or winding up of the Corporation within the meaning of this Paragraph
(A)(3).
(B) Preferred Stock. The Board of Directors is authorized, subject to limitations
prescribed by law, to provide by resolution or resolutions for the issuance of shares of Preferred
Stock in one or more series, to establish the number of shares to be included in each such series,
and to fix the voting powers (if any), designations, powers, preferences, and relative,
participating, optional or other rights, if any, of the shares of each such series, and any
qualifications, limitations or restrictions thereof. Irrespective of the provisions of Section
242(b)(2) of the DGCL, the number of authorized shares of Preferred Stock may be increased or
decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of
the holders of a majority in voting power of the stock of the Corporation entitled to vote, without
the separate vote of the holders of the Preferred Stock as a class.
ARTICLE V
BOARD OF DIRECTORS
(A) Management. The business and affairs of the Corporation shall be managed by or
under the direction of the Board of Directors. The Board of Directors may exercise all such
authority and powers of the Corporation and do all such lawful acts and things as are not by
statute or this Amended and Restated Certificate of Incorporation directed or required to be
exercised or done by the stockholders.
(B) Number of Directors. The number of directors of the Corporation shall be fixed
from time to time in the manner provided in the Amended and Restated Bylaws.
(C) Newly-Created Directorships and Vacancies. Subject to the rights of the holders of
any series of Preferred Stock then outstanding, newly created directorships resulting from any
increase in the number of directors or any vacancies in the Board of Directors resulting from
death, resignation, retirement, disqualification, removal from office or any other cause may be
filled by the Board of Directors, provided that a quorum is then in office and present, or by a
majority of the directors then in office, if less than a quorum is then in office, or by the sole
remaining director. Directors elected to fill a newly created directorship or other vacancies shall
hold office until such directors successor has been duly elected and qualified or until his or her
earlier death, resignation or removal as hereinafter provided.
(D) Removal of Directors. Subject to the rights of the holders of any series of
Preferred Stock then outstanding, any director may be removed from office at any time
forwith or without cause,
at a meeting called for that purpose, andbut only by
the affirmative vote of the holders of at least 66-2/3% of the voting power of all shares of the
Corporation entitled to vote generally in the election of directors, voting together as a single
class; provided, however, that no existing Class III director serving the remaining
portion of a multi-year term may be removed during any part of his or her remaining multi-year term
except for cause.
(E) Rights of Holders of Preferred Stock. Notwithstanding the foregoing provisions of
this Article V, whenever the holders of one or more series of Preferred Stock issued by the
Corporation shall have the right, voting separately or together by series, to elect directors at an
annual or special meeting of stockholders, the election, term of office, filling of vacancies and other features of such
directorship shall be governed by the rights of such Preferred Stock as set forth in the
certificate of designations governing such series.
(F) Written Ballot Not Required. Elections of directors need not be by written ballot
unless the Amended and Restated Bylaws of the Corporation shall otherwise provide.
B-2
(G) Bylaws . The Board of Directors is expressly authorized to adopt, amend or repeal
the bylaws of the Corporation. Any bylaws made by the directors under the powers conferred hereby
may be amended or repealed by the directors or by the stockholders. Notwithstanding the foregoing
and anything contained in this Amended and Restated Certificate of Incorporation to the contrary,
the bylaws of the Corporation shall not be amended or repealed by the stockholders, and no
provision inconsistent therewith shall be adopted by the stockholders, without the affirmative vote
of the holders of 66-2/3% of the voting power of all shares of the Corporation entitled to vote
generally in the election of directors, voting together as a single class.
(H) ClassificationElectionof
Directors. ; Declassification of Board. At each
annual meeting of stockholders, directors of the Corporation shall be elected to hold office until
the expiration of the term for which they are elected, and until their successors have been duly
elected and qualified; except that if any such election shall be not so held, such election shall
take place at a stockholders meeting called and held
in accordance with the DGCL. The Until the 2010 annual meeting of
stockholders, the directors of the Corporation shall be divided into three classes as
nearly equal in size as is practicable, hereby designated. At the
2009 annual meeting of stockholders, both the Class I and Class II directors shall be elected for
one-year terms expiring at the 2010 annual meeting of stockholders; and at the 2010 annual meeting
of stockholders, the terms of the then-serving Class I, Class II and Class
III. The term of office of the initial Class I directors shall expire at the next
succeeding annual meeting of stockholders, the term of office of the initial Class II directors
shall expire at the second succeeding annual meeting of stockholders and the term of office of the
initial Class III directors shall expire at the third succeeding annual meeting of the
stockholders. For the purposes hereof, the initial Class I, Class II and Class III directors shall
be those directors elected by the sole stockholder of the Corporation in connection with the
adoption of this Amended and Restated Certificate of Incorporation. At each annual meeting after
the first directors shall expire, and at such annual meeting and at
each annual meeting of stockholders thereafter,
all directors to replace those of a Class whose terms
expire at such annual meeting shall be elected to hold office until the
third succeeding annual meeting and until their respective successors shall have been duly elected
and qualified. If the number of directors is hereafter changed, any newly created directorships or
decrease in directorships shall be so apportioned among the classes as to make all classes as
nearly equal in number as practicable.for one-year terms expiring at the next
annual meeting and shall serve until his or her successor shall be elected and qualified. From and
after the 2010 annual meeting of stockholders, the directors shall no longer be divided into
classes. Each Class I and Class II director elected at the 2009 annual meeting of stockholders
shall serve for a one-year term as provided herein notwithstanding that the amendments to effect
the declassification of the Board of Directors as provided herein may be filed with the Secretary
of State of the State of Delaware after the 2009 annual meeting of stockholders at which such Class
I or Class II director was elected and such amendments were approved and adopted by the
stockholders.
ARTICLE VI
LIMITATION OF LIABILITY
A director of the Corporation shall not be personally liable to the Corporation or its
stockholders for monetary damages for breach of fiduciary duty as a director; provided, however,
that the foregoing shall not eliminate or limit the liability of a director (i) for any breach of
the directors duty of loyalty to the Corporation or its stockholders, (ii) for acts or omissions
not in good faith or which involve intentional misconduct or a knowing violation of law, (iii)
under Section 174 of the DGCL, or (iv) for any transaction from which the director derived an
improper personal benefit. If the DGCL is hereafter amended to permit further elimination or
limitation of the personal liability of directors, then the liability of a director of the
Corporation shall be eliminated or limited to the fullest extent permitted by the DGCL as so
amended. Any repeal or modification of this Article VI by the stockholders of the Corporation or otherwise
shall not adversely affect any right or protection of a director of the Corporation existing at the
time of such repeal or modification.
ARTICLE VII
INDEMNIFICATION
Each person who was or is made a party or is threatened to be made a party to or is involved
(including, without limitation, as a witness) in any actual or threatened action, suit or
proceeding, whether civil, criminal, administrative or investigative (hereinafter a proceeding),
by reason of the fact that he is or was a director or officer of the Corporation or is or was
serving at the request of the Corporation as a director or officer of another corporation or of a
partnership, limited liability company, joint venture, trust or other entity, including service
with respect to an employee benefit plan (hereinafter an Indemnitee), whether the basis of such
proceeding is alleged action in an official capacity as a director or officer or in any other
capacity while so serving, shall be indemnified and held harmless by the Corporation to the full
extent authorized by the DGCL, as the same exists or may hereafter be amended (but, in the case of
any such amendment, only to the extent that such amendment permits the Corporation to provide
broader indemnification rights than said law permitted the Corporation to
B-3
provide prior to such amendment), or by other applicable law as then in effect, against all
costs, expenses, liabilities and losses (including attorneys fees and related costs, judgments,
fines, excise taxes or penalties under the Employee Retirement Income Security Act of 1974, as
amended from time to time (ERISA), penalties and amounts paid or to be paid in settlement)
actually and reasonably incurred or suffered by such Indemnitee in connection therewith, and such
indemnification shall continue as to a person who has ceased to be a director, officer, partner,
member or trustee and shall inure to the benefit of his or her heirs, executors and administrators.
Each person who is or was serving as a director or officer of a subsidiary of the Corporation shall
be deemed to be serving, or have served, at the request of the Corporation.
(A) Procedure. Any indemnification (but not advancement of expenses) under this
Article VII (unless ordered by a court) shall be made by the Corporation only as authorized in the
specific case upon a determination that indemnification of the director or officer is proper in the
circumstances because he has met the applicable standard of conduct set forth in the DGCL, as the
same exists or hereafter may be amended (but, in the case of any such amendment, only to the extent
that such amendment permits the Corporation to provide broader indemnification rights than said law
permitted the Corporation to provide prior to such amendment). Such determination shall be made
with respect to a person who is a director or officer at the time of such determination (a) by a
majority vote of the directors who were not parties to such proceeding (the Disinterested
Directors), even though less than a quorum, (b) by a committee of Disinterested Directors
designated by a majority vote of Disinterested Directors, even though less than a quorum, (c) if
there are no such Disinterested Directors, or if such Disinterested Directors so direct, by
independent legal counsel in a written opinion, or (d) by the stockholders.
(B) Advances for Expenses. Expenses (including attorneys fees, costs and charges)
incurred by a director or officer of the Corporation in defending a proceeding shall be paid by the
Corporation in advance of the final disposition of such proceeding upon receipt of an undertaking
by or on behalf of the director or officer to repay all amounts so advanced in the event that it
shall ultimately be determined that such director or officer is not entitled to be indemnified by
the Corporation as authorized in this Article VII. The majority of the Disinterested Directors may,
in the manner set forth above, and upon approval of such director or officer of the Corporation,
authorize the Corporations counsel to represent such person, in any proceeding, whether or not the
Corporation is a party to such proceeding.
(C) Procedure for Indemnification. Any indemnification or advance of expenses
(including attorneys fees, costs and charges) under this Article VII shall be made promptly, and
in any event within 60 days upon the written request of the director or officer (and, in the case
of advance of expenses, receipt of a written undertaking by or on behalf of Indemnitee to repay
such amount if it shall ultimately be determined that Indemnitee is not entitled to be indemnified
therefore pursuant to the terms of this Article VII). The right to indemnification or advances as
granted by this Article VII shall be enforceable by the director or officer in any court of
competent jurisdiction, if the Corporation denies such request, in whole or in part, or if no
disposition thereof is made within 60 days. Such persons costs and expenses incurred in connection
with successfully establishing his/her right to indemnification, in whole or in part, in any such
action shall also be indemnified by the Corporation. It shall be a defense to any such action
(other than an action brought to enforce a claim for the advance of expenses (including attorneys
fees, costs and charges) under this Article VII where the required undertaking, if any, has been
received by the Corporation) that the claimant has not met the standard of conduct set forth in the
DGCL, as the same exists or hereafter may be amended (but, in the case of any such amendment, only
to the extent that such amendment permits the Corporation to provide broader indemnification rights
than said law permitted the Corporation to provide prior to such amendment), but the burden of
proving such defense shall be on the Corporation. Neither the failure of the Corporation (including
its Board of Directors, its independent legal counsel and its stockholders) to have made a
determination prior to the commencement of such action that indemnification of the claimant is
proper in the circumstances because he/she has met the applicable standard of conduct set forth in
the DGCL, as the same exists or hereafter may be amended (but, in the case of any such amendment,
only to the extent that such amendment permits the Corporation to provide broader indemnification
rights than said law permitted the Corporation to provide prior to such amendment), nor the fact
that there has been an actual determination by the Corporation (including its Board of Directors,
its independent legal counsel and its stockholders) that the claimant has not met such applicable
standard of conduct, shall be a defense to the action or create a presumption that the claimant has
not met the applicable standard of conduct.
(D) Other Rights; Continuation of Right to Indemnification. The indemnification and
advancement of expenses provided by this Article VII shall not be deemed exclusive of any other
rights to which a person seeking indemnification or advancement of expenses may be entitled under
any law (common or statutory), bylaw, agreement, vote of stockholders or disinterested directors or
otherwise, both as to action in his/her official capacity and as to action in another capacity
while holding office or while employed by or acting as agent for the Corporation, and shall
continue as to a person who has ceased to be a director or officer, and shall inure to the benefit
of the estate, heirs, executors and administers of such person. All rights to indemnification under
this Article VII shall be deemed to be a contract between the Corporation and each director or
officer of the Corporation who serves or served in such capacity at any time while this Article VII
is in effect. Any repeal or modification
B-4
of this Article VII or any repeal or modification of relevant provisions of the DGCL or any
other applicable laws shall not in any way diminish any rights to indemnification of such director
or officer or the obligations of the Corporation arising hereunder with respect to any proceeding
arising out of, or relating to, any actions, transactions or facts occurring prior to the final
adoption of such modification or repeal. For the purposes of this Article VII, references to the
Corporation include all constituent corporations absorbed in a consolidation or merger as well as
the resulting or surviving corporation, so that any person who, following such consolidation or
merger, is a director or officer of such a constituent corporation or is serving at the request of
such constituent corporation as a director or officer of another corporation, partnership, joint
venture, trust or other entity shall stand in the same position under the provisions of this
Article VII, with respect to the resulting or surviving corporation during the period following
such consolidation or merger, as he would if he/she had served the resulting or surviving
corporation in the same capacity.
(E) Insurance. The Corporation shall have power to purchase and maintain insurance on
behalf of any person who is or was or has agreed to become a director or officer of the
Corporation, or is or was serving at the request of the Corporation as a director or officer of
another corporation, partnership, joint venture, trust or other entity, against any liability
asserted against him and incurred by him or on his behalf in any such capacity, or arising out of
his status as such, whether or not the Corporation would have the power to indemnify him against
such liability under the provisions of this Article VII; provided, however, that such insurance is
available on acceptable terms, which determination shall be made by a vote of a majority of the
Board of Directors.
(F) Savings Clause. If this Article VII or any portion hereof shall be invalidated on
any ground by any court of competent jurisdiction, then the Corporation shall nevertheless
indemnify each person entitled to indemnification under the first paragraph of this Article VII as
to all costs, expenses, liabilities and losses (including attorneys fees and related costs,
judgments, fines, ERISA excise taxes and penalties, penalties and amounts paid or to be paid in
settlement) actually and reasonably incurred or suffered by such person and for which
indemnification is available to such person pursuant to this Article VII to the full extent
permitted by any applicable portion of this Article VII that shall not have been invalidated and to
the full extent permitted by applicable law.
ARTICLE VIII
ACTION BY WRITTEN CONSENT/SPECIAL MEETINGS OF STOCKHOLDERS
For so long as either the Corporations Common Stock is registered under Section 12 of the
Securities Exchange Act of 1934, as amended (the Exchange Act), or the Corporation is required to
file periodic reports with the Securities and Exchange Commission pursuant to Section 15(d) of the
Exchange Act with respect to the Corporations Common Stock: (i) the stockholders of the
Corporation may not take any action by written consent in lieu of a meeting, and must take any
actions at a duly called annual or special meeting of stockholders and the power of stockholders to
consent in writing without a meeting is specifically denied and (ii) special meetings of
stockholders of the Corporation may be called only by either the Board of Directors pursuant to a
resolution adopted by the affirmative vote of the majority of the total number of directors then in
office or by the chief executive officer of the Corporation.
ARTICLE IX
AMENDMENT
The Corporation reserves the right to amend, alter, change or repeal any provision contained
in this Amended and Restated Certificate of Incorporation, in the manner now or hereafter
prescribed by statute, and all rights conferred upon stockholders herein are granted subject to
this reservation. Notwithstanding any other provision of this Amended and Restated Certificate of
Incorporation or the Amended and Restated Bylaws of the Corporation, and notwithstanding the fact
that a lesser percentage or separate class vote may be specified by law, this Amended and Restated
Certificate of Incorporation, the Amended and Restated Bylaws of the Corporation or otherwise, but
in addition to any affirmative vote of the holders of any particular class or series of the capital
stock required by law, this Amended and Restated Certificate of Incorporation, the Amended and
Restated Bylaws of the Corporation or otherwise, the affirmative vote of the holders of at least
66-2/3% of the voting power of all shares of the Corporation entitled to vote generally in the
election of directors, voting together as a single class, shall be required to adopt any provision
inconsistent with, to amend or repeal any provision of, or to adopt a bylaw inconsistent with,
Articles V, VI, VII, VIII or IX of this Amended and Restated Certificate of Incorporation.
* * *
B-5
4. The foregoing amendment and restatement of the Certificate of Incorporation has been duly
approved by the Board of Directors of the corporation in accordance with the provisions of Sections
144, 242 and 245 of the General Corporation Law of the State of Delaware.
5. The foregoing amendment and restatement of the Certificate of Incorporation has been duly
approved by the written consent of the sole stockholder in accordance with Sections 228, 242 and
245 of the General Corporation Law of the State of Delaware.
IN WITNESS WHEREOF, the corporation has causes this Amended and Restated Certificate of
Incorporation to be signed by its on this th day of , 2009.
|
|
|
|
|
|
WELLCARE HEALTH PLANS, INC
|
|
|
By |
|
|
|
|
|
|
|
|
|
|
|
B-6
Electronic Voting Instructions
You can vote by Internet or telephone!
Available 24 hours a day, 7 days a week!
Instead of mailing your proxy, you may choose one of the two voting methods outlined below to vote
your proxy.
VALIDATION DETAILS ARE LOCATED BELOW IN THE TITLE BAR.
Proxies submitted by the Internet or telephone must be received by 1:00 a.m., Eastern Time, on July
30, 2009.
Using a black ink pen, mark your votes with an X as shown in
this example. Please do not write outside the designated areas. |
Vote by Internet
· Log on to the Internet and go to
www.investorvote.com/wcg
· Follow the steps outlined on the secured website. |
Vote by telephone
· Call toll free 1-800-652-VOTE (8683) within the United
States, Canada & Puerto Rico any time on a touch tone
telephone. There is NO CHARGE to you for the call.
· Follow the instructions provided by the recorded message. |
Annual Meeting Proxy Card |
IF YOU HAVE NOT VOTED VIA THE INTERNET OR TELEPHONE, FOLD ALONG THE PERFORATION, DETACH AND
RETURN THE BOTTOM PORTION IN THE ENCLOSED ENVELOPE. |
A Proposals The Board of Directors recommends a vote FOR all the Director nominees
listed below and FOR Proposals 2, 3 and 4. |
1. Election of Class I and Class II Directors: (A) for, in the case of Dr. Herzlinger and Messrs.
Gallitano, Hickey and Schiesser, a (i) one-year term to expire at the Companys 2010 annual meeting
if Proposal Two and Proposal Three are approved or (ii) two-year term to expire at the
Companys 2011 annual meeting if Proposal Two and Proposal Three are not approved, and (B)
for, in the case of Senator Graham and Messrs. King-Shaw and Michalik, a (i) one-year term to
expire at the Companys 2010 annual meeting if Proposal Two and Proposal Three are
approved or (ii) three-year term to expire at the Companys 2012 annual meeting if Proposal Two and
Proposal Three are not approved. |
For Withhold For Withhold
01 Kevin Hickey o o 05 Christian Michalik o o
02 Regina Herzlinger o o 06 Ruben Jose King-Shaw, Jr. o o
03 Heath Schiesser o o 07 D. Robert Graham o o
04 David Gallitano o o |
B Non-Voting Items
Change of Address Please print new address below. |
2. Approval and adoption of an amendment to the Companys
certificate of incorporation to declassify the Companys Board
of Directors. o o o |
3. Approval and adoption of an amendment to the Companys
certificate of incorporation to provide that Directors may be
removed with or without cause (except for Class III Directors
serving the remaining portion of a multi-year term, who, if the
amendment is approved and adopted, could not be removed without
cause prior to the end of such current multi-year term).
Both Proposals Two and Three are cross-conditioned on each other.
By approving Proposals Two and Three, shareholders will be approving
and adopting the proposed Amended and Restated Certificate of
Incorporation. If either Proposal Two or Three is not approved,
then neither Proposal Two or Three will be approved. o o o
For Against Abstain |
4. Ratification of the appointment of Deloitte & Touche LLP as the
Companys independent registered public accounting firm for fiscal
year 2009. o o o |
5. As the proxies may in their discretion determine in respect of
any other business properly to come before the annual meeting
(the Board of Directors currently knowing of no such other business). o o o |
C Authorized Signatures This section must be completed for your vote to be counted Date and
Sign Below
Please sign in the same form as name appears hereon. Executors and other fiduciaries should
indicate their titles. If signed on behalf of a corporation, give title of officer signing |
Date (mm/dd/yyyy) Please print date below Signature 1 Please keep signature within the
box Signature 2 Please keep signature within the box. / / |
IF YOU HAVE NOT VOTED VIA THE INTERNET OR TELEPHONE, FOLD ALONG THE PERFORATION, DETACH AND
RETURN THE BOTTOM PORTION IN THE ENCLOSED ENVELOPE. |
Proxy WellCare Health Plans, Inc. |
PROXY FOR 2009 ANNUAL MEETING ON JULY 30, 2009
SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS |
The undersigned hereby appoints Heath Schiesser, Chief Executive Officer, and Timothy S. Susanin,
Secretary, and each of them, attorneys with full power of substitution, to vote as directed on the
reverse side all shares of Common Stock of WellCare Health Plans, Inc. registered in the name of
the undersigned, or which the undersigned may be entitled to vote, at the 2009 Annual Meeting to be
held at the Grand Hyatt Tampa Bay, 2900 Bayport Drive, Tampa, Florida 33607, on July 30, 2009, at
10:00 a.m. Eastern Time and at any adjournment or postponement thereof. |
UNLESS THE STOCKHOLDER DIRECTS OTHERWISE, THIS PROXY WILL BE VOTED FOR THE ELECTION OF ALL
OF THE DIRECTOR NOMINEES LISTED IN PROPOSAL 1 AND FOR PROPOSALS 2, 3 AND 4, AND IN THE
DISCRETION OF THE PROXY HOLDERS AS TO ANY OTHER MATTERS. |